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FOREWORD
This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic 
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein. Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is 
also presented, but is described in less detail than the key studies. The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced.
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile 
begins with a public health statement that describes, in nontechnical language, a substance's relevant 
toxicological properties. Following the public health statement is information concerning levels of 
significant human exposure and, where known, significant health effects. The adequacy of information to 
determine a substance's health effects is described in a health effects summary. Data needs that are of 
significance to protection of public health are identified by ATSDR and EPA.
Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) A determination of whether adequate information on the health effects of each substance is 
available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels 
of exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the federal, state, and 
local levels; interested private sector organizations and groups; and members of the public. We plan to 
revise these documents in response to public comments and as additional data become available. 
Therefore, we encourage comments that will make the toxicological profile series of the greatest use.
Comments should be sent to:
The Agency for Toxic Substances and Disease Registry 
Division of Toxicology and Environmental Medicine 
Applied Toxicology Branch
Regular Mailing Address: Physical Mailing Address:
1600 Clifton Road, N.E. 4770 Buford Highway
Mail Stop F-62 Building 106, 8,b floor, MS F-62
Atlanta, Georgia 30333 Chamblee, Georgia 30341
Electronic Comments should be sent to: TPPublicComments@cdc.gov
vi
The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 
104(i)(l) directs the Administrator of ATSDR to “...effectuate and implement the health-related 
authorities” of the statute. This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the 
most significant potential threat to human health, as determined by ATSDR and the EPA. Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile 
for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for 
substances not found at sites on the National Priorities List, in an effort to “...establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA 
Section 104(i)(l)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise 
necessary to support the site-specific response actions conducted by ATSDR.
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been 
peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other federal scientists have 
also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel 
and is being made available for public review. Final responsibility for the contents and views expressed 
in this toxicological profile resides with ATSDR.
Thomas R. Frieden, M.D., M.P.H.
Administrator 
Agency for Toxic Substances and 
Disease Registry
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QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation o f toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
o f available toxicologic and epidemiologic information on a substance. Health care providers treating 
patients potentially exposed to hazardous substances w ill find the following information helpful for fast 
answers to often-asked questions.
P r i m a r y  C h a p t e r s / S e c t i o n s  o f  I n t e r e s t
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance. It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure.
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance o f toxicity data to human health.
Chapter 3: Health Effects: Specific health effects o f a given hazardous compound are reported by type 
o f health effect (death, systemic, immunologic, reproductive), by route o f exposure, and by length 
o f exposure (acute, intermediate, and chronic). In addition, both human and animal studies are 
reported in this section.
N O T E : Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects observed 
following exposure.
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues:
Section 1.6 How Can (Chemical X) Affect Children?
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7 Children’s Susceptibility
Section 6.6 Exposures of Children
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
A T S D R  I n f o r m a t i o n  C e n t e r
P h o n e :  I- 8 OO-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) F a x :  (770) 488-4178
E - m a i l :  cdcinfo@cdc.gov I n t e r n e t : http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance o f taking an
exposure history and how to conduct one are described, and an example o f a thorough exposure 
history is provided. Other case studies o f interest include Reproductive and Developmental
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Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies.
Managing Hazardous Materials Incidents is a three-volume set o f recommendations for on-scene
(prehospital) and hospital medical management o f patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials. Volume III— 
Medical Management Guidelines fo r Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
O t h e r  A g e n c i e s  a n d  O r g a n i z a t i o n s
The National Center fo r Environmental Health (NCEH) focuses on preventing or controlling disease,
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute fo r Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems o f health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998
• Phone: 800-35-NIOSH.
The National Institute o f Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects o f chemical, physical, and biologic environmental agents on 
human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
R e f e r r a l s
The Association o f Occupational and Environmental Clinics (AOEC) has developed a network o f clinics 
in the United States to provide expertise in occupational and environmental issues. Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976
• FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: http://www.aoec.org/.
The American College o f Occupational and Environmental Medicine (ACOEM) is an association o f 
physicians and other health care providers specializing in the field o f occupational and 
environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 
Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.
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Franco Scinicariello, M.D., M.P.H.





SRC, Inc., North Syracuse, NY
THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1. Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter o f each profile for consistency and accuracy in interpreting health effects and classifying 
end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database o f each 
profile, and makes recommendations for derivation o f MRLs.
3. Data Needs Review. The Applied Toxicology Branch reviews data needs sections to assure 
consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.
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PEER REVIEW
A peer review panel was assembled for trichlorobenzenes. The panel consisted o f the following 
members:
1. Ralph L. Kodell, Ph.D., Professor, Department o f Biostistics, University o f Arkansas for Medical 
Sciences, Little Rock, Arkansas;
2. Richard J. Bull, Ph.D., President, MoBull Consulting, Richland Washington; and
3. James E. Klaunig, Ph.D., Professor and Chair, Department o f Environmental Health, School of 
Public Health, Indiana University at Bloomington, Indiana.
These experts collectively have knowledge o f Trichlorobenzenes' physical and chemical properties, 
toxicokinetics, key health end points, mechanisms o f action, human and animal exposure, and 
quantification o f risk to humans. A ll reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) o f the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments w ill be included in the profile. A listing o f the 
peer reviewers' comments not incorporated in the profile, with a brief explanation o f the rationale for their 
exclusion, exists as part o f the administrative record for this compound.
The citation o f the peer review panel should not be understood to imply its approval o f the profile's final 
content. The responsibility for the content o f this profile lies with the ATSDR.
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This public health statement tells you about trichlorobenzenes and the effects o f exposure to them.
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation. These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities. 1,2,3-Trichlorobenzene, 1,2,4-trichlorobenzene, and 1,3,5-trichlorobenzene 
have been identified in 31, 187, and 4 o f the 1,699 hazardous waste sites, respectively. Although the 
total number o f NPL sites evaluated for these substances is not known, the possibility exists that the 
number of sites at which trichlorobenzenes are found may increase in the future as more sites are 
evaluated. This information is important because these sites may be sources o f exposure and exposure to 
these substances may be harmful.
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment. Such a release does not always lead to exposure. You 
can be exposed to a substance only when you come in contact with it. You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact.
I f  you are exposed to trichlorobenzenes, many factors w ill determine whether you w ill be harmed. These 
factors include the dose (how much), the duration (how long), and how you come in contact with them. 
You must also consider any other chemicals you are exposed to and your age, sex, diet, family traits, 
lifestyle, and state o f health.
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Description T rich lo robenzenes  are hum an-m ade com pounds th a t o ccu r in 
th ree  d iffe ren t chem ica l fo rm s. A lthough  th e y  have the  sam e 
m o lecu la r w e ig h t and m o lecu la r fo rm u la , th e y  d iffe r s truc tu ra lly  
by w he re  the  ch lo rine  a tom s are a ttached  to the  benzene  ring. 
C om pounds like these  are re ferred  to as isom ers. D raw ings o f 
the  th ree  d iffe ren t isom ers are show n in C hap te r 4. 
1 ,2 ,3 -T rich lo robenzene  and 1 ,3 ,5 -trich lo robenzene  are 
co lo rless so lids, w h ile  1 ,2 ,4 -trich lo robenzene  is a co lorless 
liquid.
A lthough  the  th ree  isom ers o f tr ich lo robenzene  are s truc tu ra lly  
s im ila r, th e y  each m ay have d iffe re n t chem ica l and tox ico log ica l 
properties.
Uses Trich lo robenzenes  have p rim arily  been used as so lven ts  and 
chem ica l in te rm ed ia tes to produce o the r com pounds. In the 
past, m ixed isom ers o f trich lo robenzene  had been used fo r 
te rm ite  contro l, but th is  is not a cu rren t use. O ne o f the  isom ers 
(1 ,2 ,4 -trich lo robenzene) is p roduced in large quan tities  and is 
used as a so lven t to  d isso lve  such spec ia l m ate ria ls  as oils, 
w axes, resins, g reases, and rubber. It is a lso frequen tly  used 
to p roduce  dyes and textiles . The o the r tw o  isom ers, 
1 ,2 ,3 -trich lo robenzene  and 1 ,3 ,5 -trich lo robenzene , are 
p roduced in low e r quan tities  and have fe w e r uses.
1.2 WHAT HAPPENS TO TRICHLOROBENZENES WHEN THEY ENTER THE 
ENVIRONMENT?
Air T rich lo robenzenes  are vo la tile  subs tances and m ay the re fo re  
partition to a ir w hen re leased to  the  env ironm en t. The ha lf-life  
(the tim e  it takes fo r 50%  o f the  com pound  to deg rade) o f 
trich lo robenzenes  in a ir is abou t 1 m onth.
Water T rich lo robenzenes  have been de tected  in groundw ate r, 
d rink ing  w ate r, and su rface  w a te r (rivers and lakes). 
T rich lo robenzenes  have a te n d e n cy  to evapora te  ove r tim e  
from  w ate r, but can a lso adsorb  to suspended  so lids  and 
sed im en t in w ater.
Soil and sediment T rich lo robenzenes  evapora te  from  so ils  and are s low ly  broken 
dow n by m icroo rgan ism s in so il and sed im ent.
Animals and fish T rich lo robenzenes  in w a te r and soil m ay be absorbed  or 
ingested by an im a ls  and fish. H igh leve ls o f trich lo robenzenes 
are often de tected  in fish o r o the r spec ies liv ing in 
con tam ina ted  w a te rs  because trich lo robenzenes  can 
accum u la te  in fa tty  tissues.
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1.3 HOW MIGHT I BE EXPOSED TO TRICHLOROBENZENES?
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Environmental exposure M onito ring  da ta  su gges t th a t the  genera l popu la tion  m ay be 
exposed to trich lo robenzenes  by inha ling  a ir and th rough  the  
ingestion o f food and d rink ing  w a te r. O th e r substances tha t 
have been re leased into the  env ironm en t, such as h igher 
ch lo rina ted  benzenes, o r the  fo rm erly  used pestic ide, lindane, 
can break dow n into trich lo robenzene . The re fo re , if you live in 
an area w here  these  products  w ere  used o r d isposed  o f 
(hazardous w aste  s ites) you m ay po ten tia lly  be exposed  to 
trich lo robenzenes  as w ell.
Ingestion of food and fish T rich lo robenzenes  have been identified in a va rie ty  o f food 
item s inc lud ing vege tab les , m ilk, eggs/m eat, and o ils produced 
from  corn, soybeans, peanuts, w a lnu ts , haze lnu ts, and rape, 
sun flow er, sesam e, and poppy seeds. P eop le  w ho  eat large 
quan tities  o f fish from  areas con tam ina ted  by trich lo robenzenes 
m ay have h igher exposu re  to  these  substances s ince  fish  tend 
to accum u la te  trich lo robenzenes  in th e ir fa tty  tissues.
Occupational exposure Y ou can be exposed  to  trich lo robenzenes  by inha la tion  and 
derm a l con tact w ith  these  substances if you are em ployed in an 
occupa tion  w here  tr ich lo robenzenes  are m anufactu red  o r used. 
A cco rd ing  to the  N ationa l O ccupa tiona l E xposure  S urvey 
(N O ES), w o rke rs  em ployed in tex tile  m ill p roduction  and 
e lec tric  and e lec tron ic  m anu factu ring  tend to  have the  g rea tes t 
po ten tia l exposure  to tr ich lo robenzenes.
1.4 HOW CAN TRICHLOROBENZENES ENTER AND LEAVE MY BODY?
Enter the body T here  is not enough in fo rm ation  to de te rm ine  how  m uch o r how 
fas t tr ich lo robenzenes  can e n te r yo u r body if you inha le  vapors  
o r con tam ina ted  air, if you sw a llow  these  chem ica ls , o r if they  
ge t onto  yo u r skin .
S tud ies in an im a ls  suggest th a t tr ich lo robenzenes  can rap id ly  
e n te r the  body th rough  the  lungs and the  gas tro in tes tina l tract. 
Less is know n abou t en tering  the  body th rough  the  skin.
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Leave the body T here  is no in fo rm ation  on how  these  com pounds could leave 
the  body in hum ans, bu t based on s tud ies in an im als, they  
p robab ly  leave p rinc ipa lly  in the  urine.
In an im als, tr ich lo robenzenes  are trans fo rm ed  in the  body into 
o the r chem ica ls , w h ich  are e lim ina ted  in the  urine, feces, and 
bile in a few  days.
S tud ies in an im a ls  suggest th a t tr ich lo robenzenes  do not 
accum u la te  in the  body o f m am m als, but accum u la te  in fish.
1.5 HOW CAN TRICHLOROBENZENES AFFECT MY HEALTH?
This section looks at studies concerning potential health effects in animal and human studies.
Effects in humans T here  is v irtua lly  no in fo rm ation  regard ing  health e ffec ts  o f 
trich lo robenzenes  in hum ans o the r than reports  o f m in im al eye 
and th ro a t irrita tion in certa in  peop le  exposed  to  vapo rs  o f 
1 ,2 ,4 -trich lo robenzene  and a report o f a w om an  w ho  deve loped  
a blood d iso rd e r due to p ro longed inha la tion  o f 
trich lo robenzenes  from  he r h u sband ’s w o rk  c lo thes.
H ow ever, based on resu lts from  stud ies in an im als, it is 
reasonab le  to  p red ic t th a t hum ans exposed to high am ounts  o f 
trich lo robenzenes  m ay deve lop  live r prob lem s.
Laboratory animals S tud ies in an im a ls  ind ica te  th a t ora l adm in is tra tion  o f 
trich lo robenzenes  fo r sho rt o r long periods p roduces m ain ly  
a lte ra tions in the  live r and k idneys.
P ro longed adm in is tra tion  o f 1 ,2 ,4 -trich lo robenzene  to rats did 
no t a ffec t th e ir capac ity  to  reproduce.
P lac ing tr ich lo robenzenes  on the  skin o r the  eyes o f an im a ls  
p roduced trans ito ry  irrita tion.
It shou ld  be noted that, in genera l, an im a ls  have been exposed 
to cons ide rab ly  h igher am ounts  o f tr ich lo robenzenes  than  the  
am ounts  th a t hum ans can e ncoun te r in the  env ironm ent.
Cancer T here  are no s tud ies o f cance r in hum ans exposed to 
trich lo robenzenes.
M ice g iven 1 ,2 ,4 -trich lo robenzene  in the  food fo r 2 years 
deve loped  cance r o f the  liver.
The EP A  has sta ted  th a t 1 ,2 ,4 -trich lo robenzene  is not 
c lass ifiab le  as to hum an ca rc inogen ic ity . H ow ever, th is  w as 
based on s tud ies conducted  p rio r to  1990; new e r in form ation 
has not been eva luated.
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1.6 HOW CAN TRICHLOROBENZENES AFFECT CHILDREN?
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years o f age.
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Effects in children T here  are no s tud ies o f ch ild ren  exposed to  tr ich lo robenzenes.
Laboratory animals F o r the  m ost part, s tud ies in rats and m ice g iven 1 ,2 ,4-trich lo ro - 
benzene  during  p regnancy have not found adverse  e ffects  in 
th e ir pups at b irth o r la te r during the  g row ing period. H ow ever, 
a s tudy  in rats found lesions in the  eyes o f the  pups.
Breast milk T rich lo robenzenes  have been found in hum an breast m ilk, 
w h ich  m eans th a t m others  can tra n s fe r these  chem ica ls  to th e ir 
bab ies by nursing.
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO 
TRICHLOROBENZENES?
Avoid sources of T rich lo robenzenes  do not have w idesp read  use in consum er
trichlorobenzenes products  th a t are read ily  ava ilab le  to  the  genera l public.
H ow ever, 1 ,2 ,4 -trich lo robenzene  is often de tected  in air, w ater, 
and aqua tic  spec ies such as fish. The h ighest leve ls are 
typ ica lly  encoun te red  near fac ilities  th a t m anufactu re  and use 
trich lo robenzenes  and o the r ch lo rina ted  subs tances or 
hazardous w aste  s ites  at w h ich  these  substances m ay have 
been d isposed  of. A vo id ing  these  areas w ill reduce yo u r risk o f 
exposure  to tr ich lo robenzenes  and o the r chem ica ls.
A vo id ing  high consum ption  o f roo t c rops and fish liv ing in 
con tam ina ted  env ironm en ts  w ill reduce the risk o f exposure .
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1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 
TRICHLOROBENZENES?
Detecting exposure T rich lo robenzenes  can be m easured in blood and body fat, but 
the  tes ts  used are not rou tine ly  ava ilab le  in the  d o c to r’s office.
There  is not enough in fo rm ation  to de te rm ine  w h e th e r 
trich lo robenzenes  de tected  in yo u r body ind ica te  th a t you have 
been exposed recen tly  to  a high am oun t o r you are 
con tinuous ly  exposed to  low e r am ounts.
Measuring exposure D etecting  trich lo robenzenes  in yo u r body g ene ra lly  m eans tha t 
you w e re  exposed  to  these  com pounds. H ow ever, de tecting  
breakdow n products  o f tr ich lo robenzenes  m ay m ean tha t you 
w ere  exposed to trich lo robenzenes  o r th a t you w ere  exposed to 
o the r chem ica ls  th a t p roduce  the  sam e breakdow n products.
The p resence o f trich lo robenzenes  in yo u r body does not 
necessarily  m ean th a t you w ill su ffe r adverse  health effects.
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health. Regulations 
can be enforced by law. The EPA, the Occupational Safety and Health Administration (OSHA), and the 
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic 
substances. Recommendations provide valuable guidelines to protect public health, but cannot be 
enforced by law. The Agency for Toxic Substances and Disease Registry (ATSDR) and the National 
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop 
recommendations for toxic substances.
Regulations and recommendations can be expressed as “not-to-exceed” levels. These are levels o f a toxic 
substance in air, water, soil, or food that do not exceed a critical value. This critical value is usually based 
on levels that affect animals; they are then adjusted to levels that w ill help protect humans. Sometimes 
these not-to-exceed levels differ among federal organizations because they used different exposure times 
(an 8-hour workday or a 24-hour day), different animal studies, or other factors.
Recommendations and regulations are also updated periodically as more information becomes available. 
For the most current information, check with the federal agency or organization that provides it.
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Some regulations and recommendations for trichlorobenzenes include the following:
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Levels in drinking water set 
by EPA
The E P A  has de te rm ined  th a t exposure  to 1 ,2 ,4 -trich lo ro - 
benzene  and 1 ,3 ,5 -trich lo robenzene  in d rink ing  w a te r at 
concen tra tions  o f 0.1 and 0.6 m illig ram s per lite r (m g/L), 
respective ly , fo r 1 o r 10 days is not expected  to cause any 
adverse  e ffects in a child.
The E P A  has de te rm ined  th a t life tim e exposu re  to 0 .07 m g/L 
1 ,2 ,4 -trich lo robenzene  and 0 .04 m g/L 1 ,3 ,5 -trich lo robenzene  is 
not expected  to cause any adverse  effects.
EPA es tab lished  a m axim um  con tam inan t level (M C L) o f 
0 .07 m g/L fo r 1 ,2 ,4 -trich lo robenzene  in d rink ing  w ater.
Bottled water The FD A  has de te rm ined  th a t the  concen tra tion  o f 
1 ,2 ,4 -trich lo robenzene  in bottled d rink ing  w a te r shou ld  not 
exceed 0.7 m g/L.
1.10 WHERE CAN I GET MORE INFORMATION?
I f  you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below.
ATSDR can also tell you the location o f occupational and environmental health clinics. These clinics 
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous 
substances.
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You may 
request a copy o f the ATSDR ToxProfiles™ CD-ROM by calling the toll-free information and technical 
assistance number at I- 8 OO-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing 
to:
Agency for Toxic Substances and Disease Registry
Division o f Toxicology and Environmental Medicine
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Organizations for-profit may request copies o f final Toxicological Profiles from the following:
National Technical Information Service (NTIS) 
5285 Port Royal Road 
Springfield, VA 22161 
Phone: 1-800-553-6847 or 1-703-605-6000 
Web site: http://www.ntis.gov/
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2. RELEVANCE TO PUBLIC HEALTH
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO TRICHLOROBENZENES IN 
THE UNITED STATES
The manufacture and use of trichlorobenzenes as solvents, chemical intermediates, and dye carriers 
(Rossberg et al. 2006) has led to their release into the environment. Trichlorobenzenes may also be 
released into the environment indirectly from the degradation o f higher chlorinated benzenes 
(tetrachlorobenzene, pentachlorobenzene, and hexachlorobenzene) and the pesticide lindane 
(y-hexachlorocyclohexane). They may also be present as a minor impurity in other chlorinated 
substances and are formed unintentionally during the combustion o f organic materials when chlorine is 
present (for example during the incineration o f wastes containing polyvinyl chloride).
Trichlorobenzenes are volatile substances that are relatively persistent in the environment. They are 
expected to possess low mobility in soil and generally do not leach into groundwater except in the case of 
a large spill or their subsurface disposal at hazardous waste sites. Volatilization is considered an 
important environmental fate process in soils and water; however, their tendency to adsorb to soil and 
sediment may attenuate the rate o f volatilization. In the atmosphere, trichlorobenzenes degrade through 
their reaction with photochemically-generated hydroxyl radicals. The half-life for this reaction in air is 
approximately 16-38 days. In soil and water, trichlorobenzenes degrade slowly under aerobic conditions 
but undergo reductive dechlorination resulting in the formation o f mono- and dichlorobenzenes as 
degradation products under methanogenic conditions.
1,2,4-Trichlorobenzene is one o f 188 chemicals that is designated as a hazardous air pollutant (HAP) 
under the Clean A ir Act. Monitoring data from 2008 indicate that average atmospheric levels in the 
United States are typically less than 1 part per billion by volume (<1 ppbv); however, maximum levels 
above 3 ppbv have been observed. In atmospheric samples, 1,2,3- and 1,3,5-trichlorobenzene are 
detected less frequently than 1,2,4-trichlorobenzene since they have fewer uses and subsequently fewer 
direct emissions. Trichlorobenzenes are detected infrequently in groundwater unless a large spill occurs 
to a soil surface. Both 1,2,3- and 1,2,4-trichlorobenzene were monitored for, but not detected in, aquifer 
samples in a comprehensive survey conducted by the U.S. Geological Survey (USGS) o f volatile organic 
compounds in private and public groundwater wells used for drinking water. Neither isomer was detected 
in samples obtained from nearly 2,000 public and private wells across the United States. Municipal 
drinking water samples have occasionally been shown to contain low levels o f trichlorobenzenes at the
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parts per trillion levels. Trichlorobenzenes have been detected in fish and wildlife, particularly in the 
vicinity o f chemical manufacturing plants that produce chlorinated substances. They have also been 
detected in various food items. Leafy vegetables, fruits, milk, and eggs/meat purchased at grocery stores 
in Canada contained trichlorobenzene levels o f 0.11-0.40, 0.12-0.14, 0.14-1.2, and 0.70-0.74 ^g/kg, 
respectively.
The general population is exposed to trichlorobenzene from inhalation o f ambient air and ingestion of 
food and drinking water. In a European Union Risk Assessment Report for 1,2,4-trichlorobenzene, the 
total daily intake was calculated as 0.0715 mg/kg/day for the exposure scenario which yielded the highest 
estimated total daily intake for humans. The estimates suggest that the most important human intake 
routes are ingestion o f root crops, fish, and drinking water. Occupational exposure may occur through 
inhalation and dermal exposure where trichlorobenzenes are produced or used. Chapter 7 provides details 
o f analytical methods used to determine whether exposure to trichlorobenzenes has occurred; however, 
not enough data are available to determine what baseline levels are in human tissues.
2.2 SUMMARY OF HEALTH EFFECTS
There is very limited information regarding health effects in humans following exposure to 
trichlorobenzenes. A review o f the literature indicates that an adult male who inhaled trichlorobenzene 
for several hours during the repair o f a pump suffered massive hemoptysis (blood-stained sputum), and 
that some trichlorobenzene production workers developed chloroacne. There is also a case report of 
aplastic anemia in a woman with prolonged exposure through the soaking o f her husband’s work clothes 
in trichlorobenzene. None o f these reports provided exposure details or specified the isomer involved. 
Citing an unpublished source, the American Conference o f Governmental Industrial Hygienists (ACGIH) 
stated that minimal eye and throat irritation could occur in some people exposed to 3-5 ppm
1,2,4-trichlorobenzene. This information is insufficient to determine a clear target for trichlorobenzenes 
in humans. However, based on information from effects o f other chlorinated benzenes in humans, and 
from limited information on the metabolism o f 1,2,4-trichlorobenzene by microsomal preparations from 
human livers that indicated that cytochrome P-450 enzymes might be involved in the metabolism of 
trichlorobenzenes, it is reasonable to assume that excessive exposure to trichlorobenzenes could induce 
liver effects such as porphyria in humans.
Studies have been conducted in animals exposed to trichlorobenzenes by the inhalation, oral, and dermal 
routes. 1,2,4-Trichlorobenzene has been the most extensively studied o f the three trichlorobenzene
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isomers. Repeated inhalation studies in multiple species exposed to up to 100 ppm 1,2,4-trichlorobenzene 
showed the liver to be a target, and rats appeared to be more sensitive than other species. Liver effects 
consisted mostly o f increases in liver weight not accompanied by histological alterations. Exposure to 
30 or 100 ppm 1,2,4-trichlorobenzene also increased the urinary excretion o f porphyrins in rats. No target 
could be identified for 1,3,5-trichlorobenzene in rats in the only 13-week inhalation study located for this 
isomer. No inhalation data were located for 1,2,3-trichlorobenzene.
Trichlorobenzenes produced transitory irritation o f the skin o f animals when applied for short periods of 
time. As the duration o f exposure increases, the severity o f the effects also increases. Trichlorobenzenes 
also produced transitory eye irritation when instilled into the eyes o f rabbits for short periods of time.
Considerable more data are available in animals exposed orally to trichlorobenzenes. Significantly more 
information is available for 1,2,4-trichlorobenzene than for the other two isomers. Acute-, intermediate-, 
and chronic-duration studies showed that the liver and kidneys are targets for 1,2,4-trichlorobenzene in 
rats. The liver was also the target for 1,2,4-trichlorobenzene in mice in an intermediate-duration study. 
Liver changes included increases in the weight o f the organ and histological alterations consisting of 
periportal cytoplasmic eosinophilia and anisokaryosis (variation in size) o f hepatocellular nuclei in acute- 
duration studies in rats dosed with >150 mg/kg/day 1,2,4-trichlorobenzene or >300 mg/kg/day 1,2,3- or
1,3,5-trichlorobenzene. Liver necrosis was reported in a 10-day study in rats dosed with 500 mg/kg/day
1,2,4-trichlorobenzene. Moderate liver histopathology was reported in rats dosed with >49 mg/kg/day of 
the trichlorobenzene isomers for 90 days. Extending the duration o f exposure to 1,2,4-trichlorobenzene to 
2 years resulted in increased incidences o f various lesions including hepatocellular hypertrophy, focal 
cystic degeneration, and diffuse fatty change in rats. No chronic-duration studies were located with the 
other two trichlorobenzene isomers.
In addition to inducing morphological alterations in the liver, 1,2,4-trichlorobenzene has been shown to 
be a potent inducer o f phase I and phase II metabolic enzymes. In addition, in rats, 1,2,4-trichlorobenzene 
induces S-aminolevulinic acid (ALA) synthetase, the rate-limiting enzyme in the biosynthesis o f heme, 
which is consistent with the development o f porphyria in rats administered 1,2,4-trichlorobenzene.
Studies by Kato and coworkers have shown that both the induction o f drug-metabolizing enzymes and 
ALA synthetase are not due to 1,2,4-trichlorobenzene itself but to its metabolite, 2,3,5-trichlorophenyl 
methyl sulfone.
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Kidney lesions were observed in male rats dosed with 144 mg/kg/day 1,2,4-trichlorobenzene for 
13 weeks. The lesions consisted o f dilated tubules, granular casts, hyaline droplets, and papillary mineral 
deposition. Also increased was the incidence or severity o f interstitial nephritis and regenerative tubular 
epithelium. These lesions, particularly the hyaline droplets, are consistent with a a2|i-globulin 
nephropathy induced by a variety o f organic chemicals in male rats. Increased incidences o f transitional 
renal cell hyperplasia and renal papilla mineralization were reported in male rats dosed with
66.5 mg/kg/day 1,2,4-trichlorobenzene for 104 weeks. This is also consistent with the occurrence of 
male-specific nephropathy. None o f these lesions were seen in female rats or in mice. 1,3,5-Trichloro- 
benzene was also reported to induce renal lesions in rats in a 13-week study. The alterations were also 
consistent with the male-specific nephropathy and were characterized by eosinophilic inclusions, 
enlargement and anisokaryosis o f the epithelial lining cells, and hyperplasia o f renal tubular epithelial 
cells.
Less clear than the effects on the liver and on the kidneys o f male rats are reported alterations on the 
thyroid o f rats induced by trichlorobenzenes. The three trichlorobenzene isomers reportedly induced mild 
histological changes in the thyroid from pregnant female rats administered the chemicals on gestation 
days (Gd) 6-15 and sacrificed on Gd 22. The alterations occurred with doses >300 mg/kg/day and were 
characterized as reductions in follicle size and increased epithelial height accompanied by cytoplasmic 
vacuolization. Similar findings were reported in rats dosed with 78-82 mg/kg/day trichlorobenzenes for 
13 weeks. However, neither study showed the data or provided quantitative analyses o f the lesions that 
would have helped determine whether differences between dose groups were statistically significant. A 
13-week study in rats that used comparable doses and a 104-week study in rats that provided quantitative 
data did not report treatment-related histological alterations in the thyroid. Intermediate- and chronic- 
duration studies in mice also did not report histological changes in the thyroid. None o f these studies 
measured levels o f thyroid hormones or thyrotrophin (TSH) in blood.
1,2,4-Trichlorobenzene did not affect fertility in rats in a multi-generation reproductive study. None of 
the intermediate-duration oral, inhalation, or dermal studies conducted with trichlorobenzenes reported 
treatment-related histological alterations in the reproductive organs o f male and female animals. Most 
studies that examined whether 1,2,4-trichlorobenzene is a developmental toxicant reported negative 
results. The only effects reported were the presence o f microscopic alterations in the lenses o f the eye o f 
fetuses from rats treated with 150 mg/kg/day 1,2,4-trichlorobenzene on Gd 6-15 and sacrificed on Gd 22. 
However, no lesions were observed in fetuses from dams dosed with 75 or 300 mg/kg/day 1,2,4-trichloro­
benzene. This lesion was also observed in fetuses from dams dosed with 150, 300, or 600 mg/kg/day
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1,3,5-trichlorobenzene. Since no quantitative data were presented, it is not known whether the incidences 
were dose-related. The lesion was characterized as central areas o f cellular disorientation and 
disaggregation with ballooning and granular degeneration. Another gestational exposure study reported 
retarded development o f the fetuses from rats dosed with 360 mg/kg/day 1,2,4-trichlorobenzene on Gd 9­
13 and sacrificed on Gd 14. This dose level was lethal to two out o f nine dams and induced significant 
weight loss in dams that survived. In studies o f pregnant mice dosed with 0 or 130 mg/kg/day
1.2.4-trichlorobenzene on Gd 8-12, the chemical did not affect pup’s viability or growth or offspring’s 
locomotor activity or fertility to produce a second generation.
1.2.4-Trichlorobenzene did not significantly increase the incidence o f malignancies in rats fed a diet that 
provided up to 66.5 mg/kg/day to males or 81.4 mg/kg/day to females. However, it did increase the 
incidence o f hepatocellular carcinoma in mice fed a diet that provided >100.6 mg/kg/day to males and 
>127 mg/kg/day to females for 104 weeks. A dermal bioassay was also conducted with 1,2,4-trichloro­
benzene in mice. Tumors developed in the lungs, kidneys, stomach, urinary bladder, mammary gland, 
and skin in both treated and control groups. Several limitations o f this study rendered it inadequate for 
assessing the potential carcinogenicity o f 1,2,4-trichlorobenzene following dermal exposure. EPA 
classified 1,2,4-trichlorobenzene in Group D: not classifiable as to human carcinogenicity, or as a 
chemical for which there is “ Inadequate Information to Assess Carcinogenic Potential” according to the 
Guidelines for Carcinogen Risk Assessment. EPA’s classification was done in 1988 and was last revised 
in 1991. No cancer studies were available for 1,2,3-trichlorobenzene or 1,3,5-trichlorobenzene.
2.3 MINIMAL RISK LEVELS (MRLs)
Estimates o f exposure levels posing minimal risk to humans (MRLs) have been made for 
trichlorobenzenes. An MRL is defined as an estimate o f daily human exposure to a substance that is 
likely to be without an appreciable risk o f adverse effects (noncarcinogenic) over a specified duration o f 
exposure. MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of 
effect or the most sensitive health effect(s) for a specific duration within a given route o f exposure.
MRLs are based on noncancerous health effects only and do not consider carcinogenic effects. MRLs can 
be derived for acute, intermediate, and chronic duration exposures for inhalation and oral routes. 
Appropriate methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional
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uncertainties inherent in the application o f the procedures to derive less than lifetime MRLs. As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds o f health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs w ill be revised.
I n h a l a t i o n  M R L s
1 . 2 . 4 - T r i c h l o r o b e n z e n e
A c u t e - D u r a t i o n  M R L .  No relevant human data were located for 1,2,4-trichlorobenzene. The only data 
in animals is that exposure o f rats (2-4/sex) to >70 ppm for 6 hours caused lethargy and initial lacrimation 
(Gage 1970), and that exposure o f two rats to an average concentration o f 293 ppm o f 1,2,4-trichloro- 
benzene vapors 6 hours/day for 12 days did not cause gross or microscopic alterations in unspecified 
organs (E.I. Dupont 1971). This information is insufficient for MRL derivation.
I n t e r m e d i a t e - D u r a t i o n  M R L .  No relevant human data were located. Several intermediate-duration 
studies in various species are available. Continuous exposure o f cynomolgous monkeys (9 males/group), 
Sprague-Dawley rats (30 males/group) rats, or New Zealand rabbits (16 males/group) to 0, 25, 50, or
100 ppm 1,2,4-trichlorobenzene vapors did not result in significant gross or microscopic appearance of 
the major organs at termination or in significant deviations in hematology or clinical chemistry tests 
conducted at various times during the study (Coate et al. 1977). Exposure-related histopathological 
changes characterized as mild (only qualitative descriptions were provided) were observed in the liver and 
kidneys from rats usually after 4 or 13 weeks o f exposure, but not at week 26. Pulmonary function tests 
and operant behavior tests conducted in monkeys during the study were unremarkable. In another 
intermediate-duration study, exposure o f Sprague-Dawley rats (20 males/group), beagle dogs 
(2 males/group), and New Zealand rabbits (4 males/group) to 0, 30, or 100 ppm 1,2,4-trichlorobenzene 
vapors 5 days/week for a total o f 30 exposures did not result in gross or histological changes in any major 
tissues and organs, including the liver and kidneys (Kociba et al. 1981). Hematology and clinical 
chemistry tests also were unremarkable. The only significant changes in organ weights were an 11% 
increase in relative liver weight in rats and a 27-30% increase in absolute and relative liver weight in 
dogs. Increased urinary excretion o f porphyrins was reported in exposed rats, which the investigators 
attributed to hepatic enzyme induction by 1,2,4-trichlorobenzene. In yet an additional intermediate- 
duration earlier study, Alderley Park rats (2-4/sex/group) were exposed 6 hours/day to 20 ppm
1.2.4-trichlorobenzene vapors for 20 exposures or to 70 or 200 ppm for 15 exposures (Gage 1970).
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Exposure to 70 or 200 ppm 1,2,4-trichlorobenzene produced lacrimation and lethargy, presumably during 
exposures, although it was not explicitly stated, but did not induce histological alterations in the lung, 
liver, heart, intestines, adrenals, spleen, or thymus. Although there is suggestive evidence from some 
studies that the liver might be a target for 1,2,4-trichlorobenzene, inadequacies in the studies (no 
quantitative data, only a few animals tested) preclude derivation o f an intermediate-duration inhalation 
MRL for this isomer.
C h r o n i c - D u r a t i o n  M R L .  No chronic-duration inhalation studies were available in humans or animals for
1.2.4-trichlorobenzene; therefore, a chronic-duration inhalation MRL was not derived for this isomer.
1 , 2 , 3 - T r i c h l o r o b e n z e n e
No inhalation studies in humans or in animals were located for 1,2,3-trichlorobenzene; therefore, no 
inhalation MRLs were derived for this compound.
1 . 3 . 5 - T r i c h l o r o b e n z e n e
A c u t e - D u r a t i o n  M R L .  No pertinent information in humans was located for 1,3,5-trichlorobenzene. The 
only acute data in animals is that head-only exposure o f Sprague-Dawley rats (8/sex) for 60 minutes to 
1,209 ppm 1,3,5-trichlorobenzene vapors appeared to cause some irritation around the eyes (Jorgenson et 
al. 1976). No clinical signs or mortality occurred during 14 days after the exposure, but exposed males 
and females weighed 44 and 60%, respectively, less than unexposed control rats. Gross necropsy did not 
reveal compound-related alterations. This information is inadequate for MRL derivation.
I n t e r m e d i a t e - D u r a t i o n  M R L .  Only one intermediate-duration inhalation study was located for
1.3.5-trichlorobenzene. In this study, male and female CD rats (20/sex/group) were exposed to 0, 1.3, 13, 
or 130 ppm 1,3,5-trichlorobenzene vapors 6 hours/day, 5 days/week for 13 weeks (Sasmore et al. 1983).
A dried red material was often seen on the faces o f rats during exposures, including controls, although the 
incidence was noticeably higher in the 13 and 130 ppm groups. Exposure to 1,3,5-trichlorobenzene had 
no significant effect on body weight or on hematology or clinical chemistry tests conducted at 
termination. Methemoglobin was slightly higher at week 13 than at week 4, but according to the 
investigators, the values did not reach significant levels (data not shown). Urinalyses performed on 
samples collected on weeks 4 and 13 showed an apparent increase in porphyrins in male rats on week 13, 
but the large standard deviations rendered the differences with controls nonsignificant. Relative liver
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weight was significantly increased (11%) in male rats on week 4 but not at termination. At termination, a 
total o f 34 organs and tissues (not all specified) from the control and high-exposure group were examined 
microscopically, including the nasal passages. The only treatment-related histopathology was the 
presence o f squamous metaplasia and hyperplasia in the respiratory epithelium o f the nasal passages of 
three high-exposure rats (3/20); this incidence is not statistically significant from controls (0/20) as 
determined by the Fisher Exact Test. The lack o f clear effects precludes the use o f this study for MRL 
derivation. The study NOAELwas the highest exposure concentration tested, 130 ppm, but the true 
NOAEL may have been higher.
Chronic-Duration MRL. No chronic-duration inhalation studies were available for 1,3,5-trichloro- 
benzene; therefore, a chronic-duration inhalation MRL was not derived for this isomer.
Oral MRLs
1,2,4-Trichlorobenzene
Acute-Duration MRL. An acute-duration oral MRL was not derived for 1,2,4-trichlorobenzene due to 
inadequacies o f the data base. No relevant human data were located. Other than acute lethality studies, 
the animal database consists o f developmental studies in rats (Black et al. 1988; Kitchin and Ebron 1983) 
and mice (Chernoff and Kavlock 1983; Gray and Kavlock 1984; Gray et al. 1986) and two studies aimed 
mainly at evaluating the effects o f 1,2,4-trichlorobenzene on porphyrin metabolism (Rimington and 
Ziegler 1963), liver weight, and liver microsomal enzymes (Carlson and Tardiff 1976). These studies 
identified the liver as a target for 1,2,4-trichlorobenzene. In the study by Black et al. (1988), microscopic 
examination o f the major tissues and organs from the dams exposed on Gds 6-15 and sacrificed on Gd 22 
showed mild histological alterations in the liver and thyroid at doses o f 300 mg/kg/day but not 
150 mg/kg/day. However, the investigators provided only qualitative descriptions o f the histological 
changes; incidences o f lesions were not provided. Hemoglobin and hematocrit were decreased 6-7% in 
rats dosed with >150 mg/kg/day 1,2,4-trichlorobenzene relative to controls. This difference is not 
considered biologically significant since the values in treated rats were within the normal range. Rats 
dosed with 300 mg/kg/day 1,2,4-trichlorobenzene showed an 11% increase in relative liver weight; the 
investigators stated that absolute weight o f rats dosed with 300 mg/kg/day was significantly increased but 
did not provide the values for the control group, and therefore the magnitude o f the increase cannot be 
assessed. There were no significant effects on number o f pregnancies, fetal weight, litter size, number o f 
resorptions and dead fetuses, or incidences o f skeletal or visceral anomalies. The only developmental 
effect reported was the presence o f microscopic lesions in the lenses o f the eyes o f fetuses from dams
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treated with 150 mg/kg/day 1,2,4-trichlorobenzene; no such lesions were reported in groups dosed with 
75 or 300 mg/kg/day. This study is inadequate for MRL derivation due to the lack o f quantitative 
histology data, which precludes constructing dose-response relationships to determine points o f departure 
for the MRL.
In the other developmental study in rats, pregnant animals were administered 0, 36, 120, or 
360 mg/kg/day 1,2,4-trichlorobenzene on Gd 9-13 and were sacrificed on Gd 14 (Kitchin and Ebron 
1983). Rats that received the highest dose, 360 mg/kg/day, lost weight and had moderate hepatocellular 
hypertrophy (only the liver was examined microscopically); the no-observed-adverse-effect level 
(NOAEL) for these effects was 120 mg/kg/day. While doses o f 360 mg/kg/day did not increase 
resorptions or cause significant embryolethality or teratogenicity, they significantly retarded fetal 
development as measured by reduced head length, crown-rump length, somite number, and protein 
content. These end points were evaluated only in dams administered 360 mg/kg/day 1,2,4-trichloro­
benzene and controls, but not in groups dosed with 36 or 120 mg/kg/day 1,2,4-trichlorobenzene, which 
makes this study inadequate for MRL derivation because the NOAEL for weight loss and liver effects 
(120 mg/kg/day) may not be the NOAEL for retarded fetal development.
In the developmental studies in mice, pregnant mice were administered 0 or 130 mg/kg 1,2,4-trichloro­
benzene on Gd 8-12 (Chernoff and Kavlock 1983; Gray and Kavlock 1984; Gray et al. 1986). This 
treatment did not significantly affect offspring viability, reactive locomotor activity o f the pups evaluated 
at various times up to 200 days o f age, or reproductive performance o f the offspring to produce a second 
generation. The use o f only one dose level in these studies precludes constructing dose-response 
relationships for the end points measured. The lack o f reported effects also precludes using this study for 
MRL derivation.
Rimington and Ziegler (1963) reported increased liver microsomal enzyme activities, increased urinary 
excretion o f porphyrins, and also elevated levels o f porphyrins in the liver o f rats following daily gavage 
doses o f 500 mg/kg/day for 10 days. The limited scope and single dose level precludes considering this 
study for MRL derivation. Carlson and Tardiff (1976) administered 1,2,4-trichlorobenzene in doses o f 0,
10, 20, or 40 mg/kg/day to male rats by gavage in corn oil for 14 days. Sacrifices were conducted on 
day 15, and liver microsomal enzymes were analyzed. Blood was also collected for hemoglobin and 
hematocrit determinations. Sections o f the liver were also prepared for histological examination. 
Administration o f 1,2,4-trichlorobenzene resulted in dose-related increases in cytochrome c reductase, 
cytochrome P-450, glucuronyltransferase, EPN detoxification, and azoreductase. 1,2,4-Trichlorobenzene
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induced a dose-related increase in relative liver weight (all doses, 15% at the lowest dose, 28% at the 
highest dose). There were no significant effects on hemoglobin concentration or hematocrit. No specific 
information regarding liver histopathology was provided. Because the Carlson and Tardiff (1976) study 
is o f limited scope and provided no information regarding histology o f the liver, it is considered 
inadequate for MRL derivation.
• An MRL o f 0.1 mg/kg/day has been derived for intermediate-duration oral exposure (15­
364 days) to 1,2,4-trichlorobenzene.
No relevant intermediate-duration studies in humans were located. The intermediate-duration oral 
database for 1,2,4-trichlorobenzene consists o f two 3-month dietary studies in rats (CMA 1989; Côté et 
al. 1988), a 13-week dietary study in mice (Hiles 1989), two studies in rats aimed mainly at evaluating 
porphyrin metabolism and enzyme induction in the liver by 1,2,4-trichlorobenzene (Carlson and Tardiff 
1976; Rimington and Ziegler 1963), and a multi-generation reproductive study in rats (Robinson et al. 
1981). As a whole, these studies suggested that the liver and kidneys are targets for 1,2,4-trichloro­
benzene and that male rats may be more sensitive than females. Administration o f 730 mg/kg/day
1.2.4-trichlorobenzene (only dose level tested) by gavage to male albino rats caused intense necrosis and 
fatty change in the liver (only organ examined) and increased urinary porphyrins (Rimington and Ziegler 
1963). Treatment o f male albino rats via the diet with a much smaller dose, 40 mg/kg/day, increased 
relative liver weight (9-14%) and induced microsomal enzymes, but did not induce histological 
alterations in the liver (Carlson and Tardiff 1976).
In the multi-generation study, doses o f up to 33 mg/kg/day in males and 54 mg/kg/day in females (mean 
doses estimated by the investigators consumed by 83 days o f age F0 generation o f rats) did not affect 
fertility in the F0 or F1 generation or affect the time o f vaginal opening in F2 females (Robinson et al. 
1981). Treatment with 1,2,4-trichlorobenzene did not affect neonates' weight, litter size, or viability 
during the pre-weaning period in any generation. Post-weaning growth o f F1 rats was not affected by
1.2.4-trichlorobenzene. Tests for locomotor activity in the F1 or F2 generation rats were unremarkable. 
O f the organs weighed in the study (which included the liver and kidneys), only the adrenals were 
affected by 1,2,4-trichlorobenzene. Absolute weight o f the adrenals o f F0 and F1 males and females were 
significantly increased relative to controls (11-12% in F0 and 4-6% in F1); no histological evaluation of 
the glands was conducted. No histological damage was found in the livers and kidneys. Results from 
blood chemistry tests in F0 and F1 rats did not reveal any treatment-related alterations. The significance 
o f the increase in adrenals weight is unknown. EPA (IRIS 2010) states that a 1-month study was 
performed by the Agency in which five rats/group were dosed by gavage with 53 mg/kg/day
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1,2,4-trichlorobenzene in com oil. Microscopic examination o f the adrenals from treated rats showed 
moderate vacuolization o f the zona fasciculata; the control group showed only slight vacuolization. A 
14% increase in absolute adrenal gland weight and a 13% increase in relative adrenal weight were found. 
According to EPA (IRIS 2010, last revised 11/01/96), this study indicated that the increase in adrenal 
gland weight observed by Robinson et al. (1981) could be associated with vacuolization o f the zona 
fasciculata. Since these observations are not supported by results from an acute-duration study (Black et 
al. 1988), two 3-month studies (CMA 1989; Côté et al. 1988), or a 104-week dietary study in rats, all o f 
which conducted gross and microscopic evaluation o f the adrenals from rats, the biological significance 
o f the effects reported by Robinson et al. (1981) remains unclear. Since aside from the changes in 
adrenals weight, no adverse effect was identified in this multi-generation study, the study is considered 
inadequate for MRL derivation.
In the 13-week study in mice, groups o f B6C3Fj mice (10/sex/group) were administered a diet with 0, 
220, 3,850, or 7,700 ppm 1,2,4-trichlorobenzene (Hiles 1989). The diet provided doses o f 0, 67, 850, or 
1,222 mg/kg/day to males and 0, 86, 1,183, or 1,345 mg/kg/day to females. End points monitored 
included clinical signs twice daily, and body weight and food consumption weekly. Hematology and 
clinical chemistry tests were conducted at initiation and during week 14. At termination, gross necropsy 
was conducted, selected organs were weighed, and selected tissues were examined microscopically. The 
lungs, liver, and kidneys from all groups were examined; other organs from only the control and high­
dose groups were examined. Ophthalmologic examinations were conducted at initiation and termination. 
One control female and one high-dose female were accidentally killed during the study. Final body 
weight was significantly reduced in high-dose males (9%) and females (8.3%). Cumulative body weight 
gain was significantly reduced in low-dose males (27%), high-dose males (40%), and high-dose females 
(33%); these changes were associated with significant reductions in food consumption throughout the 
study. Significant, treatment-related alterations occurred only in the liver from males dosed with 
>850 mg/kg/day and females dosed with >1,183 mg/kg/day; the respective NOAELs were 67 and 
86 mg/kg/day. The lesions consisted o f hepatocellular cytomegaly with karyomegaly and hepatocellular 
atrophy and degeneration. The incidences in males and females were 0/10, 0/10, 10/10, and 10/10 and 
0/9, 0/10, 10/10, and 9/9, respectively.
One o f the 3-month studies in Sprague-Dawley rats that evaluated hematology, clinical chemistry, and 
histopathology o f the major organ and tissues reported histological alterations in the liver, kidneys, and 
thyroid in the various dose groups (doses ranged from 0.07 to 82 mg/kg/day in males and from 0.11 to
101 mg/kg/day in females) (Côté et al. 1988). However, the investigators provided only a qualitative
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description o f the results, such that dose-response relationships for the histological changes could not be 
constructed. In that study, high-dose males showed increases o f 13 and 20% in absolute and relative liver 
weight, respectively, and o f 31 and 36% in absolute and relative kidneys weight, respectively. 
Hematology and clinical chemistry tests were unremarkable. Because quantitative data regarding the 
histological effects were not presented, potential points o f departure for the MRL could not be identified 
and the study is considered inadequate for MRL derivation.
In the 3-month study conducted by CMA (1989), groups o f Fisher-344 rats (10/sex/group) were fed a diet 
containing 0, 200, 600, or 1,800 ppm 1,2,4-trichlorobenzene for 14 weeks; this diet provided doses o f 0,
14.6, 45.6, or 133.7 mg/kg/day for males and 0, 17.0, 52.5, or 150.6 mg/kg/day for females. End points 
monitored included clinical signs (daily), physical examination (weekly), ophthalmology (initiation and 
termination), body weight and food consumption (weekly), hematology and clinical chemistry 
(termination), gross necropsy (all rats at termination), selected organ weights, and histopathology o f all 
major organs and tissues o f the control and high-dose group and liver and kidney o f the low- and mid­
dose groups. Treatment with 1,2,4-trichlorobenzene did not affect survival rate. Clinical signs were 
limited to chromodacryorrhea and lacrimation, which occurred more frequently in treated groups, but 
without dose-response. The test for ocular abnormalities did not reveal compound-related effects. 
Administration o f 1,2,4-trichlorobenzene did not significantly affect body weight or weight gain. Food 
consumption was significantly higher in the mid- and high-dose groups than in controls. Significant 
hematological alterations consisted o f decreased mean erythrocyte count (5%), hemoglobin (7%), and 
hematocrit (5%) in males dosed with 133.7 mg/kg/day and decreased hemoglobin (4%) and hematocrit 
(4%) in females dosed with 150.6 mg/kg/day. These changes are within the normal range and are not 
considered biologically significant. Platelets were significantly increased (16%) in males dosed with
133.7 mg/kg/day; the clinical significance o f this finding is unclear; however, thrombocytosis is usually 
caused by a reaction to injury or inflammation. Significant clinical chemistry changes included elevated 
blood urea nitrogen (BUN) in high-dose males (12%) and females (20%), elevated total protein, albumin, 
and calcium in high-dose males, and lower serum aspartate aminotransferase (AST) activity in males 
dosed with 45.6 mg/kg/day (22%) and 133.7 mg/kg/day (28%). The elevated BUN was consistent with 
microscopic alterations in kidneys from male rats. The clinical significance o f the alterations in protein 
and calcium were unclear and the lower transaminase activity was not considered o f biological 
significance. Significant changes in organ weight included dose-related increases in absolute and relative 
liver weight in all treated male groups and in females dosed with 52.5 and 150.6 mg/kg/day, and 
increased absolute and relative kidney weight and absolute testes weight in males dosed with
133.7 mg/kg/day. No compound-related gross lesions were observed. Histological alterations were
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limited to the kidneys and liver. Kidney lesions were evident in males dosed with 45.6 and
133.7 mg/kg/day and consisted o f dilated tubules, granular casts, hyaline droplets, interstitial nephritis, 
and papillary mineral deposition. In the liver, centrilobular hepatocyte hypertrophy occurred in males 
dosed with 45.6 and 133.7 mg/kg/day (0/10, 0/10, 5/10, and 10/10) and in females dosed with
150.6 mg/kg/day (0/10, 0/10, 0/10, and 10/10). Liver changes were more prominent in males than in 
females.
Both the 14-week study in rats by CMA (1989) and the 13-week study in mice by Hiles (1989) evaluated 
a comprehensive number o f end points and presented the results in a manner useful for establishing dose- 
response relationships, and can potentially be used for MRL derivation.
Data sets o f centrilobular hepatocyte hypertrophy in male rats and relative liver weights in male and 
female rats (CMA 1989), as well as hepatocyte atrophy and degeneration in male mice (Hiles 1989) were 
analyzed using the benchmark dose (BMD) approach for MRL derivation. Data for renal effects in male 
rats were not considered for modeling due to the strong suggestive evidence that this may be a unique 
response o f the male rat and not relevant for human risk assessment (EPA 1991). Specific indications that 
this may be the case include the increased incidences o f hyaline droplets, granular casts, and tubule 
dilation, and the fact that none o f these lesions occurred in female rats. In addition, since there is not 
enough evidence to dissociate the interstitial nephritis from the male-specific nephropathy, interstitial 
nephritis was also not considered for modeling. In support o f this position is the fact that interstitial 
nephritis did not occur in female rats.
Models in the EPA Benchmark Software (BMDS version 2.1) were fit to the data sets for centrilobular 
hepatocyte hypertrophy in male rats and relative liver weights in male and female rats from the CMA 
(1989) study, as well as hepatocyte atrophy and degeneration in male mice from the Hiles (1989) study.
A benchmark response (BMR) o f 10% was selected in the absence o f data that would support a lower 
BMR. In accordance with EPA (2000a) guidance, BMDs and the lower-bound confidence limits on the 
BMDs (BMDLs) associated with an extra risk o f 10% are calculated for all models. For continuous data, 
in the absence o f a clear criteria as to what level o f change in organ weight should be considered adverse, 
the BMR was defined as a change in mean body weight gain equal to 1 standard deviation from the 
control mean (EPA 2000a). Adequate model fit is judged by three criteria: goodness-of-fit (p>0.1), 
visual inspection o f the dose-response curve, and scaled residual at the data point (except the control) 
closest to the predefined BMR. Among all o f the models providing adequate fit to the data, the BMDL 
from the model with the lowest Akaike’s Information Criterion (AIC) is chosen. None o f the models
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could provide an adequate fit for relative liver weight in female rats, but the lowest dose, 17.0 mg/kg/day, 
was a NOAEL. A summary o f the modeling results is presented in Table 2-1.
Although Table 2-1 shows that the BMDLiSD o f 9.41 mg/kg/day for relative liver weight would be a 
slightly more protective point o f departure for MRL derivation than the BMDLJ0 o f 14.35 mg/kg/day for 
hepatocyte hypertrophy in male rats, the latter is preferred as the point o f departure on the basis o f being a 
more biologically meaningful end point. The MRL is derived by dividing the BMDLJ0 of 
14.35 mg/kg/day for centrilobular hepatocyte hypertrophy by an uncertainty factor o f 100 (10 for animal 
to human extrapolation and 10 for human variability). This yields an intermediate-duration oral MRL of 
0.1 mg/kg/day for 1,2,4-trichlorobenzene. Detailed information regarding the modeling o f hepatocyte 
hypertrophy in male rats is presented in Appendix A. Note that rounding to one decimal place would give 
the same MRL i f  based on relative liver weight.
• An MRL o f 0.1 mg/kg/day has been derived for chronic-duration oral exposure (365 days or 
more) to 1,2,4-trichlorobenzene.
No relevant chronic data in humans exposed orally to 1,2,4-trichlorobenzene were located, but there are 
104-week dietary bioassays in rats (Moore 1994a) and in mice (Moore 1994b). In the study in rats, 
groups o f Fisher-344 rats (50/sex/group) were fed a diet containing 0, 100, 350, or 1,200 ppm
1.2.4-trichlorobenzene for 104 weeks. The diet provided doses o f 0, 5.6, 19.4, or 66.5 mg/kg/day
1.2.4-trichlorobenzene to males and 0, 6.9, 23.5, or 81.4 mg/kg/day 1,2,4-trichlorobenzene to females. 
Parameters evaluated included mortality (twice daily), clinical signs, body weight and food consumption 
(weekly for 16 weeks and every 4 weeks thereafter), hematology (week 52 and 78 for cellular 
morphology and leukocyte differential, from control and high-dose groups), organ weight (at termination, 
brain, brainstem, liver, kidneys, testes, and epididymis), and gross necropsy and histological examination 
o f all major organs and tissues at termination. Treatment with 1,2,4-trichlorobenzene resulted in a 
significant reduction in survival rate in males dosed with 66.5 mg/kg/day. Survival rate in the control,
5.6, 19.4, and 66.5 mg/kg/day males at week 104 were 84, 80, 84, and 60% respectively. There were no 
distinct or pronounced compound-related differences in clinical signs between treated and control groups. 
Differences in body weight between treated and control rats were <10% throughout the study. Food 
consumption was decreased 4-7% in treated groups relative to controls during the study. The only 
statistically significant hematology findings were a decrease in basophiles at week 52 and monocytes at 
week 105 in males dosed with 66.5 mg/kg/day, which the investigators considered minor. No evidence of 
leukemia was noted. Gross necropsy at termination showed increased incidence o f liver and kidney 
abnormalities in males dosed with 19.4 and 66.5 mg/kg/day and a slight increase in incidence o f uterine
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Relative liver weight (male rats)a 11.27 9.41 Linear
Hepatocyte hypertrophy (male rats)a 33.G9 14.35 Gamma
Hepatocyte atrophy and degeneration (male mice)b 220.61 58.94 Gamma
aCMA 1989 
bHiles 1989
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masses in treated females relative to controls; these changes were not discussed any further. Significant 
changes in organ weight were limited to an increase in absolute and relative liver weight in both male and 
female rats receiving the highest doses o f 1,2,4-trichlorobenzene and a decrease in absolute and relative 
testes weight in males dosed with 5.6 and 19.4 mg/kg/day. Treatment-related histological alterations 
were restricted to the liver o f males and females and to the kidneys o f males and consisted o f the 
following: hepatocellular hypertrophy, focal cystic degeneration, diffuse fatty change, transitional renal 
cell hyperplasia, and increased severity o f chronic rat nephropathy in males. Incidences o f liver lesions 
are presented in Table 2-2 (note that a smaller number o f animals from the low-dose groups were 
examined for histopathology).
The incidences o f transitional cell hyperplasia in the kidneys o f male rats were as follows: 2/50, 0/19, 
2/50, and 34/50 in males dosed with 0, 5.6, 19.4, and 66.5 mg/kg/day 1,2,4-trichlorobenzene, 
respectively. Since there is strong evidence from the 14-week study (CMA 1989) suggesting that the 
renal lesions in male rats may represent a male-specific response not relevant for MRL derivation and that 
renal cell hyperplasia reported in the 104-week study is a typical response seen in the male rat 
nephropathy, renal cell hyperplasia is not considered any further as a potential end point for MRL 
derivation.
In the study in mice, groups o f B6C3Fi mice (50/sex/group) were fed a diet containing 0, 150, 700, or 
3,200 ppm 1,2,4-trichlorobenzene for 104 weeks (Moore 1994b). The diet provided doses o f 0, 21, 100.6, 
or 519.9 mg/kg/day 1,2,4-trichlorobenzene to males and 0, 26.3, 127, or 572.6 mg/kg/day 1,2,4-trichloro- 
benzene to females. End points monitored were the same as in the study in rats described above (Moore 
1994a). The liver was the target for 1,2,4-trichlorobenzene in mice. The most significant effect was an 
increase incidence o f hepatocellular carcinoma in mid- and high-dose mice (8/50, 5/50, 27/50, and 50/50 
in males and 1/50, 1/50, 28/50, and 46/50 in females). Centrilobular hepatocytomegaly was also 
significantly increased in mid- and high-dose males (0/50, 0/50, 27/50, and 20/50). Since non-neoplastic 
effects were observed only at higher doses than in rats and carcinoma occurred at that same dose level, 
this study w ill not be considered any further for MRL derivation.
Table 2-2 shows that: (1) diffuse fatty change was significantly increased in males and females only at 
the highest dose; (2) focal cystic degeneration occurred at lower incidence in the low- and mid-dose males 
compared to controls, and was significantly increased only at the highest dose; (3) hepatocellular 
hypertrophy in female rats occurred at increased frequency only at the highest dose; and (4) only
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M ales
D ose (m g/kg /day) 0 5.6 19.4 66.5
H epa toce llu la r hype rtrophy 2 /50 (4% ) 1/26 (3.8% ) 5/50 (10% ) 30/50 (60% )
Focal cys tic  degenera tion 9/50 (18% ) 3/26 (11.5% ) 4 /50 (8% ) 19/50 (38% )
D iffuse  fa tty  change 5/50 (10% ) 3/26 (11.5% ) 5/50 (10% ) 14/50 (28% )
Fem ales
D ose (m g/kg /day) 0 6.9 23.5 81.4
H epa toce llu la r hype rtrophy 6 /50 (12% ) 5/25 (20% ) 5/50 (10% ) 37/50 (74% )
D iffuse  fa tty  change 15/50 (30% ) 6/25  (24% ) 21 /50  (42% ) 30/50 (60% )
Source: Moore 1994a
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hepatocellular hypertrophy in male rats exhibited dose-response characteristics. Based on these facts, 
only the hepatocellular hypertrophy in male rats was considered for MRL derivation.
Models in the EPA Benchmark Software (BMDS version 2.1) were fit to the data set for hepatocellular 
hypertrophy in the liver o f male rats. A BMR of 10% was selected in the absence o f data that would 
support a lower BMR. In accordance with EPA (2000a) guidance, BMDs and BMDLs associated with an 
extra risk o f 10% are calculated for all models. Adequate model fit is judged by three criteria: goodness- 
o f-fit (p>0.1), visual inspection o f the dose-response curve, and scaled residual at the data point (except 
the control) closest to the predefined BMR. Among all o f the models providing adequate fit to the data, 
the BMDL from the model with the lowest AIC is chosen. The Multistage (2-degree) model provided the 
best fit for the data yielding a BMDJ0 o f 23.25 mg/kg/day and a corresponding BMDLJ0 of 
13.33 mg/kg/day.
The MRL is derived by dividing the BMDL10 o f 13.33 mg/kg/day for hepatocellular hypertrophy in male 
rats by an uncertainty factor o f 100 (10 for animal to human extrapolation and 10 for human variability). 
This yields a chronic-duration oral MRL o f 0.1 mg/kg/day for 1,2,4-trichlorobenzene. Detailed 
information regarding the modeling o f hepatocellular hypertrophy in male rats is presented in 
Appendix A.
1,2,3-Trichlorobenzene
Acute-Duration MRL. An acute-oral MRL for 1,2,3-trichlorobenzene was not derived due to inadequacy 
o f the available data. No human data were located for 1,2,3-trichlorobenzene. Only one acute-duration 
oral animal study was located for 1,2,3-trichlorobenzene. In that study, pregnant Sprague-Dawley rats 
(14/group) were administered 0, 150, 300, or 600 mg/kg/day 1,2,3-trichlorobenzene by gavage in corn oil 
on Gd 6-15 (Black et al. 1988). The dams were sacrificed on Gd 22 and the uterus and ovaries were 
removed. Dams were reweighed and the internal organs were weighed. In addition, blood was collected 
for hematology and clinical chemistry tests. Fetuses were examined grossly for birth defects and skeletal 
and visceral anomalies. Fetuses were also preserved for histological examinations. The major organs and 
tissues from the dams were examined microscopically. There were no treatment-related deaths and no 
clinical signs, but mean body weight o f the high-dose group tended to be lower (data not shown). Organ 
weights were not significantly affected. Hemoglobin was reduced in the 300 and 600 mg/kg/day groups 
(6-7%) and hematocrit was reduced (~6%) in the 600 mg/kg/day groups. Given the magnitude o f these 
hematological changes, the effects are not considered biologically significant since the values are within
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the normal range. No significant clinical chemistry effects were reported. Reported histological changes 
were limited to the kidneys, liver, and thyroid. However, the investigators provided only a qualitative 
description o f the results; incidences o f lesions were not provided. There were no significant effects on 
number o f pregnancies, fetal weight, litter size, number o f resorptions and dead fetuses, or incidences of 
skeletal or visceral anomalies. Histological examination o f the fetuses did not reveal treatment-related 
alterations. The lack o f a quantitative presentation o f the results o f the histological examination o f the 
maternal tissues renders this study inadequate for MRL derivation because o f the inability to inspect dose- 
response relationships.
Intermediate-Duration MRL. No intermediate-duration oral MRL was derived for 1,2,3-trichloro­
benzene. No relevant human data were located. Only one intermediate-duration study was available for 
this compound (Côté et al. 1988). In that study, groups o f Sprague-Dawley rats (10/sex/group) were fed a 
diet containing 0, 1, 10, 100, or 1,000 ppm 1,2,3-trichlorobenzene for 13 weeks. This diet provided doses 
o f 0, 0.08, 0.78, 7.6, 78 mg/kg/day 12,3-trichlorobenzene to males and 0, 0.13, 1.3, 12, or 113 mg/kg/day 
to females. End points evaluated included body weight (weekly), food consumption (weeks 1, 4, 8, 12), 
urinalysis (weeks 4, 8, 12), and clinical signs (daily). A t termination, the rats were necropsied and blood 
was collected for hematological and clinical chemistry testing. Hepatic microsomal aniline hydroxylase 
(AH), aminopyrine demethylase (APDM) activities, and liver protein content were also determined. Bone 
marrow from the femur was aspirated for cytological evaluation. A ll major tissues and organs were 
prepared for microscopic examination. There were no treatment-related deaths. Food consumption was 
not affected; body weight gain from high-dose males was reduced 10.2% relative to controls (only data 
for males shown). There were no significant alterations in hematology or clinical chemistry parameters, 
and urinalyses were unremarkable. No significant gross changes in tissues were reported. Statistically 
significant changes in organs weight were limited to increases in relative liver weight (14%) in males 
dosed with 78 mg/kg/day and in relative kidney weight in males dosed with 0.08 mg/kg/day (14%),
0.78 mg/kg/day (14%), and 78 mg/kg/day (21%). 1,2,3-Trichlorobenzene had no significant effect on the 
hepatic mixed function oxidase activities measured. For the most part, compound-related histopathology 
was reported as mild and was limited to the liver and thyroid o f generally high-dose rats and appeared to 
be more severe in males. However, the investigators provided only a qualitative description o f the 
histological examinations; incidences o f lesions were not presented. In the liver, most treated groups 
showed mild-to-moderate increases in cytoplasmic volume and anisokaryosis o f hepatocytes, mostly in 
perivenous and midzone areas. High-dose rats showed mild aggregated basophilia as well as mild 
widespread midzonal vacuolization due to fatty infiltration. Changes in the thyroid consisted o f reduction 
in follicular size, increased epithelial height from flattened cuboidal cells to columnar shape, and reduced
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colloid density. Changes in the high-dose group varied from mild to moderate. The urinalyses were 
unremarkable. Since no dose-responses can be constructed with the histological data and since the 
increases in relative kidney weight in males were not accompanied by any histological changes, this study 
is considered inadequate for use as basis for MRL derivation.
Chronic-Duration MRL. No chronic-duration oral data in humans or in animals were located for
1,2,3-trichlorobenzene. Therefore, a chronic-duration oral MRL was not derived for this compound.
1.3.5-Trichlorobenzene
Acute-Duration MRL. No acute-duration oral MRL was derived for 1,3,5-trichlorobenzen due to 
inadequacies o f the database. No relevant human data were located. The acute-duration oral database for
1.3.5-trichlorobenzene in animals is limited to information regarding acute lethal doses (Côté et al. 1988; 
Jorgenson et al. 1976) and a developmental study in rats (Black et al. 1988). In the developmental study, 
pregnant Sprague-Dawley rats (14/group) were administered 0, 150, 300, or 600 mg/kg/day
1.3.5-trichlorobenzene by gavage in corn oil on Gd 6-15. The dams were sacrificed on Gd 22 and the 
uterus and ovaries were removed. Dams were reweighed and the internal organs were also weighed. 
Blood was collected for hematology and clinical chemistry tests. Fetuses were examined grossly for birth 
defects and skeletal and visceral anomalies. Fetuses were also preserved for histological evaluations.
The major organs and tissues from the dams were examined microscopically. There were no treatment- 
related deaths. There were no clinical signs, but mean maternal body weight gain in the high-dose group 
was 34% lower than controls. Food consumption data were not provided. Significant increases in 
relative liver weight were observed at 300 and 600 mg/kg/day (9 and 25%, respectively); the investigators 
also stated that absolute liver weights from rats in the 300 and 600 mg/kg/day groups were significantly 
increased but did not provide the values for the control group, and therefore, the magnitude o f the changes 
cannot be assessed. Hemoglobin and hematocrit were reduced in the 600 mg/kg/day group (10-11%). 
This is not considered a biologically significant change since it is still within the normal range. Maternal 
histological changes were restricted to the kidneys, liver, and thyroid. However, only a qualitative 
description o f the histological changes was provided; incidences o f lesions were not presented. There 
were no significant effects on the number o f pregnancies, fetal weight, litter size, number o f resorptions 
and dead fetuses, or incidences o f skeletal and visceral abnormalities. However, histological examination 
o f the fetuses showed lesions in the lenses o f the eyes o f pups from all treated groups (150, 300, and
600 mg/kg/day). These changes consisted of central areas of cellular disorientation and disaggregation
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with ballooning and granular degeneration. The lack of quantitative histology data precludes the use of 
this study for MRL derivation.
Intermediate-Duration MRL. An intermediate-duration oral MRL for 1,3,5-trichlorobenzene was not 
derived due to inadequacy o f the database. No relevant human studies were located. Only one 
intermediate-duration oral study in animals was available for 1,3,5-trichlorobenzene. In that study, 
groups o f Sprague-Dawley rats (10/sex/group) were fed a diet containing 0, 1, 10, 100, or 1,000 ppm
1,3,5-trichlorobenzene for 13 weeks (Côté et al. 1988). This diet provided doses o f 0, 0.08, 0.81, 7.7, and 
82 mg/kg/day for males and 0, 0.13, 1.5, 17, and 146 mg/kg/day for females. End points evaluated 
included body weight (weekly), food consumption (weeks 1, 4, 8, 12), urinalysis (weeks 4, 8, 12), and 
clinical signs (daily). A t termination, the rats were necropsied and blood was collected for hematological 
and clinical chemistry testing. Hepatic microsomal AH, APDM activities, and liver protein content were 
also determined. Bone marrow from the femur was aspirated for cytological evaluation. A ll major 
tissues and organs were prepared for microscopic examination. Gross observations did not reveal any 
significant treatment-related alterations. Significant changes in organs weight were limited to an increase 
in relative liver weight in males dosed with 82 mg/kg/day (11%), an increase in absolute kidney weight in 
males dosed with 0.81 and 7.7 mg/kg/day (~20%), and increases in relative kidney weight in males dosed 
with 0.81 (14%), 7.7 (25%), and 82 mg/kg/day (14%). There were no significant alterations in 
hematology or clinical chemistry parameters. 1,3,5-Trichlorobenzene had no significant effect on AH and 
APDM activities. For the most part, compound-related histopathology was mild and was limited to the 
liver, thyroid, and kidneys, generally high-dose rats, and appeared to be more severe in males. However, 
the investigators only provided a qualitative description of the histological changes; incidences of lesions 
were not presented. In the liver, most treated groups showed mild-to-moderate increase in cytoplasmic 
volume and anisokaryosis o f hepatocytes mostly in perivenous and midzone areas. High-dose rats 
showed aggregated basophilia as well as widespread midzonal vacuolization due to fatty infiltration. 
Changes in the thyroid consisted of reduction in follicular size, increased epithelial height from flattened 
cuboidal cells to columnar shape, and reduced colloid density. Changes in the high-dose group varied 
from mild to moderate. Changes in the kidneys were characterized by eosinophilic inclusion, 
enlargement and anisokariosis of the epithelial lining cells, and hyperplasia of renal tubular epithelial 
cells. Only the changes associated with the high-dose diet were considered to be biologically significant 
by the investigators. Since no dose-responses can be constructed with the histological data and increases 
in relative kidneys weights in males did not coincide with biologically significant histological changes, 
this study is inadequate for use as the basis for MRL derivation.
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Chronic-Duration MRL. No chronic-duration oral data in humans or animals were located for
1,3,5-trichlorobenzene; therefore, a chronic-duration oral MRL was not derived for this compound.
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3.1 INTRODUCTION
The primary purpose o f this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology o f trichlorobenzenes. 
It contains descriptions and evaluations o f toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance o f toxicity and toxicokinetic data to public health.
A glossary and list o f acronyms, abbreviations, and symbols can be found at the end o f this profile.
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE
To help public health professionals and others address the needs o f persons living or working near 
hazardous waste sites, the information in this section is organized first by route o f exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects). These data are discussed in terms o f three exposure 
periods: acute (14 days or less), intermediate (15-364 days), and chronic (365 days or more).
Levels o f significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest- 
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels o f exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear. ATSDR acknowledges that a 
considerable amount o f judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there w ill be 
insufficient data to decide whether the effect is indicative o f significant dysfunction. However, the 
Agency has established guidelines and policies that are used to classify these end points. ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users o f the profiles to identify levels o f exposure at which 
major health effects start to appear. LOAELs or NOAELs should also help in determining whether or not
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the effects vary with dose and/or duration, and place into perspective the possible significance o f these 
effects to human health.
The significance o f the exposure levels shown in the Levels o f Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective. Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels o f exposure 
associated with more subtle effects in humans or animals or exposure levels below which no adverse 
effects have been observed. Estimates o f levels posing minimal risk to humans (Minimal Risk Levels or 
MRLs) may be o f interest to health professionals and citizens alike.
A User's Guide has been provided at the end o f this profile (see Appendix B). This guide should aid in 
the interpretation o f the tables and figures for Levels o f Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure
3.2.1.1 Death
No studies were located regarding death in humans and/or animals after inhalation exposure to 
trichlorobenzenes.
3.2.1.2 Systemic Effects
There is very limited information regarding health effects in humans following exposure to 
trichlorobenzenes. A  review o f the literature indicates that an adult male who inhaled trichlorobenzene 
for several hours during the repair o f a pump suffered massive hemoptysis, and that some 
trichlorobenzene production workers developed chloroacne (IPCS 1991). There is also a case report of 
aplastic anemia in a woman with prolonged exposure through the soaking o f her husband’s work clothes 
in trichlorobenzene (Girard et al. 1969). None o f these reports provided exposure details or specified the 
isomer involved. Citing an unpublished source, ACGIH (2001) states that minimal eye and throat 
irritation could occur in some people exposed to 3-5 ppm 1,2,4-trichlorobenzene.
No information was located regarding systemic effects in animals following inhalation exposure to
1,2,3 -trichlorobenzene.
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The highest NOAEL values and all LOAEL values o f 1,2,4-trichlorobenzene and 1,3,5-trichlorobenzene 
from each reliable study for systemic effects in each species and duration category are recorded in 
Tables 3-1 and 3-2 and plotted in Figures 3-1 and 3-2.
Respiratory Effects. Continuous exposure o f male cynomolgous monkeys to up to 100 ppm
1.2.4-trichlorobenzene vapors for 26 weeks had no significant effect on results o f pulmonary function 
tests (static compliance, diffusion capacity, distribution o f ventilation, and lung volumes) conducted in 
anesthetized monkeys at termination (Coate et al. 1977). Measurements o f mechanical properties o f the 
lungs conducted in unanesthetized monkeys also were not significantly affected by exposure to
1.2.4-trichlorobenzene. Histological examination o f the lungs showed no treatment-related effects.
Continuous exposure o f male rats to up to 100 ppm 1,2,4-trichlorobenzene vapors for up to 26 weeks did 
not induce significant histological alterations in the lungs (Coate et al. 1977). Similar results were 
reported in rats exposed to up to 200 ppm 1,2,4-trichlorobenzene vapors 6 hours/day for 15 exposures 
(Gage 1970) or in male rats exposed 7 hours/day, 5 days/week to up to 100 ppm 1,2,4-trichlorobenzene 
vapors for a total o f 30 exposures (Kociba et al. 1981). Two intermediate-duration studies in rabbits 
exposed to up to 100 ppm 1,2,4-trichlorobenzene vapors continuously (Coate et al. 1977) or intermittently 
(Kociba et al. 1981) also reported no significant alterations in the lungs upon microscopic examination. 
Similar results were reported in dogs following intermittent intermediate-duration exposure to up to 
100 ppm 1,2,4-trichlorobenzene (Kociba et al. 1981). The nasal mucosa was also examined in rats and 
rabbits in the Kociba et al. (1981) study.
The only information regarding 1,3,5-trichlorobenzene is from a study in male and female CD rats in 
which the animals were exposed 6 hours/day, 5 days/week for 13 weeks (Sasmore et al. 1983). Exposure 
to up to 130 ppm 1,3,5-trichlorobenzene vapors did not induce significant histological alterations in the 
lungs, trachea, or nasal passages.
Cardiovascular Effects. Continuous exposure o f male monkeys, rats, or rabbits up to 100 ppm
1.2.4-trichlorobenzene vapors for 26 weeks did not induce significant gross or microscopic alterations in 
the heart (Coate et al. 1977). Exposure o f male rats, dogs, and rabbits to up to 100 ppm 1,2,4-trichloro­
benzene vapors 7 hours/day, 5 days/week for a total of 30 exposures during a 40-day period did not 
induce significant gross or microscopic alterations in the heart or aorta (Kociba et al. 1981).
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Table 3-1 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Inhalation (continued)
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Table 3-1 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Inhalation (continued)
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Table 3-1 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Inhalation (continued)
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Table 3-1 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Inhalation (continued)
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Table 3-2 Levels o f S ignificant Exposure to 1,3,5-Trichlorobenzene - Inhalation
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Table 3-2 Levels o f S ignificant Exposure to 1,3,5-Trichlorobenzene - Inhalation (continued)






















130 Sasmore et al. 1983 
1,3,5-Trichlorobenzene
NOAEL is for 
histopathology of 
reproductive organs
a The number corresponds to entries in Figure 3-2.
Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; Gastro = gastrointestinal; Hemato = hematological; hr = hour(s); LOAEL = 









































c-Cat -Humans f-Ferret n-Mink Cancer Effect Level-Animals Cancer Effect Level-Humans ■  LD50/LC50
d-Dog k-Monkey j-Pigeon o-Other LOAEL, More Serious-Animals LOAEL, More Serious-Humans
r-Rat m-Mouse e-Gerbil LOAEL, Less Serious-Animals LOAEL, Less Serious-Humans
p-Pig h-Rabbit s-Hamster NOAEL - Animals NOAEL - Humans
q-Cow a-Sheep g-Guinea Pig Cancer

































































n-Mink Cancer Effect Level-Animals
o-Other LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals 
NOAEL - Animals
Cancer Effect Level-Humans 
LOAEL, More Serious-Humans 
LOAEL, Less Serious-Humans 
NOAEL - Humans
LD50/LC50 


























Exposure o f rats to up to 130 ppm 1,3,5-trichlorobenzene vapors 6 hours/day, 5 days/week for 13 weeks 
did not induce histological changes in the heart (Sasmore et al. 1983).
Gastrointestinal Effects. Exposure o f male rats, dogs, and rabbits to up to 100 ppm 1,2,4-trichloro- 
benzene vapors 7 hours/day, 5 days/week for a total of 30 exposures during a 40-day period did not 
induce significant gross or microscopic alterations in the gastrointestinal tract (Kociba et al. 1981).
Similar results were reported for the gastrointestinal tract o f rats exposed to up to 130 ppm
1,3,5-trichlorobenzene vapors 6 hours/day, 5 days/week for 13 weeks (Sasmore et al. 1983).
Hematological Effects. Complete blood counts performed on male monkeys, rats, and rabbits 
exposed continuously to up to 100 ppm 1,2,4-trichlorobenzene vapors for up to 26 weeks did not show 
any significant exposure-related differences from controls (Coate et al. 1977). Kociba et al. (1981) 
reported no significant alterations in total red blood cells, total differential leukocytes, packed cell volume 
or hemoglobin concentration in blood samples from male rats, rabbits, and dogs following 30 intermittent 
exposures to up to 100 ppm 1,2,4-trichlorobenzene vapors.
Exposure o f rats to up to 130 ppm 1,3,5-trichlorobenzene 6 hours/day, 5 days/week for 13 weeks did not 
significantly alter blood cell counts and mean corpuscular values, differential counts, or platelet counts 
(Sasmore et al. 1983). Methemoglobin was slightly higher at 13 weeks than at 4 weeks, but values did 
not reach significant levels (data not shown).
Musculoskeletal Effects. No significant alterations were reported in skeletal muscle from male rats, 
rabbits, and dogs following 30 intermittent exposures to up to 100 ppm 1,2,4-trichlorobenzene vapors 
(Kociba et al. 1981).
In the 13-week inhalation study with 1,3,5-trichlorobenzene (Sasmore et al. 1983), there is no explicit 
indication that musculoskeletal tissues were examined, although the investigators stated that 34 specific 
organs and tissues from the control and the high-exposure groups (130 ppm) were examined 
microscopically. Therefore, it is reasonable to assume that evaluations were conducted and that no 
alterations were observed.
Hepatic Effects. Continuous exposure o f male monkeys or rabbits to up to 100 ppm 1,2,4-trichloro- 
benzene vapors for 26 weeks did not induce significant gross or microscopic alterations in the liver (Coate
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et al. 1977). However, exposure-related liver changes were described in rats (only qualitative description 
provided). The changes were characterized as mild and were seen in all exposed groups (25, 50,
100 ppm) usually after 4 and 13 weeks but not at 26 weeks. Hepatocytomegaly occurred in all exposed 
groups but seemed more noticeable in the mid- and high-exposure groups. There was also a slight 
increase in the degree o f vacuolization o f hepatocytes in exposed rats that did not appear dose-related. 
Hepatocytomegaly was present in all exposed groups at 4 weeks and in the mid- and high-exposure 
groups at 13 weeks. Exposed rats also showed a slight increase in incidence o f granuloma at 4 weeks, 
which did not appear to be dose-related. No histological alterations were reported in the liver from rats 
following 15 exposures to 200 ppm 1,2,4-trichlorobenzene each lasting 6 hours (Gage 1970).
Changes in liver weight were reported in rats, dogs, and rabbits exposed to 100 ppm 1,2,4-trichloro­
benzene vapors 7 hours/day, 5 days/week for a total o f 30 exposures during a 44-day period (Kociba et al. 
1981). These changes were not accompanied by histological alterations or alterations in clinical 
chemistry tests for liver function. In rats, relative liver weight increased 11% relative to controls. 
Urinalyses conducted after 15 and 30 days o f exposure showed statistically significant increased 
coproporphyrins and uroporphyrins in both the low- (30 ppm) and high-dose rats (100 ppm), which the 
investigators attributed to the ability o f 1,2,4-trichlorobenzene to induce hepatic microsomal enzymes 
rather than to induce destruction o f heme-containing cytochromes or inhibition o f heme synthesis. In 
dogs, both absolute and relative liver weights were increased (27-30%). In rabbits, relative liver weight 
was decreased 16% relative to controls. Urinary porphyrins levels were not examined in dogs or rabbits.
Exposure o f rats to up to 130 ppm 1,3,5-trichlorobenzene vapors 6 hours/day, 5 days/week for 13 weeks 
did not significantly affect liver weight or the gross or microscopic appearance o f the liver (Sasmore et al. 
1983). Urinary porphyrin levels were elevated in males at 13 weeks, but large variability rendered the 
differences with controls nonsignificant.
Renal Effects. Continuous exposure o f male monkeys or rabbits to up to 100 ppm 1,2,4-trichloro- 
benzene vapors for 26 weeks did not induce significant gross or microscopic alterations in the kidneys 
(Coate et al. 1977). Male rats exposed in a similar manner showed kidney changes characterized as mild 
and present in all exposed groups usually after 4 and 13 weeks but not at 26 weeks o f exposure (only a 
qualitative description was provided). Exposed male rats showed hyaline degeneration in the inner zone 
o f the cortex, which appeared more severe at 4 weeks but was not dose-related; severity appeared 
increased at 13 weeks in high-dose rats. No histological alterations were reported in the kidneys from rats 
following 15 exposures to 200 ppm 1,2,4-trichlorobenzene each lasting 6 hours (Gage 1970), or in the
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kidneys from rats, rabbits, and dogs exposed to up to 100 ppm 1,2,4-trichlorobenzene vapors 7 hours/day, 
5 days/week for 30 exposures during a 44-day period (Kociba et al. 1981).
Exposure o f rats to up to 130 ppm 1,3,5-trichlorobenzene vapors 6 hours/day, 5 days/week for 13 weeks 
did not result in significant gross or microscopic alterations in the kidneys (Sasmore et al. 1983).
Endocrine Effects. Fifteen 6-hour exposures to up to 200 ppm 1,2,4-trichlorobenzene vapors did not 
induce significant gross or histological alterations in the adrenal glands from rats (Gage 1970). Exposure 
o f rats, dogs, and rabbits to up to 100 ppm 1,2,4-trichlorobenzene vapors 7 hours/day, 5 days/week for a 
total o f 30 exposures did not induce significant gross or microscopic alterations in the pituitary gland, 
adrenal gland, thyroid, or parathyroid (Kociba et al. 1981).
In the 13-week study o f rats exposed intermittently to up to 130 ppm 1,3,5-trichlorobenzene vapors, the 
investigators stated that 34 organs were examined in the control and high-dose groups but did not specify 
the organs (Sasmore et al. 1983). However, there is mention that hemosiderosis was noted in the thyroid 
gland, which, by the distribution and nature in the different groups, appeared unrelated to the treatment.
It seems reasonable to assume that other endocrine glands were also examined and that no alterations 
were observed.
Dermal Effects. Continuous exposure o f male monkeys, rats, and rabbits to up to 100 ppm
1,2,4-trichlorobenzene vapors for 26 weeks did not induce significant gross or microscopic alterations in a 
section o f abdominal skin that was examined (Coate et al. 1977).
No relevant data were located regarding 1,3,5-trichlorobenzene.
Ocular Effects. Gage (1970) reported that lacrimation occurred in rats initially during the 6-hour 
exposures to 70 ppm 1,2,4-trichlorobenzene but not during exposures to 20 ppm 1,2,4-trichlorobenzene. 
Continuous exposure o f male monkeys, rats, or rabbits to up to 100 ppm 1,2,4-trichlorobenzene vapors 
for 26 weeks did not induce significant gross or microscopic alterations in the eyes (Coate et al. 1977).
The eyes from rats, dogs, and rabbits were also examined in the intermediate-duration study by Kociba et 
al. (1981). In that study, exposure to up to 100 ppm 1,2,4-trichlorobenzene vapors did not induce 
alterations in the microscopic morphology o f the eye.
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Body Weight Effects. Continuous exposure o f male monkeys, rats, and rabbits to up to 100 ppm
1.2.4-trichlorobenzene vapors for 26 weeks (Coate et al. 1977) or intermittent exposure o f rats, dogs, and 
rabbits to up to 100 ppm for 44 days (Kociba et al. 1981) did not significantly alter body weight. Gage 
(1970) reported that rats exposed to 70 ppm 1,2,4-trichlorobenzene 6 hours/day for 15 exposures showed 
retarded weight gain, but no data were presented.
Exposure o f rats to 1,209 ppm 1,3,5-trichlorobenzene vapors for 60 minutes resulted in 44 and 60% less 
body weight gain in males and females, respectively, 14 days after exposure (Jorgenson et al. 1976).
Body weight was not affected in rats exposed intermittently to up to 130 ppm 1,3,5-trichlorobenzene 
vapors for 13 weeks (Sasmore et al. 1983).
Metabolic Effects. Intermittent exposure o f rats to up to 130 ppm 1,3,5-trichlorobenzene vapors for 
13 weeks did not significantly affect serum electrolyte levels or electrolyte balance (Sasmore et al. 1983).
No relevant data were located regarding 1,2,4-trichlorobenzene.
3.2.1.3 Immunological and Lymphoreticular Effects
No studies were located regarding immunological effects in humans after inhalation exposure to 
trichlorobenzenes.
Continuous exposure o f monkeys, rats, and rabbits to up to 100 ppm 1,2,4-trichlorobenzene vapors for 
26 weeks did not induce significant gross or microscopic changes in the spleen o f the animals (Coate et 
al. 1977). Fifteen intermittent exposures (6 hours/day) o f rats to up to 200 ppm 1,2,4-trichlorobenzene 
vapors also did not result in significant histological alterations in the spleen (Gage 1970). Similar 
experiments in rats, rabbits, and dogs exposed 7 hours/day, 5 days/week to up to 100 ppm 1,2,4-trichloro­
benzene vapors for a total o f 30 exposures during a 44-day period did not result in significant gross or 
microscopic alterations in the spleen, thymus, or lymph nodes (Kociba et al. 1981).
No histological alterations were observed in lymphoreticular tissues from rats exposed to up to 130 ppm
1.3.5-trichlorobenzene vapors 6 hours/day, 5 days/week for 13 weeks (Sasmore et al. 1983).
No relevant data were located regarding 1,2,3-trichlorobenzene.
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NOAELs for lymphoreticular effects o f 1,2,4-trichlorobenzene and 1,3,5-trichlorobenzene are presented 
in Tables 3-1 and 3-2 and are plotted in Figures 3-1 and 3-2.
3.2.1.4 Neurological Effects
No studies were located regarding neurological effects in humans after inhalation exposure to 
trichlorobenzenes.
Lethargy was reported in rats during 6-hour exposures to 70 ppm 1,2,4-trichlorobenzene vapors (Gage 
1970). No such effect was observed during exposures to 20 ppm.
Continuous exposure o f monkeys, rats, or rabbits to up to 100 ppm 1,2,4-trichlorobenzene vapors for 
26 weeks did not induce significant gross or microscopic changes in the brain and spinal cord (Coate et al. 
1977). Operant behavior tests conducted in the monkeys throughout the study showed no exposure- 
related alterations. Similar lack o f gross or histological alterations were reported in the brain, spinal cord, 
and peripheral nerves from rats, dogs, and rabbits exposed intermittently to up to 100 ppm 1,2,4-trichloro­
benzene vapors during a 44-day period (Kociba et al. 1981).
No histological alterations were observed in the brain and spinal cord from rats exposed to up to 130 ppm
1,3,5-trichlorobenzene vapors 6 hours/day, 5 days/week for 13 weeks (Sasmore et al. 1983).
No relevant data were located regarding 1,2,3-trichlorobenzene.
NOAELs and LOAELs for neurological effects are presented in Tables 3-1 and 3-2 and are plotted in 
Figures 3-1 and 3-2.
3.2.1.5 Reproductive Effects
No studies were located regarding reproductive effects in humans after inhalation exposure to 
trichlorobenzene s.
No significant gross or histological alterations were reported in the reproductive organs from male rats, 
dogs, and rabbits exposed intermittently to up to 100 ppm 1,2,4-trichlorobenzene vapors for 44 days 
(Kociba et al. 1981). It should be noted, however, that absolute and relative testes weights were 
significantly increased (30 and 43%, respectively) in rabbits exposed to 100 ppm (but not 30 ppm). The
3. HEALTH EFFECTS
***DRAFT FOR PUBLIC COMMENT***
TRICHLOROBENZENES 51
investigators considered this change unrelated to the test material since, as indicated above, microscopic 
examination did not reveal any significant histological changes.
No histological alterations were observed in the reproductive organs from male or female rats exposed to 
up to 130 ppm 1,3,5-trichlorobenzene vapors 6 hours/day, 5 days/week for 13 weeks (Sasmore et al. 
1983).
No relevant data were located regarding 1,2,3-trichlorobenzene.
NOAELs for reproductive effects are presented in Table 3-1 and are plotted in Figure 3-1.







No studies were located regarding death in humans after oral exposure to trichlorobenzenes.
Information regarding acute lethality is available for the three trichlorobenzene isomers. An LD50 of 
756 mg/kg was reported for 1,2,4-trichlorobenzene in CFE rats (Brown et al. 1969). In the same study, 
the investigators determined an oral LD50 o f 766 mg/kg for 1,2,4-trichlorobenzene in C57BL/6N mice. In 
both species, lower doses caused depression o f activity, while lethal doses induced extensor convulsions. 
Another study reported an LD50 o f 880 mg/kg for 1,2,4-trichlorobenzene in Sprague-Dawley rats (Côté et 
al. 1988). In a developmental study, six out o f six pregnant Sprague-Dawley rats died after 3 days of 
dosing with 1,200 mg/kg 1,2,4-trichlorobenzene (Kitchin and Ebron 1983).
Without providing further details, Côté et al. (1988) reported that the oral LD50 for 1,2,3-trichlorobenzene 
in Sprague-Dawley rats was 1,830 mg/kg. In a brief report in which groups o f two rats per group were 
administered 1,000 or 2,000 mg/kg 1,2,3-trichlorobenzene by gavage in corn oil, one rat in the high-dose
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group died within 2 days o f dosing (Dow Chemical 1956). The investigators stated that slight pathology 
o f the liver and spleen occurred, but no details were provided.
An oral LD50 o f 2,100 mg/kg was reported for 1,3,5-trichlorobenzene in Sprague-Dawley rats (Côté et al. 
1988). In another study, Jorgenson et al. (1976) reported LD50 values o f 1,800 and 2,800 mg/kg for
1,3,5-trichlorobenzene in male and female Sprague-Dawley rats, respectively. A ll deaths except one 
occurred between 21 and 96 hours after dosing. Clinical signs observed included rough hair coat, passive 
tremors, depression, and inactivity leading to prostration, persistent tremor, coma, and death; necropsy 
revealed no gross abnormalities. The corresponding oral LD50 values for 1,3,5-trichlorobenzene in male 
and female ICR mice were 3,350 and 3,402 mg/kg, respectively (Jorgenson et al. 1976). Clinical signs 
observed included rough hair coat, passive tremors, depression, inactivity, prostration, persistent tremors, 
coma, and death. Deaths occurred between 22 and 288 hours after dosing; necropsy revealed no gross 
abnormalities. Increased mortality rate was reported in male rats dosed with 66.5 mg/kg/day
1.2.4-trichlorobenzene for 104 weeks (Moore 1994a). Similar results were reported in male and female 
mice dosed with 519.9 and 572.6 mg/kg/day 1,2,4-trichlorobenzene, respectively, for 104 weeks (Moore 
1994b).
The limited data available suggest that 1,2,4-trichlorobenzene has a stronger acute toxicity than the other 
two isomers, and that rats may be more susceptible than mice.
Lethal doses and LD50 values are presented in Tables 3-3, 3-4, and 3-5 and plotted in Figures 3-3, 3-4, and
3-5.
3.2.2.2 Systemic Effects
No studies were located regarding systemic effects in humans after oral exposure to trichlorobenzenes.
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each 
species and duration category are recorded in Tables 3-3, 3-4, and 3-5 and plotted in Figure 3-3, 3-4, and
3-5.
Respiratory Effects. No gross or microscopic alterations were observed in the lungs, bronchi, or 
trachea from rats administered up to 300 mg/kg/day 1,2,4-trichlorobenzene or 600 mg/kg/day 1,2,3- or
1.3.5-trichlorobenzene on Gd 6-15 and sacrificed on Gd 22 (Black et al. 1988). In intermediate-duration
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Table Z-Z Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Oral
















































































































Black et al. 19SS 
1,2,4-trichIorobenzene
NOAELs are for organ 
and tissues 
histopathology











Hemato 40 M Carlson and Tardiff 1976 
1,2,4-trichIorobenzene
Hepatic 10 M (15% increase in relative 
liver weight; increased 







Bd Wt 45Ü (4% weight loss in 3
days)





































Table 3-3 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to  Species Frequency NOAEL Less Serious Serious Reference







Hepatic 36 F 120 F (increased phase I and
phase II metabolic 
enzyme activity)




hypertrophy at 360 
mg/kg/day







Hepatic 500 M (intense necrosis and 
fatty change)
Rimington and Ziegler 1963 
1,2,4-trichIorobenzene






Bd Wt 130 F Chernoff and Kavlock 19S3 
1,2,4-trichIorobenzene
NOAEL is for maternal 



















Black et al. 19SS 
1,2,4-trichIorobenzene
NOAEL is for 
histopathology of the 
thymus and spleen
Black et al. 19SS 
1,2,4-trichIorobenzene
NOAEL is for 
histopathology of the 



































Table 3-3 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Frequency NOAEL Less Serious Serious Reference

















Black et al. 19SS 
1,2,4-trichIorobenzene
Black et al. 19SS 
1,2,4-trichIorobenzene
NOAEL is for 
histopathology of the 
ovaries and uterus
Lesions in pup's lenses 









360 F (retarded fetal 
development)







130 Chernoff and Kavlock 19S3 
1,2,4-trichIorobenzene







130 Gray and Kavlock 19S4 
1,2,4-trichIorobenzene
NOAEL is for viability of 







130 Gray et al. 19S6 
1,2,4-trichIorobenzene
NOAEL is for reactive 
locomotor activity of 


































Table 3-3 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Oral (continued)















20 Rat 90 d
(albino) 1 x/d
(GO)
Hemato 40 M Carlson and Tardiff 1976 
1,2,4-trichIorobenzene
No liver histopathology
Hepatic 20 M 40 M (14% increase in relative
liver weight after 30-day 
recovery period; 
increased phase I 
metabolic enzymes)


































Table 3-3 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Freq uency NOAEL Less Serious Serious Reference
Figure (Strain) (_____ )_________ System (mg/kg/day) (mg/kg/day)___________________(mg/kg/day)________________ Chemical Form__________________ Comments
21 Rat 14 wk
(Fischer- 344) ad lib 
(F)
Resp 150.6 F CMA 1989
1,2,4-trichlorobenzene







Hepatic 14.6 M 45.6 M (increased liver weight, 
hepatocyte hypertrophy)
Renal 45.6 M 133.7 M (increased kidney weight;












































Table 3-3 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Frequency NOAEL Less Serious Serious Reference
Figure (Strain) (_____ )_________ System (mg/kg/day) (mg/kg/day)___________________(mg/kg/day)________________ Chemical Form__________________ Comments









Cote et al. 1988 
1,2,4-trichIorobenzene
NOAELs are for organ 
histopathology
82 M (13-20% increased
absolute and relative liver 
weight)
Renal 7.8 M 82 M (31-36% increase















Hepatic 730 M (intense necrosis and 
fatty change)
Rimington and Ziegler 1963 
1,2,4-trichIorobenzene


































Table 3-3 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Frequency NOAEL Less Serious Serious Reference






Resp 1345 F Hiles 1989
1,2,4-trichIorobenzene







Hepatic 67 M 850 M (hepatocyte hypertrophy, 
atrophy, vacuolar 
degeneration, necrosis; 
higher ALT and SDH 
activities)
Immuno/ Lymphoret
25 Rat 14 wk










150.6 F CMA 1989
1,2,4-trichIorobenzene
NOAEL is for 
histopathology of 
lymphoreticular tissues





Cote et al. 1988 
1,2,4-trichIorobenzene




































Table 3-3 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Frequency NOAEL Less Serious Serious Reference








28 Rat 14 wk

















31 Rat 14 wk











NOAEL is for 
histopathology of 
central and peripheral 
nervous tissues
Cote et al. 1988 
1,2,4-trichlorobenzene
NOAEL is for 
histopathology of 




NOAEL is for 




NOAEL is for 
histopathology of 
reproductive organs





Cote et al. 1988 
1,2,4-trichlorobenzene




































Table 3-3 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Oral (continued)





















Robinson et al. 1981 
1,2,4-trichIorobenzene
NOEAL is for fertility of 




















53.6 F Robinson et al. 1981 
1,2,4-trichIorobenzene
NOAEL is for standard 
neonatal indices, 
locomotor activity, 




36 Rat 104 wk
(Fischer- 344) ad lib 
(F)







519.9 M (decreased survival) 




































Table 3-3 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Freq uency NOAEL Less Serious Serious Reference
Figure (Strain) (_____ )_________ System (mg/kg/day) (mg/kg/day)___________________(mg/kg/day)________________ Chemical Form__________________ Comments
Systemic
38 Rat 104 wk
(Fischer- 344) ad lib 
(F)
Resp 81.4 F Moore 1994a 
1,2,4-trichIorobenzene












19.4 M 66.5 M (increased liver weight; 
hepatocellular 
hypertrophy)











































Table 3-3 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Oral (continued)





















Resp 572.6 F Moore 1994b 
1,2,4-trichlorobenzene







Hepatic 21 M 100.6 M (centrilobular
hepatocytomegaly)











100.6 M 519.9 M (16% decreased final 
body weight)
Immuno/ Lymphoret
40 Rat 104 wk
(Fischer- 344) ad lib 
(F)
81.4 F Moore 1994a 
1,2,4-trichlorobenzene




































Table 3-3 Levels o f S ignificant Exposure to 1,2,4-Trichlorobenzene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Freq uency NOAEL Less Serious Serious Reference








42 Rat 104 wk



































NOAEL is for 
histopathology of 



















































Key to  Species
Figure (Strain)







46 Mouse 104 wk
(B6C3F1) ad lib 
(F)




127 F (CEL: hepatocellular 
carcinoma)
a The number corresponds to entries in Figure 3-3.
b Used to derive an intermediate-duration oral MRL of 0.1 mg/kg/day for 1,2,4-trichlorobenzene; the MRL was derived by dividing the BMDL10 by an uncertainty factor of 100 (10 for 
animal to human extrapolation and 10 for human variability).
c Used to derive a chronic-duration oral MRL of 0.1 mg/kg/day for 1,2,4-trichlorobenzene; the MRL was derived by dividing the BMDL10 by an uncertainty factor of 100 (10 for animal 
to human extrapolation and 10 for human variability).
ad lib = ad libitum; Bd Wt = body weight; Cardio = cardiovascular; CEL = cancer effect level; d = day(s); Endocr = endocrine; (F) = feed; F = Female; (G) = gavage; Gastro = 
gastrointestinal; Gd = gestation day; (GO) = gavage in oil; Hemato = hematological; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; Metab = 



































Figure 3-3 Levels of Significant Exposure to 1,2,4-Trichlorobenzene - Oral
Acute (<14 days)
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NOAEL - Humans
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n-Mink Cancer Effect Level-Animals
o-Other LOAEL, More Serious-Animals
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*Doses represent the lowest dose tested per study that produced a tumorigenic 
















n-Mink Cancer Effect Level-Animals
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Table 3-4 Levels o f S ignificant Exposure to 1,2,3-Trichlorobenzene - Oral




























2000 (1 out of 2 rats died
within two days of 
dosing)






















Black et al. 19SS 
1,2,3-Trichlorobenzene
NOAELs are for organ 
and tissues 
histopathology





























Table 3-4 Levels o f S ignificant Exposure to 1,2,3-Trichlorobenzene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to  Species Freque" cy NOAEL Less Serious Serious Reference

































Black et al. 1988 
1,2,3-Trichlorobenzene
NOAEL is for 
histopathology of 
spleen and thymus
Black et al. 1988 
1,2,3-Trichlorobenzene
NOAEL is for 
histopathology of brain 
and peripheral nerve
Black et al. 1988 
1,2,3-Trichlorobenzene
NOAEL is for 
histopathology of 
reproductive organs
Black et al. 1988 
1,2,3-Trichlorobenzene
NOAELs are for 
histopathology of 







































Key to  Species
Figure (Strain) (Route)














Resp 113 F Cote et al. 19SS 
1,2,3-Trichlorobenzene











?.6 M ?S M 14% increase in relative 
liver weight)



























Cote et al. 19SS 
1,2,3-Trichlorobenzene
Cote et al. 19SS 
1,2,3-Trichlorobenzene
NOAEL is for 
histopathology of 
lymphoreticular tissues
NOAEL is for 
histopathology of 



































Table 3-4 Levels o f S ignificant Exposure to 1,2,3-Trichlorobenzene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to  Species Frequency NOAEL Less Serious Serious Reference










Cote et al. 1988 
1,2,3-Trichlorobenzene
NOAEL is for 
histopathology of 
reproductive organs
a The number corresponds to entries in Figure 3-4.
ad lib = ad libitum; Bd Wt = body weight; Cardio = cardiovascular; d = day(s); (F) = feed; F = Female; (G) = gavage; Gastro = gastrointestinal; Gd = gestation day; (GO) = gavage in 
oil; Hemato = hematological; Immuno/Lymphoret = immunological/lymphoreticular; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; Metab = 


































Figure 3-4 Levels of Significant Exposure to 1,2,3-Trichlorobenzene - Oral
Acute (<14 days)
S ystem ic
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n-Mink Cancer Effect Level-Animals
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NOAEL - Animals
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Table 3-5 Levels o f S ignificant Exposure to 1,3,5-Trichlorobenzene - Oral






























1S00 M (LD50) 
2SGG F (LD5G)





















Bd Wt 300 F
Metab a00 F
3350 M (LD50) 
3402 F (LD50)
a00 F (25% increase in relative 
liver weight)
a00 F (34% reduced body 
weight gain)
Jorgenson et al. 197a 
1,3,5-Trichlorobenzene
Black et al. 19SS 
1,3,5-Trichlorobenzene






































Table 3-5 Levels o f S ignificant Exposure to 1,3,5-Trichlorobenzene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to' Species Freq uency NOAEL Less Serious Serious Reference

















Black et al. 1988 
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Black et al. 1988 
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histopathology
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histopathology of the 
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Black et al. 1988 
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Black et al. 1988 
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Table 3-5 Levels o f S ignificant Exposure to 1,3,5-Trichlorobenzene - Oral (continued)
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14a F Cote et al. 19SS 
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Table 3-5 Levels o f S ignificant Exposure to 1,3,5-Trichlorobenzene - Oral (continued)
Exposure/ LOAEL
Duration/
Key to  Species Frequency NOAEL Less Serious Serious Reference










Cote et al. 1988 
1,3,5-Trichlorobenzene
NOAEL is for 
histopathology of 
reproductive organs
a The number corresponds to entries in Figure 3-5.
ad lib = ad libitum; Bd Wt = body weight; Cardio = cardiovascular; d = day(s); (F) = feed; F = Female; (G) = gavage; Gastro = gastrointestinal; Gd = gestation day; (GO) = gavage in 
oil; Hemato = hematological; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; Metab = metabolic; Musc/skel = musculoskeletal; NOAEL = 



































Figure 3-5 Levels of Significant Exposure to 1,3,5-Trichlorobenzene - Oral
Acute (<14 days)
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studies, there were also no significant histological alterations in the lungs, trachea, or bronchi from rats 
exposed via the diet to up to 101 mg/kg/day (Côté et al. 1988) or 150.6 mg/kg/day (CMA 1989)
1.2.4-trichlorobenzene. A  13-week dietary study in mice reported no significant histological alterations in 
the lungs or trachea from animals dosed with up to 1,345 mg/kg/day 1,2,4-trichlorobenzene (Hiles 1989). 
Chronic-duration exposure to 1,2,4-trichlorobenzene also did not induce significant histological 
alterations in the lungs and trachea from rats dosed via the diet with up to 81.4 mg/kg/day 1,2,4-trichloro­
benzene (Moore 1994a) or from mice dosed with up to 572.6 mg/kg/day 1,2,4-trichlorobenzene (Moore 
1994b).
Black et al. (1988) also studied the 1,2,3- and 1,3,5- isomers and reported no significant effects in the 
lungs, bronchi, and trachea o f  pregnant rats dosed by gavage with up to 600 mg/kg/day o f  either isomer 
on Gd 6-15  and sacrificed on Gd 22. Similar results were reported in rats treated with up to 
113 mg/kg/day 1,2,3-trichlorobenzene or 146 mg/kg/day 1,3,5-trichlorobenzene in the diet for 13 weeks 
(Côté et al. 1988).
Cardiovascular Effects. N o significant gross or microscopic alterations were observed in the heart 
o f  rats dosed by gavage with up to 300 mg/kg/day 1,2,4-trichlorobenzene or 600 mg/kg/day 1,2,3- or
1.3.5-trichlorobenzene on Gd 6-15  and sacrificed on Gd 22 (Black et al. 1988). Similar results were 
reported regarding the heart and aorta from rats treated with up to 101 mg/kg/day 1,2,4-trichlorobenzene, 
113 mg/kg/day 1,2,3-trichlorobenzene, or 146 mg/kg/day 1,3,5-trichlorobenzene in the diet for 13 weeks 
(Côté et al. 1988), or 150.6 mg/kg/day 1,2,4-trichlorobenzene for 14 weeks (CMA 1989). Treatment o f  
mice with up to 1,345 mg/kg/day 1,2,4-trichlorobenzene for 13 weeks via the diet did not significantly 
alter the gross or microscopic appearance o f  the heart or aorta (Hiles 1989). Treatment o f  rats with up to
81.4 mg/kg/day 1,2,4-trichlorobenzene or mice with up to 572.6 mg/kg/day 1,2,4-trichlorobenzene 
through the diet for 104 weeks did not induce gross or microscopic changes in the heart (Moore 1994a, 
1994b).
Gastrointestinal Effects. N o significant gross or microscopic alterations were reported in the 
gastrointestinal tract o f  rats dosed by gavage with up to 300 mg/kg/day 1,2,4-trichlorobenzene or 
600 mg/kg/day 1,2,3- or 1,3,5-trichlorobenzene on Gd 6-15  and sacrificed on Gd 22 (Black et al. 1988). 
Similar results were reported in rats treated with up to 101 mg/kg/day 1,2,4-trichlorobenzene,
113 mg/kg/day 1,2,3-trichlorobenzene, or 146 mg/kg/day 1,3,5-trichlorobenzene in the diet for 13 weeks 
(Côté et al. 1988), or 150.6 mg/kg/day 1,2,4-trichlorobenzene for 14 weeks (CMA 1989). Examination o f  
the gastrointestinal tract from mice dosed with up to 1,345 mg/kg/day 1,2,4-trichlorobenzene for
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13 weeks via the diet did not reveal significant treatment-related gross or histological alterations (Hiles 
1989). No gross or histological alterations were reported in the gastrointestinal tract from rats or mice 
dosed via the diet with up to 81.4 or 572.6 mg/kg/day 1,2,4-trichlorobenzene, respectively for 104 weeks 
(Moore 1994a, 1994b).
Hematological Effects. Changes in hematological parameters have been reported in some acute- and 
intermediate-duration studies. However, since the reductions in hemoglobin and hematocrit reported in 
some o f  these studies are within the normal range for these parameters, they are not listed as LOAELs in 
Table 3-2; instead, the highest doses tested are listed as NOAELs for hematological effects.
Treatment o f  pregnant rats with 150 or 300 mg/kg/day 1,2,4-trichlorobenzene during Gd 6-15 resulted in 
reductions in hemoglobin (6-7% ) and hematocrit (6%) (Black et al. 1988). In the same study, doses o f  
300 and 600 mg/kg/day 1,2,3-trichlorobenzene reduced hemoglobin by 6-7%  and doses o f  
600 mg/kg/day reduced the hematocrit by approximately 6%. Rats treated with 600 mg/kg/day
1.3.5-trichlorobenzene showed reduction in hemoglobin and hematocrit o f  approximately 10-11%  (Black 
et al. 1988). In another acute-duration study in rats, doses o f  up to 40 mg/kg/day 1,2,4-trichlorobenzene 
by gavage for 14 days did not affect hemoglobin or hematocrit levels (Carlson and Tardiff 1976).
Some intermediate-duration dietary studies have reported mild hematological changes following exposure 
to 1,2,4-trichlorobenzene. For example, treatment o f  male rats with 133.7 mg/kg/day, but not
45.6 mg/kg/day, 1,2,4-trichlorobenzene in the diet for 14 weeks reduced mean erythrocyte count (5%), 
hemoglobin (1.2%), and hematocrit (6%) (CMA 1989). In female rats, doses o f  150.6 mg/kg/day reduced 
hemoglobin and hematocrit by 3.6-4% . Platelets were increased in males dosed with 133.7 mg/kg/day.
In a similar study, administration o f  doses o f  up to 82 mg/kg/day to male rats and 101 mg/kg/day to 
females did not alter hematological parameters (Côté et al. 1988). N o significant hematological changes 
were observed in male mice dosed with up to 1,222 mg/kg/day 1,2,4-trichlorobenzene for 13 weeks (Hiles 
1989). In the same study, female mice dosed with 1,345 mg/kg/day 1,2,4-trichlorobenzene had lower (5­
9%) hemoglobin, hematocrit, mean corpuscular volume, and mean corpuscular hemoglobin; since the 
these changes occurred only in females, the investigator (Hiles 1989) did not consider them to be 
treatment-related.
Administration in the diet o f  up to 113 mg/kg/day 1,2,3-trichlorobenzene or 146 mg/kg/day
1.3.5-trichlorobenzene to rats for 13 weeks did not alter hematological parameters (Côté et al. 1988).
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In the chronic-duration oral studies with 1,2,4-trichlorobenzene, cellular morphology and leukocyte 
differential were monitored on weeks 52, 78, and at termination (Moore 1994a, 1994b). The results 
showed no significant treatment-related alterations in the parameters monitored in rats dosed through the 
diet with up to 81.4 mg/kg/day or in mice dosed with up to 572.6 mg/kg/day 1,2,4-trichlorobenzene. No  
evidence o f  leukemia was seen in either study.
Musculoskeletal Effects. N o significant gross or histological alterations were reported in skeletal 
muscle from pregnant rats dosed with up to 300 mg/kg/day 1,2,4-trichlorobenzene or 600 mg/kg/day
1.2.3-trichlorobenzene or 1,3,5,-trichlorobenzene on Gd 6-15  and sacrificed on Gd 22 (Black et al. 1988).
Similar results were reported in rats dosed via the diet with up to 150.6 mg/kg/day 1,2,4-trichlorobenzene, 
113 mg/kg/day 1,2,3-trichlorobenzene, or 146 mg/kg/day 1,3,5-trichlorobenzene for 3 months (CMA 
1989; Côté et al. 1988). An intermediate-duration dietary study in mice dosed with up to 1,345 
mg/kg/day 1,2,4-trichlorobenzene for 13 weeks also did not find morphological alterations in bone or 
skeletal muscle (Hiles 1989). Chronic-duration studies did not find morphological alterations in bone or 
skeletal muscle from rats or mice dosed with up to 81.4 or 572.6 mg/kg/day 1,2,4-trichlorobenzene via the 
diet, respectively, for 104 weeks (Moore 1994a, 1994b).
Hepatic Effects. Acute-, intermediate-, and chronic-duration oral studies in animals indicate that the 
liver is a target for trichlorobenzenes. An acute-duration study with 1,2,4-trichlorobenzene described 
intense necrosis and fatty change in rats following administration o f  500 mg/kg/day 1,2,4-trichloro­
benzene by gavage for 10 days (Rimington and Ziegler 1963). In a 14-day gavage study in male rats,
1.2.4-trichlorobenzene induced a dose-related increase in relative liver weight (all doses, 15.3% at
10 mg/kg/day, 28.9%  at 40 mg/kg/day) (Carlson and Tardiff 1976). Moderate hepatocellular hypertrophy 
was reported in the liver from pregnant rats following administration o f  360 mg/kg/day for 4 days; the 
NOAEL for this effect was 120 mg/kg/day (Kitchin and Ebron 1983). In another developmental study, 
mild hepatic changes consisting o f  increased periportal cytoplasmic eosinophilia and mild anisokaryosis 
o f  hepatocellular nuclei were reported in pregnant rats dosed with 150 and 300 mg/kg/day 1,2,4-trichloro­
benzene on Gd 6-15 (Black et al. 1988). The same was reported in pregnant rats dosed with 300 and 
600 mg/kg/day 1,2,3- or 1,3,5-trichlorobenzene. Because no quantitative histological data were presented 
in the latter study, this information is not listed in Tables 3-3, 3-4, and 3-5. Histological alterations in the 
liver were almost always accompanied by increases in liver weight.
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In a 90-day study in male rats, gavage administration of 1,2,4-trichlorobenzene (10, 20, 40 mg/kg/day) 
increased relative liver weight 14% in high-dose rats after a 30-day recovery period; however, no 
significant histological alterations were seen in the liver (Carlson and Tardiff 1976). Dietary 
administration of >14.6 mg/kg/day 1,2,4-trichlorobenzene to male rats or >52.5 mg/kg/day to females for 
14 weeks induced dose-related increases in absolute and relative liver weights (CMA 1989). Microscopic 
examination of the liver revealed an increased incidence of centrilobular hepatocyte hypertrophy in male 
rats dosed with >45.6 mg/kg/day 1,2,4-trichlorobenzene and in female rats dosed with 150.6 mg/kg/day; 
the corresponding NOAELs were 14.6 and 52.5 mg/kg/day (CMA 1989). Centrilobular hepatocyte 
hypertrophy was used as the basis for derivation of an intermediate-duration oral MRL for 1,2,4-trichloro­
benzene. An additional intermediate-duration dietary study reported significant increases in relative liver 
weight in male rats dosed with 78-82 mg/kg/day of each trichlorobenzene isomer (Côté et al. 1988). The 
investigators stated that most treated groups (doses ranged from approximately 0.1 to 140 mg/kg/day) 
showed mild-to-moderate increases in cytoplasmic volume and anisokaryosis of hepatocytes mostly in 
perivenous and midzone areas. High-dose rats showed aggregated basophilia as well as widespread 
midzonal vacuolation due to fatty infiltration. However, since only a qualitative description of the 
histological changes was provided, it is impossible to determine with certainty NOAELs or LOAELs for 
the lesions; therefore, they are not listed in Tables 3-3, 3-4, or 3-5, but the organ weight changes are.
A significant increase in absolute and relative liver weight was reported in male mice dosed via the diet 
with >850 mg/kg/day 1,2,4-trichlorobenzene and female mice dosed with >1,183 mg/kg/day
1,2,4-trichlorobenzene for 13 weeks (Hiles 1989). These changes in liver weight correlated with 
microscopic changes characterized by hepatocellular cytomegaly with karyomegaly and multinucleation 
complex with adjacent hepatocellular compression, atrophy, anisocytosis, vacuolar degeneration, and 
necrosis. The NOAELs for these alterations were 67 and 86 mg/kg/day in males and females, 
respectively. In addition, changes in clinical chemistry that were considered treatment-related consisted 
of higher total protein in mid-dose males (850 mg/kg/day) and high-dose males (1,222 mg/kg/day) and 
females (1,345 mg/kg/day), increased albumin and globulin in high-dose males and females, increased 
serum alanine aminotransferase (ALT) in mid-dose males and in high-dose males and females, and 
increased sorbitol dehydrogenase (SDH) in mid- and high-dose males and females. According to the 
investigators, the higher protein was probably caused by dehydration.
In a 104-week dietary study with 1,2,4-trichlorobenzene in rats, doses of 66.5 mg/kg/day in males and
81.4 mg/kg/day in females produced significant increases in absolute and relative liver weight at 
termination (Moore 1994a). The corresponding NOAELs were 19.4 and 23.5 mg/kg/day. Significant
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increases in the incidence of liver lesions were reported in rats that received the highest doses,
66.5 mg/kg/day in males and 81.4 mg/kg/day in females. The histological alterations consisted of 
hepatocyte hypertrophy, focal cystic degeneration, and diffuse fatty change. The increased incidence of 
hepatocyte hypertrophy in male rats served as the basis for derivation of a chronic-duration oral MRL for
1.2.4-trichlorobenzene. In a similar study in mice, doses >21 mg/kg/day 1,2,4-trichlorobenzene induced a 
dose-related increase in absolute and relative liver weight in males, whereas doses >100.6 mg/kg/day
1.2.4-trichlorobenzene increased relative liver weight (Moore 1994b). In females, doses >26.3 mg/kg/day 
also increased absolute and relative liver weight. Histological examination of the liver showed a 
significant increase in the incidence of centrilobular hepatocytomegaly in males dosed with
>101 mg/kg/day 1,2,4-trichlorobenzene. The neoplastic effects in mice are described in Section 3.2.2.7, 
Cancer.
In addition to inducing changes in liver weight and morphological alterations in the liver, 1,2,4-trichloro­
benzene has been shown to be a potent inducer of phase I and phase II metabolic enzymes (Ariyoshi et al. 
1975a, 1975b; Carlson and Tardiff 1976; Kato and Kimura 2002; Kato et al. 1988, 1993; Kitchin and 
Ebron 1983). For example, administration of >10 mg/kg/day 1,2,4-trichlorobenzene to rats by gavage for
14 days resulted in dose-related increases in cytochrome c reductase, cytochrome P-450, 
glucuronyltransferase, EPN detoxification, and azoreductase (Carlson and Tardiff 1976). Extending the 
dosing period to 90 days resulted in smaller increases in enzyme activities, except for 
glucuronyltransferase activity, which was reduced relative to controls (Carlson and Tardiff 1976). In rats,
1.2.4-trichlorobenzene also induced ALA synthetase, the rate-limiting enzyme in the biosynthesis of 
heme, which is consistent with the development of porphyria in rats administered 1,2,4- trichlorobenzene 
(Rimington and Ziegler 1963). For example, doses of 250-500 mg/kg/day significantly increased the 
urinary excretion of coproporphyrin and, to a smaller extent, the excretion of uroporphyrins. Liver 
uroporphyrin was also increased by 1,2,4-trichlorobenzene; liver coproporphyrin and protoporphyrin were 
increased in rats showing marked porphyrinuria. Studies by Kato and coworkers (Kato and Kimura 2002; 
Kato et al. 1988, 1993) have shown that both the induction of drug-metabolizing enzymes and ALA 
synthetase are not due to 1,2,4-trichlorobenzene itself but its metabolite 2,3,5-trichlorophenyl methyl 
sulfone. Further information on the mechanism of porphyria can be found in Section 3.5, Mechanisms of 
Action.
Renal Effects. No gross or microscopic alterations were reported in the kidneys from pregnant rats 
dosed on Gd 6-15 with up to 300 mg/kg/day 1,2,4-trichlorobenzene or 600 mg/kg/day 1,2,3-trichloro­
benzene or 1,3,5-trichlorobenzene and sacrificed on Gd 22 (Black et al. 1988).
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In a 13-week dietary study in rats with trichlorobenzenes, the three isomers increased relative kidney 
weight in male rats in doses ranging between 78 and 82 mg/kg/day (no data on females were presented), 
but only 1,3,5-trichlorobenzene reportedly induced morphological alterations in the kidneys (Côté et al.
1988). The changes were characterized by eosinophilic inclusion, enlargement and anisokariosis of the 
epithelial lining cells, and hyperplasia of renal tubular epithelial cells. Only the changes associated with 
the highest dose levels, 78-82 mg/kg/day, were considered to be biologically significant by the 
investigators. Since only a qualitative description of the histology was provided, NOAELs and LOAELs 
for histological changes are not presented in Tables 3-3, 3-4, and 3-5, but the organ weight changes are.
In a 14-week dietary study with 1,2,4-trichlorobenzene in rats, doses >45.6 mg/kg/day in males and 
>52.5 mg/kg/day in females significantly increased relative kidney weight, but morphological alterations 
were seen only in high-dose males (133.7 mg/kg/day) and consisted of dilated tubules, granular casts, 
hyaline droplets, and interstitial nephritis (CMA 1989). BUN was also significantly elevated in high-dose 
males and females (150.6 mg/kg/day). Mice administered up to 1,345 mg/kg/day 1,2,4-trichlorobenzene 
via the diet for 13 weeks did not show significant gross or microscopic alterations in the kidneys (Hiles
1989).
In the 104-week dietary studies with 1,2,4-trichlorobenzene in rats and mice, kidney alterations were 
reported only in rats (Moore 1994a). Gross necropsy at termination showed increases incidence of kidney 
abnormalities in mid- (19.4 mg/kg/day) and high-dose (66.5 mg/kg/day) males. Microscopically, there 
was an increased incidence in marked renal papilla mineralization in high-dose males and in transitional 
renal cell hyperplasia, also in males; only the latter effect showed dose-response. In addition, there was 
an increase in severity of chronic nephropathy in males. In mice, there were no significant gross or 
microscopic alterations in the kidneys following dosing with up to 572.6 mg/kg/day 1,2,4-trichloro­
benzene (Moore 1994b).
Endocrine Effects. The only relevant information from acute-duration exposures is that from the 
study by Black et al. (1988) in which pregnant rats were administered trichlorobenzenes by gavage on 
Gd 6-15 and were sacrificed on Gd 22. No significant gross or microscopic alterations were reported in 
the pituitary, parathyroid, adrenals, or pancreas from dams following doses of up to 300 mg/kg/day
1,2,4-trichlorobenzene or 600 mg/kg/day 1,2,3-trichlorobenzene or 1,3,5-trichlorobenzene. However, 
mild thyroid histopathology was reported in rats dosed with >300 mg/kg/day of each isomer; the NOAEL 
in each case was 150 mg/kg/day. The alterations were described as reduction of follicle size and
S. HEALTH EFFECTS
***DRAFT FOR PUBLIC COMMENT***
TRICHLOROBENZENES 88
increased epithelial height accompanied by cytoplasmic vacuolization. Since no quantitative data were 
presented, NOAELs and LOAELs for thyroid effects are not presented in Tables 3-3, 3-4, and 3-5.
Côté et al. (1988) examined the same organs in a 13-week study in Sprague-Dawley rats and reported 
similar results. Morphological alterations were limited to the thyroid and were described as mild and 
appeared to be more severe in males. Reported changes consisted o f  reduction in follicular size, increased 
epithelial height from flattened cuboidal cells to columnar shape, and reduced colloid density. Changes in 
the high-dose groups (78-82  mg/kg/day) varied from mild to moderate. Since no quantitative data were 
presented, NOAELs and LOAELs for histological alterations in the thyroid are not listed in Tables 3-3, 
3-4, and 3-5. In contrast, CMA (1989) did not find significant histological alterations in the thyroid from 
Fisher-344 rats dosed with up to 150.6 mg/kg/day 1,2,4-trichlorobenzene in the diet for 14 weeks. 
Whether this can be attributed to differences in sensitivity between rat strains is unknown. N o significant 
alterations were reported in endocrine glands from mice dosed via the diet with up to 1,345 mg/kg/day
1.2.4-trichlorobenzene for 13 weeks (Hiles 1989) or from rats or m ice dosed with up to 81.4 or
572.6 mg/kg/day 1,2,4-trichlorobenzene, respectively, for 104 weeks (Moore 1994a, 1994b).
Dermal Effects. None o f  the studies that examined the skin o f  animals following oral administration 
o f  trichlorobenzenes reported treatment-related gross or microscopic alterations. These include the acute 
developmental study by Black et al. (1988) (300 mg/kg/day 1,2,4-trichlorobenzene; 600 mg/kg/day
1,2,3-trichlorobenzene and 1,3,5-trichlorobenzene), a 13-week dietary study (Côté et al. 1988) (78­
82 mg/kg/day), and 104-week dietary studies with 1,2,4-trichlorobenzene in rats (Moore 1994a)
(81.4 mg/kg/day) and mice (Moore 1994b) (572.6 mg/kg/day).
Ocular Effects. Examination o f  the eyes o f  animals exposed orally to trichlorobenzenes did not show  
treatment-related gross or histological alterations. These include the acute developmental study by Black 
et al. (1988; 300 mg/kg/day 1,2,4-trichlorobenzene; 600 mg/kg/day 1,2,3-trichlorobenzene and
1.3.5-trichlorobenzene), 3-month dietary studies in rats (Côté et al. 1988; 78 -82  mg/kg/day, and CMA 
1989; 150.6 mg/kg/day), a 13-week dietary study with 1,2,4-trichlorobenzene in mice (Hiles 1989;
1,345 mg/kg/day), and 104-week dietary studies with 1,2,4-trichlorobenzene in rats (Moore 1994a;
81.4 mg/kg/day) and mice (Moore 1994b; 572.6 mg/kg/day).
Body Weight Effects. Alm ost all studies o f  trichlorobenzenes monitored body weight o f  the animals. 
Pregnant rats administered 300 mg/kg/day 1,2,4-trichlorobenzene or 600 mg/kg/day 1,2,3-trichloro­
benzene on Gd 6-15 gained less weight than controls, but quantitative data for these isomers were not
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provided (Black et al. 1988). However, administration o f  600 mg/kg/day 1,3,5-trichlorobenzene resulted 
in a reduction in weight gain o f  34% relative to controls on Gd 22 (Black et al. 1988). In another 
developmental study, doses o f  360 mg/kg/day 1,2,4-trichlorobenzene on Gd 9-13 induced weight loss; 
120 mg/kg/day had no significant effect (Kitchin and Ebron 1983). W eight loss was also reported in a 
study in rats dosed by gavage with 500 mg/kg/day 1,2,4-trichlorobenzene for 10 days or with 
780 mg/kg/day 1,2,3-trichlorobenzene for 7 day (Rimington and Ziegler 1963). None o f  these studies 
provided information on food consumption.
Fifteen days o f  dosing with 730 mg/kg/day 1,2,4-trichlorobenzene by gavage resulted in loss o f  appetite 
and weight loss in rats (Rimington and Ziegler 1963). Neither food consumption nor weight gain was 
significantly affected in rats dosed vai the diet with up to 101 mg/kg/day 1,2,4-trichlorobenzene or 
146 mg/kg/day 1,3,5-trichlorobenzene for 13 weeks (Côté et al. 1988). Similar results were reported in 
rats dosed through the diet with up to 150.6 mg/kg/day 1,2,4-trichlorobenzene for 14 weeks (CMA  
1989). Male rats treated with 78 mg/kg/day 1,2,3-trichlorobenzene for 13 weeks gained 10.2% less 
weight than controls (Côté et al. 1988); the NOAEL was 7.6 mg/kg/day. Final body weight was 
significantly reduced in male mice dosed with 1,222 mg/kg/day 1,2,4-trichlorobenzene (9%) and in 
female mice dosed via the diet with 1,345 mg/kg/day 1,2,4-trichlorobenzene (8.3%) for 13 weeks (Hiles
1989). Cumulative body weight gain was significantly reduced in males dosed with 67 mg/kg/day
1,2,4-trichlorobenzene (27%), in males dosed with 1,222 mg/kg/day 1,2,4-trichlorobenzene (40%), and in 
females dosed with 1,345 mg/kg/day 1,2,4-trichlorobenzene (33%); these changes were associated with 
significant reductions in food consumption throughout the study.
Final body weight o f  rats dosed through the diet with up to 81.4 mg/kg/day 1,2,4-trichlorobenzene for 
104 weeks was not significantly different than controls (Moore 1994a). Final body weight o f  male mice 
dosed with 519.9 mg/kg/day 1,2,4-trichlorobenzene in the diet for 104 weeks was 16% lower than 
controls; food consumption in this group was reduced during the first 52 weeks o f  the study (Moore 
1994b). Final body weight was not significantly affected in female mice dosed with up to
572.6 mg/kg/day 1,2,4-trichlorobenzene. The NOAEL for body weight changes in male mice was
100.6 mg/kg/day.
Metabolic Effects. Administration o f  up to 300 mg/kg/day 1,2,4-trichlorobenzene or up to
600 mg/kg/day 1,2,3- or 1,3,5-trichlorobenzene to pregnant rats on Gd 6-15  did not significantly alter the
concentration o f  electrolytes or glucose in blood (Black et al. 1988).
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None o f  the intermediate-duration studies with trichlorobenzenes reported adverse metabolic effects. 
Treatment o f  rats with dietary doses o f  up to 150.6 mg/kg/day or mice with up to 1,345 mg/kg/day
1.2.4-trichlorobenzene for 3 months had no significant effect on serum electrolyte or glucose levels 
(CMA 1989; Côté et al. 1988; Hiles 1989). Similar results were reported in rats dosed via the diet with 
up to 113 mg/kg/day 1,2,3-trichlorobenzene or 146 mg/kg/day 1,3,5-trichlorobenzene (Côté et al. 1988).
3.2.2.3 Immunological and Lymphoreticular Effects
N o studies were located regarding immunological and lymphoreticular effects in humans after oral 
exposure to trichlorobenzenes.
Information from studies in animals is limited to evaluations o f  the gross and microscopic morphology o f  
lymphoreticular organs and tissues. In pregnant rats that were exposed to up to 300 mg/kg/day
1.2.4-trichlorobenzene or 600 mg/kg/day 1,2,3-trichlorobenzene or 1,3,5-trichlorobenzene on Gd 6­
15, there were no significant morphological changes in the spleen or thymus on Gd 22 (Black et al. 1988).
Intermediate-duration studies showed that exposure o f  rats to up to 150.6 mg/kg/day 1,2,4-trichloro­
benzene, 113 mg/kg/day 1,2,3-trichlorobenzene, or 146 mg/kg/day 1,3,5-trichlorobenzene, or mice to up 
to 1,345 mg/kg/day 1,2,4-trichlorobenzene in the diet for 3 months did not alter the gross or microscopic 
morphology o f  the spleen, thymus, or lymph nodes (CMA 1989; Côté et al. 1988). Similar results were 
reported in rats and mice dosed with up to 81.4 and 572.6 mg/kg/day 1,2,4-trichlorobenzene, respectively, 
in the diet for 104 weeks (Moore 1994a, 1994b).
These values are presented as NOAELs for lymphoreticular effects in Table 3-3, 3-4, and 3-5 and are 
plotted in Figures 3-3, 3-4, and 3-5.
3.2.2.4 Neurological Effects
N o studies were located regarding neurological effects in humans after oral exposure to 
trichlorobenzenes.
N o gross or histological alterations were observed in the brain and peripheral nerves from rats exposed to 
up to 300 mg/kg/day 1,2,4-trichlorobenzene or 600 mg/kg/day 1,2,3-trichlorobenzene or 1,3,5-trichloro­
benzene on Gd 6-15 and sacrificed on Gd 22 (Black et al. 1988).
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Côté et al. (1988) examined the brain, spinal cord, and sciatic nerve from rats following a 13-week 
exposure period via the diet to doses o f  up to 101 mg/kg/day 1,2,4-trichlorobenzene, 113 mg/kg/day
1.2.3-trichlorobenzene, or 146 mg/kg/day 1,3,5-trichlorobenzene and reported no significant gross or 
microscopic alterations in those tissues. Similar results were reported in rats dosed via the diet with up to
150.6 mg/kg/day 1,2,4-trichlorobenzene for 14 weeks (CMA 1989) and in mice dosed with up to
1,345 mg/kg/day 1,2,4-trichlorobenzene for 13 weeks (Hiles 1989). Dietary exposure o f  rats and mice to 
up to 81.4 and 572.6 mg/kg/day 1,2,4-trichlorobenzene, respectively, in the diet for 104 weeks also did 
not induce histological alterations in the brain, spinal cord, or sciatic nerve (Moore 1994a, 1994b).
The NOAELs for morphological changes in the central and peripheral nervous systems are listed in 
Tables 3-3, 3-4, and 3-5 and are plotted in Figures 3-3, 3-4, and 3-5.
3.2.2.5 Reproductive Effects
N o studies were located regarding reproductive effects in humans after oral exposure to 
trichlorobenzenes.
Examination o f  the ovaries and uteri from rats dosed by gavage with up to 300 mg/kg/day 1,2,4-trichloro­
benzene or 600 mg/kg/day 1,2,3-trichlorobenzene or 1,3,5-trichlorobenzene on Gd 6-15  and sacrificed on 
Gd 22 did not show significant gross or microscopic alterations (Black et al. 1988).
N o treatment-related morphological alterations were reported in the reproductive organs from male or 
female rats dosed via the diet with 1,2,4-trichlorobenzene (82 mg/kg/day males, 101 mg/kg/day females),
1.2.3-trichlorobenzene (78 mg/kg/day males, 113 mg/kg/day females), or 1,3,5-trichlorobenzene
(82 mg/kg/day males, 146 mg/kg/day females) for 13 weeks (Côté et al. 1988). N o alterations were noted 
in the reproductive organs from male and female rats dosed via the diet with up to 133.7 and
150.6 mg/kg/day 1,2,4-trichlorobenzene, respectively, for 14 weeks (CMA 1989) or male and female 
mice dosed with up to 1,222 and 1,345 mg/kg/day, respectively, for 13 weeks (Hiles 1989).
Two-year dietary studies with 1,2,4-trichlorobenzene in rats (66.5 mg/kg/day males, 81.4 mg/kg/day 
females) and mice (519.9 mg/kg/day males, 572.6 mg/kg/day females) also did not find gross or 
microscopic alterations in the reproductive organs (Moore 1994a, 1994b).
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Robinson et al. (1981) conducted a multi-generation reproductive study in rats in which the F0 and F1 
generations were exposed to 1,2,4-trichlorobenzene via the mother’s milk until weaning and then directly 
through their drinking water. At approximately 90 days o f  age in the F0 and F1 generations, the rats were 
mated to produce the subsequent generation. The results showed that treatment o f  males and females 
with up to 33 or 53.6 mg/kg/day 1,2,4-trichlorobenzene, respectively, did not affect fertility. The doses 
correspond to the intake o f  test material by the F0 generation at 83 days o f  age and were estimated by the 
investigators.
The NOAELs for reproductive organs histology and the NOAEL for fertility from Robinson et al. (1981) 
are presented in Tables 3-3, 3-4, and 3-5 and are plotted in Figures 3-3, 3-4, and 3-5.
3.2.2.6 Developmental Effects
N o studies were located regarding developmental effects in humans after oral exposure to 
trichlorobenzenes.
Black et al. (1988) examined the developmental effects o f  trichlorobenzenes in Sprague-Dawley rats.
Rats were administered 0, 75, 150, or 300 mg/kg/day 1,2,4-trichlorobenzene or 0, 150, 300, or 
600 mg/kg/day 1,2,3-trichlorobenzene or 1,3,5-trichlorobenzene by gavage in corn oil on Gd 6-15 . Dams 
were sacrificed on Gd 22, and the uterus and ovaries were removed. Fetuses were examined grossly for 
birth defects and were also examined for skeletal and visceral anomalies. A lso, entire fetuses were fixed, 
stained, and examined microscopically. Gestational exposure to the trichlorobenzenes did not 
significantly alter the number o f  pregnancies, fetal weight, litter size, resorptions, or dead fetuses, or the 
incidences o f  skeletal and visceral anomalies. However, fetuses from the 150 mg/kg/day 1,2,4-trichloro­
benzene group and all groups exposed to 1,3,5-trichlorobenzene showed histological alterations in the 
lenses o f  the eye consisting o f  central areas o f  cellular disorientation and disaggregation with ballooning 
and granular degeneration. The investigators stated that autolysis and incomplete preservation made 
examination o f  other fetal tissues difficult, but there did not appear to be any significant treatment-related 
changes. In an additional study, pregnant rats were dosed with 0 or 360 mg/kg/day 1,2,4-trichloro­
benzene on Gd 9-13 and were sacrificed on Gd 14 (Kitchin and Ebron 1983). Treatment did not increase 
resorptions or induce significant embryolethality or teratogenicity; however, it significantly retarded 
development as measured by reduced head length, crown-rump length, somite number, and protein 
content. It should be noted that dams administered 360 mg/kg/day 1,2,4-trichlorobenzene lost 
considerable body weight, which probably contributed to the delayed development o f  the offspring.
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A  series o f  studies were conducted with 1,2,4-trichlorobenzene in which pregnant mice were administered 
0 or 130 mg/kg/day 1,2,4-trichlorobenzene by gavage on Gd 8-12  (Chernoff and Kavlock 1983; Gray and 
Kavlock 1984; Gray et al. 1986). Treatment with 1,2,4-trichlorobenzene had no significant effect on 
average litter weight, pup viability, or growth. Testing o f  the pups in a figure 8 maze for reactive 
locomotor activity levels on postnatal days 22, 58, and 200 showed no significant differences between 
pups from treated groups and controls. Examination o f  female pups at age 30 days showed no significant 
effect on percent vaginal patency. Breeding o f  the F1 pups resulted in no significant effects on percent 
pregnant, age at parturition, F2 litter size, or abnormalities in the F2 generation. Necropsy o f  F1 males at 
about 250 days o f  age showed no significant effects on body weight and weight o f  the liver, testes, 
seminal vesicles, or right kidneys.
In the multi-generation reproductive study conducted by Robinson et al. (1981), treatment with
1,2,4-trichlorobenzene did not affect neonates' weight, litter size, or viability during the pre-weaning 
period in any generation. In addition, there were no treatment-related effects on locomotor activity in the 
F1 or F2 generation rats. O f the organs weighed in the pups (liver, lungs, heart, kidneys, adrenals, and 
gonads, as w ell as seminal vesicles in males), only the adrenals were affected by 1,2,4-trichlorobenzene. 
Absolute weight o f  the adrenals o f  high-dose F0 and F1 males and females were significantly increased 
relative to controls (7-12% ), although with no clear dose-response relationship. Microscopic examination 
o f  liver and kidneys from F1 rats showed no histological damage. Results from blood chemistry tests in 
F0 and F1 rats did not reveal any treatment-related alterations. The dose levels o f  1,2,4-trichlorobenzene 
at which the increase in adrenal weight were observed in F0 males and females were estimated by the 
investigators to be 33 and 53.6 mg/kg/day, respectively.
NOAELs and LOAELs for developmental effects are presented in Tables 3-3, 3-4, and 3-5 and are plotted 
in Figure 3-3, 3-4, and 3-5.
3.2.2.7 Cancer
Two long-term bioassays are available for 1,2,4-trichlorobenzene. Groups o f  F-344 rats (50/sex/group) 
were fed a diet containing 0, 100, 350, or 1,200 ppm 1,2,4-trichlorobenzene for 104 weeks (Moore 
1994a). The diet provided doses o f  0, 5.6, 19.4, or 66.5 mg/kg/day to males and 0, 6.9, 23.5, or
81.4 mg/kg/day to females. In the study in mice, groups o f  B6C3Fi mice (50/sex/group) were fed a diet 
containing 0, 150, 700, or 3,200 ppm 1,2,4-trichlorobenzene (98.9% pure) for 104 weeks (Moore 1994b).
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The diet provided doses o f  0, 21, 100.6, or 519.9 mg/kg/day to males and 0, 26.3, 127, or
572.6 mg/kg/day to females. Parameters evaluated in both studies included mortality (twice daily), 
clinical signs, body weight, and food consumption (weekly for 16 weeks and every 4 weeks thereafter), 
hematology (week 52 and 78 for cellular morphology and leukocyte differential, from control and high­
dose groups), organ weight (at termination, brain, brainstem, liver, kidneys, testes, and epididymis), and 
necropsy and histopathology findings (at termination, all major organs and tissues).
There was no evidence o f  treatment-related increases in the incidences o f  neoplasia in rats. In mice, 
treatment with 1,2,4-trichlorobenzene resulted in significant early mortality in both high-dose male and 
female groups. Percent survival on week 105 was 90, 88, 82, and 10% in males and 78, 76, 84, and 0% in 
females from the control, low-, mid-, and high-dose mice, respectively. Histological examination o f  
tissue and organs from both unscheduled deaths and terminal sacrifice showed significantly increased 
incidence o f  hepatocellular carcinoma in mid- and high-dose groups (males: 8/50, 5/50, 27/50, and 50/50; 
females: 1/50, 1/50, 28/50, and 46/50). Neoplasms in other organs showed comparable incidences 
between the control and treated groups.
EPA classified 1,2,4-trichlorobenzene in Group D: not classifiable as to human carcinogenicity (IRIS 
2010), or as a chemical for which there is “Inadequate Information to A ssess Carcinogenic Potential” 
according to the Guidelines for Carcinogen Risk Assessm ent (EPA 2005a). EPA’s classification was 
done in 1988 and was last revised in 1991.
3.2.3 Dermal Exposure
3.2.3.1 Death
N o studies were located regarding death in humans after dermal exposure to trichlorobenzenes.
A  dermal LD50 o f  6,139 mg/kg was reported for 1,2,4-trichlorobenzene in Sprague-Dawley rats (Brown et 
al. 1969). This value is presented in Table 3-6. The investigators noted that low  doses caused depression 
o f  activity, whereas lethal doses induced extensor convulsions, and that all deaths occurred within 5 days 
o f  exposure. Dermal LD50 values o f  300 and 305 mg/kg were estimated for 1,2,4-trichlorobenzene in 
mice applied doses ranging from 122 to 769 mg/kg (Y amamoto et al. 1978). During the 7-day 
observation period, no deaths occurred in the group dosed with 122 mg/kg 1,2,4-trichlorobenzene. No  
information was located regarding 1,2,3-trichlorobenzene or 1,3,5-trichlorobenzene.
3. HEALTH EFFECTS





























6139 B (LD5Ü) 
mg/kg
Brown et al.1969 
1,2,4-trichIorobenzene
Mouse
(CD-1) 3ÜÜ M (LD5Ü) 
mg/kg
Yamamoto et al. 197S 
1,2,4-trichIorobenzene





Hepatic 591 B 
mg/kg
769 B (liver congestion and 
mg/kg necrosis)




Dermal 7Ü B 
%volume
(erythema)




3 wk Dermal 0.05 M (moderate to severe skin 
mL irritation in older guinea
pigs)
E.I. Dupont 1971 
1,2,4-trichIorobenzene
No to mild irritation was 
reported in young 
guinea pigs; TCB was 




Rabbit 3 d nermal „  0 . Brown et al.1969
2 B (spongiosis, acanthosis,
mL parakeratosis) 1,2,4-trichlorobenzene














































Gn Pig S wk
(albino) 0.05 M 
mL
E.I. Dupont 1971 
1,2,4-trichIorobenzene
NOAEL is for skin 
sensitization; applied 









0.5 B (death of unspecified 
mL/day number of g. pigs)
Brown et al.1969 
1,2,4-trichIorobenzene
Neither number of g. 









Hepatic 0.5 B (necrotic foci in the liver) 
mL/day
Brown et al.1969 
1,2,4-trichIorobenzene








Dermal 1 B (spongiosis, acanthosis, 
mL/day parakeratosis)



















































Cardio 97 B 
mg/kg
Powers et al. 1975 
1,2,4-trichIorobenzene
Effects increased in 
severity as the dose 
increased to 97 mg/kg
Hepatic 97 B 
mg/kg
Renal 97 B 
mg/kg
Dermal 4.8 B (slight skin redness and 
mg/kg scaling with
desquamation)

















































Resp 450 B 
mg/kg
Rao et al. 1982 
1,2,4-trichIorobenzene
NOAELs are for 
histopathology or 
organs and tissues
Cardio 450 B 
mg/kg
Gastro 450 B 
mg/kg
Hemato 450 B 
mg/kg
Musc/skel 450 B 
mg/kg
Hepatic 450 B 
mg/kg
Renal 450 B 
mg/kg
Endocr 450 B 
mg/kg
Dermal 30 B (slight gross and 
























































Brown et al.1969 
1,2,4-trichIorobenzene







Powers et al. 1975 
1,2,4-trichIorobenzene





















Dermal 30 B (keratinization of 
%volume epidermis, inflammation)
Rao et al. 1982 
1,2,4-trichIorobenzene
Rao et al. 1982 
1,2,4-trichIorobenzene
Yamamoto et al. 1982 
1,2,4-trichIorobenzene
NOAEL is for 
histopathology of 
lymphoreticular organs
NOAELs are for 
histopathology or 
organs and tissues
The applied amount 
was 0.03 mL
Bd Wt 60 B
%volume
B = both; Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; F = Female; Gastro = gastrointestinal; Gn Pig = guinea pig; Hemato = hematological; hr = 
hour(s); Immuno/Lymphoret = immunological/lymphoreticular; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; Musc/skel = musculoskeletal; 























Application o f  0.5 mL o f  undiluted 1,2,4-trichlorobenzene to a shaven area o f  the back o f  guinea pigs 
6 hours/day, 5 days/week for 3 weeks resulted in the death o f  an unspecified number o f  guinea pigs; the 
time o f  death was also not specified (Brown et al. 1969).
3.2.3.2 Systemic Effects
The highest NOAEL values and all LOAEL values from each study for systemic effects in each species 
and duration category are recorded in Tables 3-6, 3-7, and 3-8.
N o studies were located regarding systemic effects in humans after dermal exposure to trichlorobenzenes.
Respiratory Effects. Application o f  technical-grade 1,2,4-trichlorobenzene to a shaved area o f  the 
back skin o f  rabbits in doses o f  up to 450 mg/kg 5 days/week for 4 weeks did not induce histological 
alterations in the respiratory tract including the nasal turbinates (Rao et al. 1982).
Cardiovascular Effects. N o histological alterations were observed in the heart from rabbits 
administered 0.2 mL o f  a 100% solution o f  technical-grade 1,2,4-trichlorobenzene (97 mg/kg) to the ear 
3 times/week for 13 weeks (Powers et al. 1975). Similar results were reported in rabbits following 
application o f  technical-grade 1,2,4-trichlorobenzene to a shaved area o f  the back skin in doses o f  up to 
450 mg/kg, 5 days/week for 4 weeks (Rao et al. 1982).
Gastrointestinal Effects. Application o f  technical-grade 1,2,4-trichlorobenzene to a shaved area o f  
the back skin o f  rabbits in doses o f  up to 450 mg/kg 5 days/week for 4 weeks did not induce histological 
alterations in the gastrointestinal tract, including the nasal turbinates (Rao et al. 1982).
Hematological Effects. N o treatment-related hematological alterations were reported in rabbits 
following application o f  technical-grade 1,2,4-trichlorobenzene to a shaved area o f  the back skin in doses 
o f  up to 450 mg/kg, 5 days/week for 4 weeks (Rao et al. 1982).
Musculoskeletal Effects. Histological examination o f  skeletal and bone from rabbits administered 
technical-grade 1,2,4-trichlorobenzene to a shaved area o f  the back skin in doses o f  up to 450 mg/kg,
5 days/week for 4 weeks did not show treatment-related effects (Rao et al. 1982).
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Hepatic Effects. In an acute lethality study in mice applied single doses o f  1,2,4-trichlorobenzene 
ranging from 123 to 769 mg/kg onto the skin, mice that survived the highest dose showed congestion and 
necrosis o f  the liver (Yamamoto et al. 1978). Guinea pigs that died following application o f  0.5 mL o f  
undiluted 1,2,4-trichlorobenzene to a shaven area o f  the back for 6 hours/day, 5 days/week for 3 weeks 
showed necrotic foci in the liver (Brown et al. 1969).
N o histological alterations were observed in the liver from rabbits administered 0.2 mL o f  a 100% 
solution o f  technical-grade 1,2,4-trichlorobenzene (97 mg/kg) to the ear 3 times/week for 13 weeks 
(Powers et al. 1975). Application o f  technical-grade 1,2,4-trichlorobenzene to a shaved area o f  the back 
skin o f  rabbits in doses o f  up to 450 mg/kg, 5 days/week for 4 weeks did not induce histological 
alterations in the liver; grossly, however, the liver o f  rabbits treated with 450 mg/kg did show slight pallor 
(Rao et al. 1982).
Renal Effects. N o histological alterations were reported in the kidneys from rabbits applied 0.2 mL o f  
a 100% solution o f  technical-grade 1,2,4-trichlorobenzene (97 mg/kg) to the ear 3 tim es/week for 
13 weeks (Powers et al. 1975). N o histological alterations were reported in the kidneys from rabbits 
following application o f  technical-grade 1,2,4-trichlorobenzene to a shaved area o f  the back skin in doses 
o f  up to 450 mg/kg, 5 days/week for 4 weeks (Rao et al. 1982). However, urinalysis revealed a slight but 
significant increase in urinary coproporphyrin in high-dose males on day 24 o f  the study, which was 
considered only a slight or questionable effect o f  treatment.
Endocrine Effects. Microscopic examination o f  the pituitary gland, pancreas, adrenal gland, and 
thyroid and parathyroid glands from rabbits administered technical-grade 1,2,4-trichlorobenzene to a 
shaved area o f  the back skin in doses o f  up to 450 mg/kg, 5 days/week for 4 weeks showed no significant 
treatment-related alterations (Rao et al. 1982).
Dermal Effects. Application o f  1,2,4-trichlorobenzene in concentrations o f  70-100%  to the skin o f  
mice produced erythema, but histological examination o f  the skin showed no remarkable change 
(Y amamoto et al. 1978). Application o f  0.05 mL o f  a 75% solution o f  1,2,4-trichlorobenzene to the 
shaved intact shoulder o f  guinea pigs for 24 hours produced no to mild irritation in young animals, but 
moderate to severe irritation in older guinea pigs (E.I. DuPont 1971). In a repeated treatment study, 1 mL 
o f  undiluted 1,2,4-trichlorobenzene was applied in a patch o f  lint to the shaved skin o f  rabbits for 6 hours 
during 3 consecutive days (Brown et al. 1969). Seven days after the first application, histological 
examination o f  the skin showed spongiosis, acanthosis, and parakeratosis.
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Repeated applications o f  a 10% solution o f  1,2,3-trichlorobenzene to the abraded belly o f  rabbits caused 
questionable irritation and edema that healed normally (Dow Chemical 1956). When the solution was 
applied to intact skin, essentially no response was observed except for slight exfoliation after six 
applications. Application o f  undiluted 1,2,3-trichlorobenzene to the intact skin induced slight reddening 
to slight exfoliation after seven applications. However, in the abraded area, the undiluted chemical 
produced moderate reddening o f  the skin, slight edema, and trace o f  necrosis; healing was described as 
ordinary (Dow Chemical 1956).
In a study with 1,3,5-trichlorobenzene, 500 mg o f  the chemical was applied to the abraded or intact skin 
o f  six rabbits (Jorgenson et al. 1976). The test sites were covered and 24 hours later, the excess 
compound was removed and the sites were scored for erythema and edema. A ll treated rabbits showed 
erythema and edema at the 24-hour reading, and only three rabbits showed erythema at the 72-hour 
reading. The chemical was considered mildly irritating.
Intermittent application o f  0.5 mL o f  undiluted 1,2,4-trichlorobenzene to guinea pigs or 1 mL to rabbits 
for 3 weeks produced spongiosis, acanthosis, and parakeratosis in both species (Brown et al. 1969). 
Rabbits applied 0.2 mL o f  a 5% solution o f  technical-grade 1,2,4-trichlorobenzene (4.8 mg/kg) onto the 
ventral surface o f  the ear 3 tim es/week for 13 weeks showed slight redness with slight scaling and 
desquamation that did not increase in severity after 39 exposures (Powers et al. 1975). Rabbits applied 
25 or 100% solutions (24 or 97 mg/kg) showed moderate to severe irritation characterized by slight to 
severe erythema, severe scaling, desquamation and encrustation with slight enlargement o f  the follicles, 
some hair loss, and scarring. There was no evidence o f  acne form dermatitis.
A  study was conducted in rabbits in which the animals were applied technical-grade 1,2,4-trichloro­
benzene to a shaved area o f  the back skin in doses o f  0, 30, 150, or 450 mg/kg, 5 days/week for 4 weeks 
(Rao et al. 1982). At termination, the skin o f  all treated rabbits showed localized effects considered slight 
at the low - and mid-dose levels and moderate at the high-dose level. The effects consisted o f  an area 
where regrowing fur was matted by a white bran-like scale, slight thickening o f  the skin, fissures which 
progressed to erosions and shallow ulcers, and erythema. Increasing dose increased the affected area. 
Microscopically, the skin site showed changes including inflammation, focal erosion and ulcers, and 
accumulation o f  inflammatory cells with varying degrees o f  exudation. Some rabbits showed slight 
superficial edema with slight fibrosis.
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Painting 0.03 mL o f  a 30% solution o f  1,2,4-trichlorobenzene 2 tim es/week for 2 years induced 
thickening and keratinization o f  the epidermis followed by inflammation (Y amamoto et al. 1982).
Ocular Effects. Instillation o f  a 10% solution o f  1,2,3-trichlorobenzene to the eyes o f  rabbits followed  
by washing with water produced marked pain, slight conjunctival irritation, and trace o f  corneal injury 
(Dow Chemical 1956). The corneal injury almost completely healed in 24 hours, and irritation almost 
completely healed in 48 hours. In the unwashed eye, there was marked pain, conjunctival irritation and 
no corneal injury; complete healing occurred in 24 hours. In unwashed eyes instilled with undiluted
1,2,3-trichlorobenzene, there was a trace o f  pain, slight conjunctival irritation, and no corneal injury; 
healing occurred in 48 hours. The same was found in the washed eye, but healing occurred in 24 hours.
In a study with 1,3,5-trichlorobenzene, an amount o f  100 mg o f  the chemical was applied into the eyes o f  
rabbits (Jorgenson et al. 1976). Some rabbits had the compound washed out at 30 seconds or 5 minutes 
after application, or did not have the compound washed out. The eye was graded for ocular lesions at 24, 
48, 72, and 96 hours. There was no corneal damage in rabbits that underwent washing, but minor damage 
was observed in the no-wash group. The cornea returned to normal within 3 days. Occasional 
circumcorneal injection was seen in some rabbits, but all effects on the iris disappeared by posttreatment 
day 4. Conjunctival responses occurred in all treated rabbits and generally involved varying degrees o f  
redness, chemosis, and discharge. The eyes o f  the rabbits in the 30-second wash group returned to normal 
within 24 hours, but the 5-minute wash group was not normal until day 3, and the no-wash group did not 
return to normal until day 7. The investigators concluded that 1,3,5-trichlorobenzene produced mild 
transitory eye irritation.
Histological examination o f  the eyes from rabbits administered technical-grade 1,2,4-trichlorobenzene to 
a shaved area o f  the back skin in doses o f  up to 450 mg/kg, 5 days/week for 4 weeks showed no 
significant treatment-related alterations (Rao et al. 1982).
Body Weight Effects. Application o f  0.2 mL o f  a 100% solution o f  technical-grade 1,2,4-trichloro­
benzene (97 mg/kg) to the ear o f  rabbits 3 times/week for 13 weeks did not affect body weight (Powers et 
al. 1975). Application o f  technical-grade 1,2,4-trichlorobenzene to a shaved area o f  the back skin o f  
rabbits in doses o f  up to 450 mg/kg, 5 days/week for 4 weeks did not significantly affect body weight 
(Rao et al. 1982).
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3.2.3.3 Immunological and Lymphoreticular Effects
N o histological alterations were reported in the spleen from rabbits administered 0.2 mL o f  a 100% 
solution o f  technical-grade 1,2,4-trichlorobenzene (97 mg/kg) to the ear 3 tim es/week for 13 weeks 
(Powers et al. 1975). Similar results were reported for the spleen, thymus, and lymph nodes from rabbits 
following application o f  technical-grade 1,2,4-trichlorobenzene to a shaved area o f  the back skin in doses 
o f  up to 450 mg/kg, 5 days/week for 4 weeks (Rao et al. 1982).
Tests for skin sensitization conducted with 1,2,4-trichlorobenzene or 1,3,5-trichlorobenzene in guinea 
pigs were negative (Brown et al. 1969; E.I. DuPont 1971; Jorgenson et al. 1976).
3.2.3.4 Neurological Effects
Microscopic examination o f  the brain, spinal cord, and peripheral nerve from rabbits applied technical- 
grade 1,2,4-trichlorobenzene onto a shaved area o f  the back skin in doses o f  up to 450 mg/kg,
5 days/week for 4 weeks showed no significant treatment-related alterations (Rao et al. 1982).
3.2.3.5 Reproductive Effects
Application o f  technical-grade 1,2,4-trichlorobenzene to a shaved area o f  the back skin o f  male and 
female rabbits in doses o f  up to 450 mg/kg, 5 days/week for 4 weeks did not induce gross or microscopic 
alterations in the reproductive organs (Rao et al. 1982).
3.2.3.6 Developmental Effects
N o studies were located that assessed developmental effects in humans or animals following dermal 
exposure to trichlorobenzenes.
3.2.3.7 Cancer
A  2-year cancer study was conducted with 1,2,4-trichlorobenzene in mice (Yamamoto et al. 1982). 
Groups o f  Slc:ddY mice (75/sex/group) were painted with 0.03 mL o f  a 30 or 60% solution o f
1,2,4-trichlorobenzene 2 times/week for 104 weeks. There was high mortality both in the treated and 
control groups, beginning on week 30. At week 83, <10% o f  treated females and <15% o f  treated males 
survived. The main causes o f  death were respiratory infections, amyloidosis, and tumors. Histological 
alterations in tissues appeared more prevalent in the high-dose group, but the number o f  mice examined
3. HEALTH EFFECTS
***DRAFT FOR PUBLIC COMMENT***
TRICHLOROBENZENES 107
was not indicated. Tumors developed in the lungs, kidneys, stomach, urinary bladder, mammary gland, 
and skin in both treated and control groups. There was no indication of the time to first tumor appearance 
or whether the tumors were all found in different animals or were multiple tumors in the same animal. 
Skin tumors were classified as squamous cell carcinoma, papilloma, and fibroma. This study is 
inadequate for assessing the potential carcinogenicity of 1,2,4-trichlorobenzene following dermal 
exposure.
3.3 GENOTOXICITY
For the most part, genotoxicity data for trichlorobenzenes have provided negative evidence of 
mutagenicity in i n  v i t r o  tests with prokaryotic organisms (i.e., S a l m o n e l l a  t y p h i m u r i u m ) and positive 
evidence of deoxyribonucleic acid (DNA) damage at concentrations that were generally also cytotoxic in 
mammalian cell systems i n  v i t r o . I n  v i v o  studies suggest that trichlorobenzenes are clastogenic. The role, 
i f  any, that these effects may play in the liver carcinogenicity of 1,2,4-trichlorobenzene in mice (Moore 
1994b) is unknown. Tables 3-9 and 3-10 provide a summary of genotoxicity data for these test systems.
In vitro Exposure Studies. As shown in Table 3-9, i n  v i t r o  assays of gene mutation in various strains of 
S .  t y p h i m u r i u m  provided mostly negative results, regardless of the presence or absence o f metabolic 
activation in the incubation medium (Ethyl Corp. 1975; Haworth et al. 1983; Jorgenson et al. 1976; Kubo 
et al. 2002; Lawlor et al. 1979; Nohmi et al. 1985; Ono et al. 1992; Schoeny et al. 1979).
Studies with mammalian cell systems i n  v i t r o  assessed mainly clastogenicity, cytotoxicity, and DNA 
damage, and for the most part, yielded positive results. A series of experiments conducted by Fratello et 
al. (1997) showed 1,2,3-trichlorobenzene and 1,2,4-trichlorobenzene to induce DNA damage as assessed 
by detecting loss o f DNA fragment by means of cytofluorimetric analysis. Since the preparations used 
(Chinese hamster V79 cells) were devoid of cytochrome P-450 activity, the DNA damage was attributed 
to the parent compound rather than to a toxic metabolite. 1,3,5-Trichlorobenzene was considerably less 
cytotoxic than the other two isomers (Fratello et al. 1997). A similar study also found 1,2,4-trichloro- 
benzene to be cytotoxic in Chinese hamster ovary cells by inhibiting protein and DNA synthesis (Garret 
and Lewtas 1983). 1,2,4-Trichlorobenzene produced positive results in tests for cytotoxicity in rat 
hepatocytes and was positive in a transformation assay in rat liver epithelial (ARL) cells in the absence of 
metabolic activation, but at concentrations that were toxic to the cells (Shimada et al. 1983). Conversely, 
in an hepatocyte primary culture (HPC)/DNA repair assay conducted by Shimada et al. (1983),
1,2,4-trichlorobenzene was not genotoxic to rat hepatocytes in the absence of metabolic activation.
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Table 3-9. Genotoxicity of Trichlorobenzenes In Vitro
Results
With Without






1,2,3-TCB Gene mutation Haworth et al. 1983
S. typhimurium, TA98, 
TA100
1,2,3-TCB Gene mutation — — Kubo et al. 2002
S. typhimurium, TA98, 
TA100, TA2637
1,2,3-TCB Gene mutation — - Nohmi et al. 1985
S. typhimurium, 
TA1535/pSK1002
1,2,3-TCB Gene mutation — — Ono et al. 1992
S. typhimurium, TA98, 
TA100, TA1535, 
TA1537
1,2,4-TCB Gene mutation Haworth et al. 1983
S. typhimurium, TA98, 
TA100
1,2,4-TCB Gene mutation — — Kubo et al. 2002
S. typhimurium, TA98, 
TA100, TA2637
1,2,4-TCB Gene mutation - — Nohmi et al. 1985
S. typhimurium, 
TA1535/pSK1002
1,2,4-TCB Gene mutation — + Ono et al. 1992






Schoeny et al. 1979
S. typhimurium, TA98, 
TA100, TA1535, 
TA1537, TA1538
1,2,4-TCB Gene mutation Ethyl Corp. 1975
Saccharomyces 
cerevisiae D3





S. typhimurium, TA98, 
TA100, TA1535, 
TA1537
1,3,5-TCB Gene mutation Haworth et al. 1983
S. typhimurium, TA98, 
TA100, TA2637
1,3,5-TCB Gene mutation — — Nohmi et al. 1985
S. typhimurium, 
TA1535/pSK1002
1,3,5-TCB Gene mutation — — Ono et al. 1992
S. typhimurium, TA98, 
TA100, TA1535, 
TA1537, TA1538
1,3,5-TCB Gene Mutation Jorgenson et al. 1976
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Table 3-9. Genotoxicity of Trichlorobenzenes In Vitro
Results
Species (test system) Compound
With Without 




1.3.5-TCBE. coli, W3110 and 
p3478
Bacillus subtilis, H17 1,3,5-TCB
and M45
S. cerevisiae D3 1,3,5-TCB
Mammalian cells:
Chinese hamster lung 1,2,3-TCB 
(CHL) cells
Chinese hamster ovary 1,2,3-TCB 
(CHO) cells
Chinese hamster V79 1,2,3-TCB
cells
Chinese hamster V79 1,2,3-TCB
cells
Chinese hamster V79 1,2,3-TCB
cells
Chinese hamster V79 1,2,4-TCB
cells
Chinese hamster V79 1,2,4-TCB
cells
Chinese hamster V79 1,2,4-TCB
cells
CHO cells
Rat hepatocyte (male 1,2,4-TCB 
F344 Fischer)
Rat hepatocyte (male 1,2,4-TCB 
F344 Fischer)
Rat liver epithelial 1,2,4-TCB 
(ARL) cells (male F344 
Fischer)




DNA repair No data
assay











Cell replication No data
(Colony
forming ability)




Cell replication No data
(Colony
forming ability)
DNA damage No data
1,2,4-TCB Cytotoxicity No data




Gene mutation, No data
Transformation
Assay
Cytotoxicity, No data 
neutral red 
uptake assay
-  Jorgenson et al. 1976
-  Jorgenson et al. 1976
-  Jorgenson et al. 1976
(+) Jorgenson et al. 1976
-  McElroy et al. 2003
-  McElroy et al. 2003
+ Fratello et al. 1997
+ Fratello et al. 1997
+ Fratello et al. 1997
+ Fratello et al. 1997
+ Fratello et al. 1997
+ Fratello et al. 1997
+ Garrett and Lewtas
1983
-  Shimada et al. 1983
+ Shimada et al. 1983
+ Shimada et al. 1983
(+) Fratello et al. 1997
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Table 3-9. Genotoxicity of Trichlorobenzenes In Vitro
S p e c ie s  (test sy stem ) C om pound End point
R esu lts
With W th out  
activation activation R eferen ce
Chinese hamster V79 1,3,5-TCB Cell replication No data (+) Fratello et al. 1997cells (Colony
forming ability)
Chinese hamster V79 1,3,5-TCB DNA damage No data (+) Fratello et al. 1997cells
+ = positive result; (+) = weakly positive result; — = negative result; DNA = deoxyribonucleic acid; HPC = hepatocyte 
primary culture; TCB = trichlorobenzene
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Table 3-10. Genotoxicity of Trichlorobenzenes In Vivo
Species (test system) Compound End point Results Reference
Mouse (male NMR, 
5/dose)
1,2,3-TCB Chromosomal aberrations, 
micronucleus assay
+ Mohtashamipur et al. 1987
Mouse (male Swiss 
CD-1)
1,2,3-TCB Chromosomal aberrations, 
micronucleous assay
+ Parrini et al. 1990
Mouse (male NMR, 
5/dose)
1,2,4-TCB Chromosomal aberrations, 
micronucleus assay
+ Mohtashamipur et al. 1987
Mouse (male Swiss 
CD-1)
1,2,4-TCB Chromosomal aberrations, 
micronucleous assay
+ Parrini et al. 1990
Mouse (male NMR, 
5/dose)
1,3,5-TCB Chromosomal aberrations, 
micronucleus assay
+ Mohtashamipur et al. 1987
Mouse (male Swiss 
CD-1)
1,3,5-TCB Chromosomal aberrations, 
micronucleous assay
+ Parrini et al. 1990
Drosophila
melanogaster
1,3,5-TCB Gene mutation, sex-linked 
recessive lethal test
— Zimmering et al. 1985
+ = positive result; -  = negative result; TCB = trichlorobenzene
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1.2.4-Trichlorobenzene did not induce chromosomal aberrations in Chinese hamster lung (CHL) or ovary 
(CHO) cells in assays conducted with and without metabolic activation (McElroy et al. 2003).
I n  v i v o  E x p o s u r e  S t u d i e s .  There were few  studies available for review that examined the potential i n  
v i v o  genotoxicity o f  trichlorobenzenes; however, as seen in Table 3-10, the results o f  the available studies 
were mostly positive. Intraperitoneal administration o f  either one o f  the trichlorobenzene isomers to male 
NMRI mice in doses ranging from 210 to 1,700 mg/kg resulted in dose-related increases in micronuclei in 
polychromatic erythrocytes o f  the femoral bone marrow 30 hours after the first o f  two injections 
(Mohtashamipur et al. 1987). A  similar study in male Swiss CD1 mice also reported increases in 
micronuclei frequency in the femoral bone marrow 6 hours after a second intraperitoneal injection o f  
500-650 mg/kg o f  either one o f  the trichlorobenzene isomers (Parrini et al. 1990). There were no 
significant differences among the trichlorobenzenes in either study. In a sex-linked recessive lethal test,
1.3.5-trichlorobenzene was negative for mutagenesis in D r o s o p h i l a  m e l a n o g a s t e r  (Zimmering et al.
1985).
3.4 TOXICOKINETICS
Results from studies o f  orally exposed animals indicate that trichlorobenzene isomers are rapidly and 
extensively absorbed, widely distributed, and quickly eliminated. Urinary excretion o f  radiolabeled
1,2,3-, 1,2,4-, and 1,3,5-trichlorobenzene has illustrated that at least 50-80%  o f  the administered 
radioactivity is absorbed and excreted in rats within 24 hours o f  dose administration. Urinary elimination 
o f  metabolites is the major route o f  elimination, with fecal elimination representing a minor pathway. In 
bile duct-cannulated rats, significant enterohepatic circulation o f  metabolites has been demonstrated. 
Results from rat studies indicate that, once absorbed, all three isomers are widely distributed throughout 
the body and are detectable in tissue within 0.5 hours o f  dosing. Tissues with the highest peak 
concentrations following oral administration included fat, skin, liver, kidneys, bladder, and the 
gastrointestinal tract. Identification o f  metabolites in urine, feces, and bile following exposure o f  rabbits, 
rats, and monkeys to the individual isomers indicates that the parent compounds are metabolized to 
phenolic compounds through arene oxide intermediates, which are conjugated to glutathione, glucuronic 
acid, or sulfates before elimination in the urine, feces, or bile. Some evidence is available suggesting that 
conjugation with glutathione predominates in rats, whereas glucuronidation predominates in monkeys. 
Enzymes involved in the proposed metabolic schemes for each isomer have not been definitively 
identified. However, the initial formation o f  arene oxides and phenols is likely to be catalyzed by
3. HEALTH EFFECTS
***DRAFT FOR PUBLIC COMMENT***
TRICHLOROBENZENES 113
cytochrome P450 (CYP) oxygenases. The relevance o f  the animal toxicokinetic information for humans 
has not been established because, as indicated below, there are no human data.
Studies describing the absorption, distribution, metabolism, and elimination o f  1,2,3-, 1,2,4-, and
1,3,5-trichlorobenzene following oral exposure in humans, as w ell as inhalation and dermal exposure in 
humans and animals, are not available.
3.4.1 Absorption
N o information was located regarding absorption o f  trichlorobenzenes in humans following any route o f  
exposure.
3.4.1.1 Inhalation Exposure
Quantitative data on the absorption o f  trichlorobenzenes following inhalation exposure are not available 
for animals. However, indirect evidence that 1,2,4-trichlorobenzene is absorbed through inhalation can 
be inferred from minor liver effects in rats following inhalation exposure (Kociba et al. 1981).
3.4.1.2 Oral Exposure
Evidence from elimination studies in animals indicate that trichlorobenzene isomers are rapidly and 
extensively absorbed through the gastrointestinal tract in animals.
1 , 2 , 3 - T r i c h l o r o b e n z e n e .  Radiolabeled 1,2,3-trichlorobenzene has been detected in both the urine and 
feces o f  rats following oral exposure. Specifically, 92% o f  administered radioactivity was eliminated 
through the urine and feces within 24 hours o f  administration o f  a single 10 mg/kg gavage dose o f  
14C-labeled 1,2,3-trichlorobenzene to male Sprague-Dawley rats (Chu et al. 1987). Overall excretion 
increased to 95% at 48 hours post ingestion. The percentage o f  the administered radioactivity in urine 
alone accounted for 56 and 59% o f  the total ingested dose at 24 and 48 hours, respectively. Therefore, 
assuming that none o f  the radioactivity excreted in the feces was absorbed, at least 59% o f  the 
administered dose was absorbed. These results are also consistent with as much as 95% o f  the 
administered dose may have been absorbed i f  all radiolabeled material excreted in the feces had first been 
absorbed and excreted through the biliary system.
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1 . 2 . 4 - T r i c h l o r o b e n z e n e .  Within 7 days after receiving a dose o f  50 mg/kg o f  14C-labeled 1,2,4-trichloro- 
benzene, male Wistar rats excreted 66 and 17% o f  the radioactivity in urine and feces, respectively, 
suggesting that at least 66% o f  the administered dose was absorbed (Tanaka et al. 1986). Radioactivity in 
expired air accounted for 2.1% o f  the absorbed dose. Excretion in all three excreta reached a peak on day 
3, indicating rapid absorption and elimination. Measurements o f  biliary excretion for 4 days in bile- 
cannulated rats showed that radioactivity in bile accounted for 45% o f  the administered dose (Tanaka et 
al. 1986). Bakke et al. (1992) reported that >60% o f  a 21 mg/kg dose o f  14C-1,2,4-trichlorobenzene was 
excreted in bile, while 21% was excreted in the urine o f  bile-cannulated male Sprague-Dawley rats within 
24 hours. Findings from this study indicate an 81% absorption rate following oral exposure to
1.2.4-trichlorobenzene. In control non-cannulated rats, 70 and 9% o f  the radioactivity was excreted 
within 24 hours in urine and feces, respectively (Bakke et al. 1992). Following 7 consecutive days o f  oral 
dosing o f  male Sprague-Dawley rats with 181.5 mg/kg/day 14C-1,2,4-trichlorobenzene, radioactivity in 
urine was still detectable 21 days after the first oral administration; total radioactivity detected in urine 
accounted for approximately 72% o f  the administered dose (Smith and Carlson 1980). Radioactivity in 
the feces was not detectable past day 15 and accounted for only 4% o f  the administered dose. Thus, 
between 72 and 76% o f  the administered dose was absorbed in this study.
14C-Labeled material was excreted by both monkeys and rats following oral exposure to a 10 mg/kg dose 
o f  14C-labeled 1,2,4-trichlorobenzene. By 24 hours after dosing, female Rhesus monkeys had excreted 
about 40% o f  the administered radioactivity in the urine and <1% in the feces. Male albino rats, however, 
excreted 84% o f  the administered radioactivity in the urine and 11% in the feces by 24 hours. With 
intravenous administration o f  10 mg/kg 14C-labeled 1,2,4-trichlorobenzene, monkeys eliminated about 
22% o f  the administered radioactivity in urine within 24 hours (none was detected in feces), whereas 
radioactivity in 24-hour urine and feces in rats accounted for 78 and 7% o f  the administered dose, 
respectively (Lingg et al. 1982). These data suggest that differences in elimination rates between rats and 
monkeys may be due to species differences in metabolic rate or elimination rate, rather than absorption 
rate.
1 . 3 . 5 - T r i c h l o r o b e n z e n e .  The excretion o f  radioactivity derived from 1,3,5-trichlorobenzene in both the 
urine and feces o f  rats has also been monitored following oral exposure. Within 24 hours o f  a single
10 mg/kg dose o f  14C-labeled 1,3,5-trichlorobenzene to male Sprague-Dawley rats, 82% o f  radioactivity 
was eliminated through the urine and feces (Chu et al. 1987). Overall excretion increased to 89% at 
48 hours post ingestion. The percentage o f  administered radioactivity in urine accounted for 47 and 50% 
at 24 and 48 hours, respectively. Thus, assuming that none o f  the radioactivity excreted in the feces was
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absorbed, at least 50% o f  the administered dose was absorbed. These results are also consistent with as 
much as 89% o f  the administered dose may have been absorbed i f  all radiolabeled material excreted in the 
feces had first been absorbed and excreted through the biliary system.
3.4.1.3 Dermal Exposure
N o quantitative data were located on the absorption o f  trichlorobenzenes following dermal exposure o f  
animals. Theoretical predictive models based on chemical and physical properties, however, have 
indicated that 1,2,4-trichlorobenzene has a significant potential for dermal absorption (Fiserova- 
Bergerova et al. 1990). Specifically, the findings o f  this study suggest that dermal exposure to
1,2,4-trichlorobenzene is expected to raise the biological levels o f  this isomer 30% above those occurring 
during inhalation exposure to threshold limit values. 1,2,4-Trichlorobenzene absorption can also be 
inferred from evidence o f  systemic toxicity in animals following dermal exposure (Brown et al. 1969; 
Yamamoto et al. 1978).
3.4.2 Distribution
1,2,3- and 1,3,5-Trichlorobenzene were detected in autopsies o f  Canadian citizens at median levels o f  
1.9 and 1.1 ng/g, respectively, and at maximum levels o f  9.1 and 3.7 ng/g, respectively (Mes 1992).
Levels were below the detection limits in blood samples. 1,2,4-Trichlorobenzene was detected in human 
follicular fluid at a mean concentration o f  214 pg/mL for patients undergoing i n  v i t r o  fertilization in 
Canada (Y ounglai et al. 2002). Trichlorobenzenes detected in the general population are the result o f  
inhalation o f  ambient air and ingestion o f  food and drinking water contaminated with trichlorobenzenes. 
N o specific information was located regarding distribution o f  trichlorobenzenes in children.
3.4.2.1 Inhalation Exposure
N o data on the distribution o f  trichlorobenzenes following inhalation exposure were located for animals.
3.4.2.2 Oral Exposure
Trichlorobenzene isomers are readily distributed throughout bodily tissues in animals. However, the level 
o f  distribution and length o f  retention vary between isomers. Several studies have been conducted with 
14C-labeled trichlorobenzenes. It should be noted that generally in these studies no distinction can be
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made between parent compound, metabolites, and recycled carbon incorporated into body 
macromolecules.
1 . 2 . 3 - T r i c h l o r o b e n z e n e .  Radioactivity was present in the blood and tissues o f  male Sprague-Dawley rats 
0.5 hours following gavage administration o f  10 mg/kg 14C-labeled 1,2,3-trichlorobenzene (Chu et al. 
1987). Tissue concentrations peaked at 24 hours with very high concentrations appearing in the 
gastrointestinal tract (2,180 ppb), liver (277 ppb), fat (1,920 ppb), kidney (399 ppb), and bladder
(284 ppb). Seven days after dosing, radioactivity in the brain, muscle, testes, and seminal vesicles were 
no longer detectible. Radioactivity was nearly undetectable in the liver, fat, and skin by 56 days after 
dosing (Chu et al. 1987). Chu et al. (1987) reported gas chromatography (GC) data that indicated that 
most o f  the radioactivity in skin, liver, and fat was the parent compound, whereas that in muscle and 
kidney was predominantly more polar metabolites.
1 . 2 . 4 - T r i c h l o r o b e n z e n e .  Radioactivity was found in the blood and tissues o f  male Sprague-Dawley rats 
0.5 hours after oral dosing with 10 mg/kg 14C-labeled 1,2,4-trichlorobenzene (Chu et al. 1987). Levels 
peaked around 4 hours and declined thereafter. High concentrations remained present in the bladder 
(1,280 ppb), kidney (1,160 ppb), fat (4,260 ppb), skin (243 ppb), liver (680 ppb), and adrenal glands 
(850 ppb) at 24 hours. Seven days after dosing, radioactivity was no longer detectable in the brain, 
spleen, muscle, testes, seminal vesicles, epididymis, or prostate. Most tissues showed levels o f  
radioactivity barely distinguishable from background levels 28 days after dosing (<10 ppb except adrenals 
with 40 ppb) (Chu et al. 1987). Sprague-Dawley rats given a daily oral dose o f  181.5 mg/kg 14C-labeled
1.2.4-trichlorobenzene for 7 consecutive days showed the highest initial concentration o f  radioactivity in 
the adrenal glands (Smith and Carlson 1980). This level declined rapidly and no radioactivity could be 
detected 11 days after dosing. Abdominal fat had the highest concentrations on day 1 (2,033 dpm/g) and 
maintained detectable concentrations (~20% o f  day 1 level) through the remainder o f  the 16-day 
observation period. The liver also maintained detectable concentrations (1,075 dpm/g on day 1 and
317 dpm/g on day 19) throughout the entire observation period (Smith and Carlson 1980). High levels o f  
radioactivity were found in adipose tissue and skin (81 and 15% o f  administered dose, respectively)
12 hours following administration o f  a single 50 mg/kg oral dose o f  14C-labeled 1,2,4-trichlorobenzene to 
male Wistar rats. Radioactivity was also detectable in muscle and intestine at this time (~8 and 5% o f  
administered dose). By 168 days after dosing, radioactivity was virtually undetectable in all examined 
tissues (Tanaka et al. 1986).
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1.3.5-Trichlorobenzene. An early study by Parke and Williams (1960) indicated a wide distribution of
1.3.5-trichlorobenzene following a 500 mg/kg dose in rabbits. Specifically, 13% of the administered dose 
was detected in the feces, 23% in the gut, 5% in the pelt, 5% in the depot fat, and 22% in the carcass
8 days after administration. A later study revealed radioactivity in the blood and tissues 0.5 hours after 
oral dosing of male Sprague-Dawley rats with 10 mg/kg of 14C-labeled 1,3,5-trichlorobenzene (Chu et al. 
1987). As with the other isomers, levels of radioactivity peaked at 1 day after administration. The peak 
concentrations in tissues with the highest concentrations showed the following order: fat (8,960 ppb)
> gastrointestinal tract > salivary gland > adrenal « bladder > liver > kidney > pancreas > epididymis
> prostate > skin > lung > seminal vesicle (410 ppb). Peak tissue concentrations were generally higher 
following administration of 1,3,5-trichlorobenzene compared with 1,2,3- and 1,2,4-trichlorobenzene (Chu 
et al. 1987). Chu et al. (1987) reported GC data that indicated that most of the radioactivity in skin, liver, 
and fat was the parent compound, whereas that in muscle and kidney was predominantly more polar 
metabolites. Côté et al. (1988) found an accumulation of trichlorobenzene isomers in the fat and liver of 
rats, indicating that 1,3,5-trichlorobenzene accumulated at a higher level in these tissues than 1,2,4- and
1,2,3-trichlorobenzene when presented at 1,000 ppm in food for 13 weeks. The levels of isomer in the fat 
(15.5-76 ppm in males; 7.8-49 ppm in females) were one order of magnitude higher than those found in 
the liver (1.4-4.3 ppm in males; 0.73-1.9 ppm in females).
Trichlorobenzenes have been identified in human breast milk; therefore, infants may also be potentially 
exposed through breast feeding (see Section 6.6, Exposures of Children).
3.4.2.3 Dermal Exposure
Quantitative data on the distribution of trichlorobenzenes following dermal exposure were not located for 
humans or animals.
3.4.3 Metabolism
There is no information regarding the metabolism of trichlorobenzenes in humans following exposure by 
any route or regarding the metabolism of trichlorobenzenes in animals following inhalation or dermal 
exposure. Several studies have examined and identified urinary metabolites following oral, 
intraperitoneal, or intravenous exposure of rabbits (Jondorf et al. 1955; Kohli et al. 1976; Parke and 
Williams 1960), rats (Bakke et al. 1992; Lingg et al. 1982), and monkeys (Lingg et al. 1982). Identified 
metabolites are consistent with the initial formation of phenolic intermediates (indicative of arene oxide 
intermediates), which become conjugated with glutathione or glucuronic acid prior to excretion in the
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urine or bile. A  comparison o f  rat and monkey urinary metabolites indicated that glutathione conjugation 
was the predominant pathway in rats, whereas glucuronidation was predominant in monkeys (Lingg et al. 
1982). Figure 3-6 diagrams hypothesized metabolic pathways o f  trichlorobenzene isomers. To date, 
enzymes involved in the proposed steps have not been definitively established, but based on analogy to 
benzene and other halogenated benzenes, cytochrome P450 isozym es likely catalyze the initial formation 
o f  phenols through arene oxides.
1 . 2 . 3 - T r i c h l o r o b e n z e n e .  Jondorf et al. (1955) identified urinary metabolites o f  all three isomers in 
Chinchilla rabbits given a single oral 500 mg/kg dose. Spectrophotometric analysis indicated that
1.2.3-trichlorobenzene was the most rapidly metabolized o f  the three isomers. This isomer was mostly 
metabolized to 2,3,4-trichlorophenol, but lesser amounts o f  3,4,5-trichlorophenol and 3,4,5-trichloro- 
catechol were also detected. O f the administered dose, 62% was excreted in urine as oxygen conjugates 
containing glucuronic and sulphuric acids within 5 days. Major metabolite excretions rose to a maximum  
on the first day after dosing and were no longer detectable in rabbit urine after 5 days.
Kohli et al. (1976) identified urinary metabolites o f  trichlorobenzene isomers following a single 60­
75 mg/kg intraperitoneal injection in male rabbits, finding similar results as those reported by Jondorf et 
al. (1955). Specifically, GC and mass spectrometry (MS) revealed the major metabolite o f
1.2.3-trichlorobenzene to be 2,3,4-trichlorophenol with 2,3,6- and 3,4,5-trichlorophenol appearing at 
lower levels.
1 . 2 . 4 - T r i c h l o r o b e n z e n e .  The only relevant information regarding metabolism o f  1,2,4-trichlorobenzene 
in humans is that incubation o f  1,2,4-trichlorobenzene with microsomes derived from cell lines 
expressing human CYP1A1, CYP1A2, CYP3A4, CYP2E1, and CYP2D6 showed that CYP2E1had the 
highest enzymatic activity towards the chemical (Bogaards et al. 1995). The investigators also reported 
that in microsomal preparations from 22 human livers, CYP2E1 was the major enzyme involved in the 
formation o f  2,3,5-trichlorophenol and 2,3,4-trichlorophenol from 1,2,4-trichlorobenzene, whereas 
CYP3A4 was responsible for the formation o f  2,3,6-trichlorophenol.
In Chinchilla rabbits given a single 500 mg/kg dose by gavage, 1,2,4-tricholorobenzene was primarily 
metabolized to 2,4,5- and 2,3,5-trichlorophenol, with 5-day urinary metabolites o f  the isomer consisting 
o f  38% glucuronic and sulphuric acid conjugates (Jondorf et al. 1955). Similar findings were obtained in 
a study examining urinary metabolites o f  trichlorobenzene isomers following a single 60-75  mg/kg 
intraperitoneal injection in male rabbits (Kohli et al. 1976). This study indicated that the primary
3. HEALTH EFFECTS
***DRAFT FOR PUBLIC COMMENT***
TRICHLOROBENZENES 119
3. HEALTH EFFECTS
Figure 3-6. Hypothesized Metabolic Pathways for Trichlorobenzene Isomers

























___ - Glutathione conjugation (rat)




TCB = trichlorobenzene; TCBO = trichlorobenzene oxide; TCP = trichlorophenol
Source: Adapted from Kohli et al. (1976), with information from Bakke et al. (1992), Lingg et al. (1982), and Parke 
and Williams (1960).
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metabolites o f  1,2,4-trichlorobenzene were 2,3,5- and 2,4,5-trichlorophenol, while those o f
1,3,5-trichlorobenzene were 2,3,5- and 2,4,6-trichlorophenol.
Further studies o f  1,2,4-trichlorobenzene metabolism monitored urinary metabolites from rats and 
monkeys following oral or intravenous administration o f  single 10 mg/kg doses (Lingg et al. 1982). 
Although this study revealed similar metabolites as those previously observed in rabbits, some species- 
specific differences in conjugated metabolites were apparent. In rats, 60-62%  o f  the urinary metabolites 
consisted o f  the mercapturic acids 2,3,5- and 2,4,5-N-acetyl-S-(trichlorophenyl)-L-cysteine 24 hours after 
dose administration. This finding suggests that conjugation with glutathione is the major metabolic 
pathway and that arene oxides, such as 3,4,6-trichlorobenzene oxide, are likely reactive metabolic 
intermediates in rats. In the urine o f  monkeys, isomeric glucuronides o f  3,4,6-trichloro-3,5 cyclo- 
hexadiene accounted for between 48 and 61% o f  urinary metabolites. Sulfur-containing metabolites were 
not found in the urine o f  monkeys following oral dosing with 10 mg/kg, indicating that conjugation o f  
metabolic intermediates to glucuronic acid, not glutathione conjugation, is important in the monkey.
A  later study in bile-duct cannulated male Sprague-Dawley rats reported that over 60% o f  a 21 mg/kg oral 
dose o f  14C-1,2,4-trichlorobenzene was excreted in bile, while 21 and 2% were excreted in the urine and 
feces, respectively, within 24 hours (Bakke et al. 1992). In intact rats, about 70 and 9% o f  the 
administered dose were excreted in the urine and feces, respectively, within 24 hours. In urine from 
cannulated rats, the major identified metabolites were consistent with catabolism following glutathione 
conjugation o f  phenolic intermediates. S-(trichlorophenyl)-Af-(acetyl) cysteine was the major urinary 
metabolite identified; ^-(dichloro-hydroxyphenol)-^-(acetyl) cysteine (another mercapturic acid), 
trichlorothiophenol, and trichlorophenol were present at lesser concentrations. Only trace levels o f  
glucuronides and sulphate esters were detected. Bile showed a wider range o f  metabolites consistent with 
catabolism o f  glutathione conjugates and relatively more trichlorothiophenol compared with urine. A  
single 3.5 mg intraperitoneal injection o f  14C-2,4,5-trichlorothiophenol resulted in excretion o f  17% o f  the 
administered dose as S-glucuronide and 36% as S-(methylsulphonyl-dichlorophenyl)-mercapturic acid, 
metabolites not found in the excrement o f  rats dosed with 1,2,4-trichlorobenzene. These findings led to 
the suggestion that trichlorothiophenols are not major intermediates or end-products o f  enzymatic 
metabolism o f  trichlorobenzene in rats, but were formed from enterohepatic circulation via intestinal 
flora. This was later confirmed by Kato et al. (1993) who suggested that the formation o f  methylsulfonyl 
metabolites o f  1,2,4-trichlorobenzene involves the initial biliary secretion o f  1,2,4-trichlorobenzene 
metabolites into the intestinal tract, followed by metabolism by intestinal microflora and the absorption o f  
secondary metabolites into the systemic circulation.
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The metabolism o f 1,2,4-trichlorobenzene in vitro has also been investigated. Incubation of
1.2.4-trichlorobenzene with liver microsomes from male rats pretreated with dexamethasone (DEX) 
showed the formation o f trichlorohydroquinone in addition to various trichlorophenols (Den Besten et al. 
1991). Trichlorohydroquinone, which appeared to be formed as a result o f secondary metabolism, was 
found to covalently interact with microsomal protein. Both the conversion and the covalent binding of
1.2.4-trichlorobenzene were mediated by cytochrome P-450 as shown by the dependence on the presence 
o f NADPH and the inhibitory action o f metyrapone. The addition o f glutathione reduced the covalent 
binding almost completely through the formation o f water soluble conjugates. Pretreatment o f the rats 
with different inducers resulted in preferential formation o f different trichlorophenols. Induction with 
DEX resulted in preferential formation o f 2,3,6-trichlorophenol, whereas other inducers preferentially 
produced 2,4,5-trichlorophenol. 2,4,6-Trichlorophenol was a minor metabolite in all microsomal 
suspensions, whereas 2,3,4-trichlorophenol and 2,3,5-trichlorophenol were formed only in trace amounts. 
Adding DNA to the microsomal suspension resulted in covalent binding o f 1,2,4-trichlorophenol with the 
DNA, although to a much lesser extent than with proteins.
1.3.5-Trichlorobenzene. Following oral administration o f a 500 mg/kg dose o f 1,3,5-trichlorobenzene in 
Chinchilla rabbits, only one phenol was detected in the urine (2,4,6-trichlorophenol), and only 23% o f the 
administered dose was excreted as conjugates o f glucuronic and sulfuric acids within 5 days (Jondorf et 
al. 1955). A subsequent study by Parke and Williams (1960) further detailed the metabolism of
1.3.5-trichlorobenzene in Chinchilla rabbits given a single 500 mg/kg dose by gavage. Within the first
3 days after dosing, 2,4,6-trichlorophenol and some minor monochlorophenols were excreted in the urine.
2.4.6-Trichlorophenol continued to be excreted from days 4 through 9 with the addition o f 4-chlorophenol 
elimination. The principal urinary metabolites identified in urine collected from male rabbits following 
an intraperitoneal injection o f 300 mg 1,3,5-trichlorobenzene were 2,3,5- and 2,4,6-trichlorophenol (Kohli 
et al. 1976). A third more polar metabolite was identified, but insufficient material was available to 
determine the structure o f the compound by MS.
3.4.4 Elimination and Excretion
No information was located regarding elimination and excretion o f trichlorobenzenes in humans 
following any route o f exposure.
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3.4.4.1 Inhalation Exposure
No data were found on the elimination and excretion o f trichlorobenzenes following inhalation exposure 
in animals.
3.4.4.2 Oral Exposure
A ll three isomers o f trichlorobenzene have been shown to be rapidly and efficiently eliminated following 
oral exposure, principally via metabolites in the urine in rabbits (Jondorf et al. 1955) and rats (Bakke et al. 
1992; Chu et al. 1987), although enterohepatic biliary circulation has been demonstrated in bile- 
cannulated rats (Bakke et al. 1992).
1.2.3-Trichlorobenzene. Jondorf et al. (1955) illustrated the rapid elimination o f 1,2,3-trichlorobenzene 
in Chinchilla rabbits administered a 500 mg/kg oral dose. Five days after dosing, 78% o f the 
administered dose had been excreted as trichlorophenols and 62% as oxygen conjugates in urine, with no 
trace o f the isomer found in feces. In rats, 92% o f 14C-labeled 1,2,3-trichlorobenzene was eliminated 
through the urine and feces within 24 hours o f a single 10 mg/kg gavage dose (Chu et al. 1987). Overall 
excretion increased to 95% at 48 hours post ingestion. The percentage o f the radiolabeled 1,2,3-isomer in 
urine alone accounted for 56 and 59% at 24 and 48 hours, respectively. Data for radioactivity in tissues 
measured at 0.5, 1, 2, and 4 hours and 1, 2, 7, 14, 28, and 56 days after dose administration were fit to a 
two-compartment elimination model; estimated half-lives were 9.2 and 145 hours for the first and second 
compartments, respectively.
1.2.4-Trichlorobenzene. Chinchilla rabbits excreted 42% o f a single 500 mg/kg oral dose of
1.2.4-trichlorobenzene as trichlorophenols 5 days after administration (Jondorf et al. 1955). This same 
study also noted that 38% o f the administered dose was excreted in the urine as oxygen conjugates during 
the same time frame. A later study in rats dosed with 50 mg/kg 14C-labeled 1,2,4-trichlorobenzene 
revealed 66 and 17% excretion o f radioactivity in urine and feces, respectively, 7 days post administration 
(Tanaka et al. 1986). Radioactivity in expired air consisted o f 2.1% o f the absorbed dose. Excretion in 
all three excreta reached a peak on day 3. Biliary excretion accounted for 45% o f the radioactivity. The 
authors considered the enterohepatic circulation o f trichlorobenzene metabolites in the body as a possible 
explanation for the difference in biliary and fecal excretion rates. Bakke et al. (1992) reported that >60% 
of a 21 mg/kg dose o f 14C-1,2,4-trichlorobenzene was excreted in bile, while 21% was excreted in the 
urine o f bile-cannulated Sprague-Dawley rats within 24 hours. In control rats without bile cannulation,
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70 and 9% o f the administered radioactivity was excreted within 24 hours in the urine and feces, 
respectively (Bakke et al. 1992).
Following a longer period o f exposure, 181.5 mg/kg/day o f 14C-labeled 1,2,4-trichlorobenzene for 
7 consecutive days, Smith and Carlson (1980) found that the urinary and fecal excretion o f the isomer- 
derived radioactivity in Sprague-Dawley rats peaked during the first 3 days o f dosing and declined rapidly 
thereafter. Radioactivity in the feces was not detectable past day 15 and accounted for only 4% o f the 
administered dose. Urinary excretion, however, displayed detectable radioactivity 21 days after the first 
oral administration. Radioactivity in the urine accounted for approximately 72% o f the administered 
dose.
Showing variations between species, Lingg et al. (1982) measured excretion rates in both monkeys and 
rats given a 10 mg/kg oral dose o f 14C-labeled 1,2,4-trichlorobenzene. By 24 hours after dosing, monkeys 
had excreted 40% o f the administered dose in the urine. Less than 1% was found in the feces. Rats 
excreted 84% o f the oral dose via the urine by 24 hours; 11% was found in feces. Following intravenous 
administration o f 10 mg/kg 14C-labeled 1,2,4-trichlorobenzene, monkeys eliminated about 22% o f the 
administered radioactivity in urine and none in the feces 24 hours after exposure. Rats, on the other hand, 
excreted 78 and 7% of the administered dose in urine and feces at 24 hours, respectively. Regardless of 
the route o f exposure, rats excreted radioactivity at a rate roughly 2-3 times faster than monkeys 
following administration o f 14C-labeled 1,2,4-trichlorobenzene.
1,3,5-Trichlorobenzene. In Chinchilla rabbits dosed with a single 500 mg/kg dose by gavage, 9% o f the 
administered dose was excreted as trichlorophenols in the urine during the 5 days after dosing (Jondorf et 
al. 1955), while 23% was excreted as oxygen conjugates. A follow-up study indicated that only 4 and 
14% of a 500 mg/kg dose were eliminated as phenols 8 and 9 days after dosing, respectively (Parke and 
Williams 1960). A much higher level o f excretion, 82% o f 14C-labeled 1,3,5-trichlorobenzene, was found 
in the urine and feces o f Sprague-Dawley rats within 24 hours o f a single 10-mg/kg gavage dose (Chu et 
al. 1987). Overall excretion increased to 89% at 48 hours post ingestion. The percentage o f the 
radiolabeled 1,3,5-isomer in urine alone accounted for 47 and 50% at 24 and 48 hours, respectively. Data 
for radioactivity in tissues measured at 1, 2, 7, 14, 28, and 56 days after dose administration were fit to a 
two-compartment elimination model; estimated half-lives were 8 and 67.5 hours for the first and second 
compartments, respectively (Chu et al. 1987).
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3.4.4.3 Dermal Exposure
No data on the elimination and excretion o f trichlorobenzenes following dermal exposure were located for 
animals.
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions o f the uptake and 
disposition o f chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry 
models. PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties o f a chemical that w ill be delivered to any given target tissue following various 
combinations o f route, dose level, and test species (Clewell and Andersen 1985). Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions o f the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic endpoints.
PBPK/PD models refine our understanding o f complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose o f the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al.
1987; Andersen and Krishnan 1994). These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior o f chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species. The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use o f uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993). PBPK models for a particular substance require estimates o f the chemical substance- 
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates o f these model parameters are incorporated within a set o f differential and algebraic 
equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations 
provides the predictions o f tissue dose. Computers then provide process simulations based on these 
solutions.
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The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities o f biological systems. I f  the uptake and disposition o f the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes. A simplified scheme reduces the magnitude o f cumulative uncertainty. The 
adequacy o f the model is, therefore, o f great importance, and model validation is essential to the use of 
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). 
PBPK models provide a scientifically sound means to predict the target tissue dose o f chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results o f studies where doses were higher or were administered in different species. 
Figure 3-7 shows a conceptualized representation o f a PBPK model.
I f  PBPK models for trichlorobenzenes exist, the overall results and individual models are discussed in this 
section in terms o f their use in risk assessment, tissue dosimetry, and dose, route, and species 
extrapolations.
No PBPK/PD models have been developed for trichlorobenzenes.
3.5 MECHANISMS OF ACTION
3.5.1 Pharmacokinetic Mechanisms
Studies in animals indicate that trichlorobenzenes are rapidly and efficiently absorbed through the 
gastrointestinal tract. However, the specific mechanisms by which this occurs have not been evaluated. 
Given that they are fairly soluble in lipids, it is reasonable to assume that absorption w ill occur through 
passive diffusion. No specific information was located regarding mechanisms o f inhalation or dermal 
absorption. In addition, no relevant information was located regarding mechanisms o f transport of 
trichlorobenzenes (or metabolites) in the blood, distribution to tissues, or storage in tissues.
The role o f metabolism on the liver effects o f 1,2,4-trichlorobenzene, specifically enzyme induction and 
alterations in heme metabolism, has been examined by Kato and coworkers (Kato and Kimura 2002; Kato 
et al. 1988, 1993). Intraperitoneal injection o f the metabolite 2,3,5-trichlorophenyl methyl sulfone to
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Figure 3-7. Conceptual Representation of a Physiologically Based 
Pharmacokinetic (PBPK) Model for a 
Hypothetical Chemical Substance
I n h a le d  c h e m i c a l -------1 |------ ► E x h a le d  c h e m ic a l
C h e m i c a l s  
c o n t a c t in g  s k in
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance. The chemical substance is shown to be absorbed via the skin, by inhalation, or by 
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source: adapted from  Krishnan and Andersen 1994
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male Wistar rats resulted in significant increases in the activities o f aminopyrine N-demethylase and 
cytochrome P-450 content in liver microsomes, reaching a maximum at 48-72 hours after the injection 
(Kato et al. 1993). Significant increases in aniline hydroxylase and cytochrome b5 contents were also 
observed at 12-120 hours and 24-120 hours, respectively. The rise and fall in enzyme activities 
correlated with the rise and fall o f the hepatic concentration o f 2,3,5-trichlorophenyl methyl sulfone rather 
than with the hepatic concentration o f 1,2,4-trichlorobenzene. This was consistent with the estimated 
elimination half-lives from the liver o f 5.2 hours and 37.8 hours for 1,2,4-trichlorobenzene and 
2,3,5-trichlorophenyl methyl sulfone, respectively. In this study, 2,4,5-trichlorophenyl methyl sulfone 
was found to be a weaker inducer, although an earlier study had shown 2,4,5-trichlorophenyl methyl 
sulfone to induce a component o f the microsomal electron transport system and also uridine diphosphate- 
glucuronyltransferase, a phase II metabolic enzyme (Kato et al. 1988). Overall, these findings strongly 
suggest that the inducing effect o f 1,2,4-trichlorobenzene on liver microsomal drug-metabolizing 
enzymes is not due to the parent compound, but to its methysulfonyl metabolite 2,4,5-trichlorophenyl 
methyl sulfone.
1.2.4-Trichlorobenzene has been shown to induce ALA synthetase, the rate-limiting enzyme in the 
biosynthesis o f heme (Ariyoshi et al. 1975a, 1975b) and also heme oxygenase, the rate-limiting enzyme in 
the degradation o f heme (Kato and Kimura 2002). Administration o f 1,2,4-trichlorobenzene or
2.3.5-trichlorophenyl methyl sulfone to male Wistar rats resulted in significant increases in ALA 
synthetase activity, but only 1,2,4-trichlorobenzene induced heme oxygenase (Kato and Kimura 2002). In 
both cases, there were significant increases in the contents o f cytochrome P-450, which paralleled 
increases in total heme content. In rats with reduced liver glutathione levels by pretreatment with 
buthionine-^^-sulfoxim ine (BSO) and dosed with 1,2,4-trichlorobenzene, 2,3,5-trichlorophenyl methyl 
sulfone was present in the liver at much lower concentrations than in rats not pretreated with BSO. In 
addition, 1,2,4-trichlorobenzene did not induce ALA synthetase in BSO-treated rats, but 2,3,5-trichloro­
phenyl methyl sulfone did, suggesting that the induction o f ALA synthetase in rats dosed with
1.2.4-trichlorobenzene is not due to 1,2,4-trichlorobenzene, but to 2,3,5-trichlorophenyl methyl sulfone. 
Kato and Kimura (2002) suggested that the prolonged induction o f ALA synthetase by 2,3,5-trichloro­
phenyl methyl sulfone results in excess heme biosynthesis, which overrides the destruction o f heme that 
results from the induction o f heme oxygenase by 1,2,4-trichlorobenzene or a metabolite other than
2.3.5-trichlorophenyl methyl sulfone. This is consistent with the induction o f porphyria in rats dosed with
1,2,4-trichlorobenzene (i.e., Rimington and Ziegler 1963).
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No studies were located that examined the effect o f dose on metabolism or excretion pathways of 
trichlorobenzenes.
3.5.2 Mechanisms of Toxicity
The toxicity o f trichlorobenzenes does not appear to be route-dependent, and the liver appears to be the 
main target regardless o f the duration o f exposure.
The mechanism(s) o f liver toxicity induced by trichlorobenzenes has not been elucidated, but it probably 
involves arene oxide intermediates which form during the initial transformation to trichlorophenols. As 
mentioned above, 1,2,4-trichlorobenzene, and presumably the other isomers, induce a number o f drug- 
metabolizing enzymes in the liver o f rats which w ill affect the biotransformation o f other chemicals. 
Whether or not this w ill result in increased toxicity o f other xenobiotics w ill depend on whether the 
toxicity o f the other chemical is due to the parent compound or to a metabolite. Also, as mentioned 
above, exposure to 1,2,4-trichlorobenzene induced porphyria in rats by inducing ALA synthetase and thus 
increasing heme production. Trichlorobenzenes and other chlorinated benzenes induce nephropathy in 
the male rat by a mechanism that involves a series o f events beginning with an excessive accumulation o f 
hyaline droplets. This appears to be unique to the male rat and is not relevant for human risk assessment. 
A study o f 1,2,4-trichlorobenzene with liver microsomes from male rats in vitro reported the formation of 
trichlorohydroquinone as a result o f secondary metabolism (Den Besten et al. 1991). Trichloro- 
hydroquinone was found to covalently interact with microsomal protein and with added DNA. Whether 
or not this plays a role in the in vivo toxicity o f 1,2,4-trichlorobenzene is unknown.
3.5.3 Animal-to-Human Extrapolations
There is virtually no information on health effects o f trichlorobenzenes in humans, so the animal species 
that is the most appropriate model for human exposure is not known. The liver is the target for 
trichlorobenzenes in animals, and rats appear to be more sensitive than other species. Based on 
information from effects o f other chlorinated benzenes in humans, and from limited information on the 
metabolism o f 1,2,4-trichlorobenzene by microsomal preparations from human livers that indicated that 
cytochrome P-450 enzymes might be involved in the metabolism o f trichlorobenzenes, it is reasonable to 
assume that excessive exposure to trichlorobenzenes could induce liver effects such as porphyria in 
humans.
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3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects o f certain chemicals on the endocrine 
system because o f the ability o f these chemicals to mimic or block endogenous hormones. Chemicals 
with this type o f activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial. The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “ ...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...” . To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC) which in 
1998 completed its deliberations and made recommendations to EPA concerning endocrine disruptors.
In 1999, the National Academy o f Sciences released a report that referred to these same types of 
chemicals as hormonally active agents. The terms endocrine modulators have also been used to convey 
the fact that effects caused by such chemicals may not necessarily be adverse. Many scientists agree that 
chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to the health 
o f humans, aquatic animals, and wildlife. However, others think that endocrine-active chemicals do not 
pose a significant health risk, particularly in view o f the fact that hormone mimics exist in the natural 
environment. Examples o f natural hormone mimics are the isoflavinoid phytoestrogens (Adlercreutz 
1995; Livingston 1978; Mayr et al. 1992). These chemicals are derived from plants and are similar in 
structure and action to endogenous estrogen. Although the public health significance and descriptive 
terminology o f substances capable o f affecting the endocrine system remains controversial, scientists 
agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or elimination o f 
natural hormones in the body responsible for maintaining homeostasis, reproduction, development, and/or 
behavior (EPA 1997). Stated differently, such compounds may cause toxicities that are mediated through 
the neuroendocrine axis. As a result, these chemicals may play a role in altering, for example, metabolic, 
sexual, immune, and neurobehavioral function. Such chemicals are also thought to be involved in 
inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; Giwercman et al. 
1993; Hoel et al. 1992).
There is no evidence from the reproductive and developmental studies, summarized in Sections 3.2.2.5 
and 3.2.2.6, respectively, that suggests that trichlorobenzenes affect the neuroendocrine axis.
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The only relevant information that was located regarding in vitro tests is that 1,2,4-trichlorobenzene and
1,2,3-trichlorobenzene tested negative for estrogenic activity in a reporter gene expression assay using 
yeast cells (Nishihara et al. 2000). A substance was considered positive when its activity was more than 
10% o f the activity o f 10-7M 17p-estradiol.
3.7 CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years o f age in humans, when all biological systems w ill have fully developed. Potential 
effects on offspring resulting from exposures o f parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.
Relevant animal and in vitro models are also discussed.
Children are not small adults. They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals. Children’s unique physiology and behavior can influence the 
extent o f their exposure. Exposures o f children are discussed in Section 6.6, Exposures o f Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993). Children may be more or less 
susceptible than adults to health effects and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are 
critical periods o f structural and functional development during both prenatal and postnatal life, and a 
particular structure or function w ill be most sensitive to disruption during its critical period(s). Damage 
may not be evident until a later stage o f development. There are often differences in pharmacokinetics 
and metabolism between children and adults. For example, absorption may be different in neonates 
because o f the immaturity o f their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption o f lead is greatest in infants 
and young children (Ziegler et al. 1978). Distribution o f xenobiotics may be different; for example, 
infants have a larger proportion o f their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964). The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975). Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages o f growth 
and development, levels o f particular enzymes may be higher or lower than those o f adults, and
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sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996). Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification. There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948). 
Children and adults may differ in their capacity to repair damage from chemical insults. Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer.
Certain characteristics o f the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical. For example, although infants breathe more air per 
kilogram o f body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993).
No studies were located that described health effects in children following exposure to trichlorobenzenes. 
Also, no studies were located that compared the health effects o f these compounds in young and adult 
animals to ascertain potential age-related differences in susceptibility.
Standard developmental toxicity studies in animals do not suggest that trichlorobenzenes are embryotoxic 
or teratogenic or that they alter the development o f young animals. The only effects reported in a study 
with 1,2,4-trichlorobenzene in rats were the presence o f microscopic alterations in the lenses o f the eye of 
fetuses from dams treated with 150 mg/kg/day 1,2,4-trichlorobenzene on Gd 6-15 and sacrificed on 
Gd 22 (Black et al. 1988). However, no lesions were observed in fetuses from dams dosed with 
300 mg/kg/day 1,2,4-trichlorobenzene. This lesion was also observed in fetuses from dams dosed with 
150, 300, or 600 mg/kg/day 1,3,5-trichlorobenzene; however, since no quantitative data were presented, it 
is not known whether the incidences were dose-related. Another gestational exposure study reported 
retarded development o f the fetuses from rats dosed with 360 mg/kg/day 1,2,4-trichlorobenzene on Gd 9­
13 and sacrificed on Gd 14 (Kitchin and Ebron 1983). This dose level was lethal to two out nine dams 
and induced significant weight loss in dams that survived, which may have contributed to the delayed 
development o f the fetuses. In studies o f pregnant mice dosed with 0 or 130 mg/kg/day 1,2,4-trichloro­
benzene on Gd 8-12, the chemical did not affect pup’s viability or growth, or offspring’s locomotor
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activity or fertility to produce a second generation (Chernoff and Kavlock 1983; Gray and Kavlock 1984; 
Gray et al. 1986).
Trichlorobenzenes have been identified in breast milk; therefore, infants may also be potentially exposed 
through breast feeding (see Section 6.6, Exposures o f Children). No information was located regarding 
the pharmacokinetics o f these compounds in children, regarding biomarkers o f exposure or effect for 
these compounds in children, or regarding interactions with other chemicals in children.
3.8 BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers o f exposure, markers o f effect, and markers o f susceptibility (NAS/NRC 
1989).
Due to a nascent understanding o f the use and interpretation o f biomarkers, implementation o f biomarkers 
as tools o f exposure in the general population is very limited. A biomarker o f exposure is a xenobiotic 
substance or its metabolite(s) or the product o f an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment o f an organism (NAS/NRC 1989). The 
preferred biomarkers o f exposure are generally the substance itself, substance-specific metabolites in 
readily obtainable body fluid(s), excreta. However, several factors can confound the use and 
interpretation o f biomarkers o f exposure. The body burden o f a substance may be the result o f exposures 
from more than one source. The substance being measured may be a metabolite o f another xenobiotic 
substance (e.g., high urinary levels o f phenol can result from exposures to several different aromatic 
compounds). Depending on the properties o f the substance (e.g., biologic half-life) and environmental 
conditions (e.g., duration and route o f exposure), the substance and all o f its metabolites may have left the 
body by the time samples can be taken. It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium). Biomarkers o f exposure to trichlorobenzenes are discussed in Section 3.8.1.
Biomarkers o f effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs o f dysfunction such as increased blood pressure or decreased lung
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capacity. Note that these markers are not often substance specific. They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers o f effects caused 
by trichlorobenzenes are discussed in Section 3.8.2.
A biomarker o f susceptibility is an indicator o f an inherent or acquired limitation o f an organism's ability 
to respond to the challenge o f exposure to a specific xenobiotic substance. It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. I f  biomarkers o f susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Trichlorobenzenes
Trichlorobenzenes have been detected in blood (Bristol et al. 1982; Mes 1992; Pellizzari et al. 1985a), 
adipose tissue (Mes 1992), and exhaled breath (Pellizzari et al. 1985b) and their presence in the body can 
be used as biomarkers o f exposure to trichlorobenzenes. However, metabolites o f trichlorobenzenes, such 
as trichlorophenols, cannot be used as specific biomarkers for exposure to trichlorobenzenes because they 
can also be generated from the metabolism o f other chlorinated compounds such as the pesticide lindane 
(Agency for Toxic Substances and Disease Registry 2005).
3.8.2 Biomarkers Used to Characterize Effects Caused by Trichlorobenzenes
No specific biomarker o f effects could be identified from the very limited information regarding humans 
exposed to trichlorobenzenes (see Section 3.2.1.2, Systemic Effects). Based on the existing information 
regarding the effects o f trichlorobenzenes in animals, it is difficult to envision a health condition that 
could be attributed solely to exposure to trichlorobenzenes.
3.9 INTERACTIONS WITH OTHER CHEMICALS
No studies were located regarding interactions among trichlorobenzenes and limited data were found 
regarding interactions between trichlorobenzenes and other chemicals. Since trichlorobenzenes are 
inducers o f liver microsomal enzymes (Ariyoshi et al. 1975a, 1975b; Carlson and Tardiff 1976; Kato and 
Kimura 2002; Kato et al. 1988, 1993; Kitchin and Ebron 1983), they w ill affect the metabolism o f other 
compounds. For example, gavage administration o f 1,2,4-trichlorobenzene at 600 mg/kg/day to rats for
14 days significantly decreased hexobarbital sleeping time (Carlson and Tardiff 1976). In another study,
1,2,4-trichlorobenzene increased the LD50 values for malathion, malaoxon, parathion, and paraoxon in
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mice (Townsend and Carlson 1981). In the same study, 1,2,4-trichlorobenzene protected against the 
decrease in brain cholinesterase induced by malathion, but not against reductions in liver, plasma, or RBC 
cholinesterase. The protection afforded by 1,2,4-trichlorobenzene correlated well with increased 
carboxylesterase activity. These examples can be considered inhibitory types o f interactions.
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
A susceptible population w ill exhibit a different or enhanced response to trichlorobenzenes than w ill most 
persons exposed to the same level o f trichlorobenzenes in the environment. Reasons may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). 
These parameters may result in reduced detoxification or excretion o f trichlorobenzenes, or compromised 
function o f organs affected by trichlorobenzenes. Populations who are at greater risk due to their 
unusually high exposure to trichlorobenzenes are discussed in Section 6.7, Populations with Potentially 
High Exposures.
A specific target for trichlorobenzene toxicity in humans exposed to these compounds has not been 
identified, but it is reasonable to assume that the liver could be a main target based on studies in animals. 
Therefore, individuals with compromised liver function may represent a susceptible population. No 
information was located regarding whether or not children represent a group unusually susceptible to 
trichlorobenzenes.
3.11 METHODS FOR REDUCING TOXIC EFFECTS
This section w ill describe clinical practice and research concerning methods for reducing toxic effects o f 
exposure to trichlorobenzenes. However, because some o f the treatments discussed may be experimental 
and unproven, this section should not be used as a guide for treatment o f exposures to trichlorobenzenes. 
When specific exposures have occurred, poison control centers and medical toxicologists should be 
consulted for medical advice. No texts were identified that provide specific information about treatment 
following exposures to trichlorobenzenes.
3.11.1 Reducing Peak Absorption Following Exposure
The following information has been extracted from HSDB (2010). Methods for reducing peak absorption 
o f trichlorobenzenes include gut dilution with water or milk and eye irrigation with water or sterile saline. 
Activated charcoal is not recommended, as it may promote vomiting and make endoscopic evaluation
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difficult. I f  exposure occurs via the dermal route, contaminated clothing should be removed and affected 
areas should be washed with soap. Exposure to fresh air or oxygen treatment is recommended to reduce 
absorption after inhalation exposure to trichlorobenzenes.
3.11.2 Reducing Body Burden
No information was located regarding reducing body burden o f trichlorobenzenes following exposure to 
these chemicals.
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
Studies in animals indicate that isomers o f trichlorobenzene enhance xenobiotic metabolism via the 
induction o f numerous hepatic drug-metabolizing enzymes including cytochromes c and P-450, 
glucuronyltransferase, glutathione S-transferase, and microsomal proteins (Ariyoshi et al. 1975a, 1975b; 
Kato and Kimura 2002; Kato et al. 1988, 1993). Also induced by 1,2,4-trichlorobenzene is ALA 
synthetase, the rate-limiting enzyme in heme biosynthesis (Ariyoshi et al. 1975a, 1975b), which is the 
cause o f hepatic porphyria in rats treated with 1,2,4-trichlorobenzene (Rimington and Ziegler 1963). 
Studies suggest that both the induction o f hepatic microsomal drug-metabolizing enzymes and ALA 
synthetase may not be mediated directly by 1,2,4-trichlorobenzene, but by its metabolite 2,3,5-trichloro- 
phenyl methyl sulfone (Kato and Kimura 2002; Kato et al. 1988, 1993). Since 2,3,5-trichlorophenyl 
methyl sulfone results from the conjugation o f glutathione with a 1,2,4-trichlorobenzene hydroxyl 
derivative, theoretically, reducing glutathione levels would prevent, at least in part, the effects of
1,2,4-trichlorobenzene.
3.12 ADEQUACY OF THE DATABASE
Section 104(I)(5) o f CERCLA, as amended, directs the Administrator o f ATSDR (in consultation with the 
Administrator o f EPA and agencies and programs o f the Public Health Service) to assess whether 
adequate information on the health effects o f trichlorobenzenes is available. Where adequate information 
is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to 
assure the initiation o f a program o f research designed to determine the health effects (and techniques for 
developing methods to determine such health effects) o f trichlorobenzenes.
The following categories o f possible data needs have been identified by a joint team o f scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that i f  met would
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reduce the uncertainties o f human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs w ill be 
evaluated and prioritized, and a substance-specific research agenda w ill be proposed.
3.12.1 Existing Information on Health Effects of Trichlorobenzenes
The existing data on health effects o f inhalation, oral, and dermal exposure o f humans and animals to
1.2.3- ,1,2,4-, and 1,3,5-trichlorobenzenes are summarized in Figures 3-8, 3-9, and 3-10, respectively.
The purpose o f these figures is to illustrate the existing information concerning the health effects of 
trichlorobenzene. Each dot in the figures indicates that one or more studies provide information 
associated with that particular effect. The dot does not necessarily imply anything about the quality o f the 
study or studies, nor should missing information in this figure be interpreted as a “data need” . A data 
need, as defined in ATSDR’s Decision Guide fo r Identifying Substance-Specific Data Needs Related to 
Toxicological Profiles (Agency for Toxic Substances and Disease Registry 1989), is substance-specific 
information necessary to conduct comprehensive public health assessments. Generally, ATSDR defines a 
data gap more broadly as any substance-specific information missing from the scientific literature.
There is virtually no information regarding health effects in humans exposed to trichlorobenzenes. 
Information is available regarding health effects in animals exposed orally and dermally to each one of 
the three trichlorobenzene isomers and exposed by inhalation to 1,2,4-trichlorobenzene and
1,3,5-trichlorobenzene. 1,2,4-Trichlorobenzene has been the most widely studied o f the three isomers. 
Chronic-duration studies in animals are available only for 1,2,4-trichlorobenzene and only via the oral 
route o f exposure. Studies in animals showed that the liver is a target for trichlorobenzene toxicity, 
particularly in rats. The kidney was also affected in male rats, but this effect appears to be a unique 
response o f male rats to exposure to a variety o f organic chemicals and not relevant to humans.
1.2.4-Trichlorobenzene was evaluated for carcinogenicity in rats and mice; this isomer induced malignant 
liver tumors in mice. Trichlorobenzenes induced transitory skin and eye irritation when applied onto the 
skin or instilled into the eyes o f animals.
3.12.2 Identification of Data Needs
Acute-Duration Exposure. No acute-duration studies were located in humans exposed by inhalation 
to trichlorobenzenes that could be used for derivation o f an acute-duration MRL for this route. A review 
of the literature indicates that an adult male who inhaled trichlorobenzene for several hours during the 
repair o f a pump suffered massive hemoptysis, and that some trichlorobenzene production workers
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developed chloroacne (IPCS 1991). Citing an unpublished source, ACGIH (2001) stated that minimal 
eye and throat irritation could occur in some people exposed to 3-5 ppm 1,2,4-trichlorobenzene. No 
relevant inhalation studies were located o f animals exposed to 1,2,4-trichlorobenzene or 1,3,5-trichloro- 
benzene, and no information was located for 1,2,3-trichlorobenzene. A decision to conduct studies in 
animals for possible derivation o f acute-duration inhalation MRLs for trichlorobenzenes has to be made 
after evaluating the likelihood that exposure to high concentrations o f these chemicals for short periods of 
time w ill occur. No information was located regarding oral toxicity o f trichlorobenzenes in humans.
Aside from studies that provided information on lethal doses o f trichlorobenzenes in animals (Brown et 
al. 1969; Côté et al. 1988; Jorgenson et al. 1976), there are few studies available that examined the effects 
o f acute oral exposure to these compounds. A developmental study in rats exposed to the three 
trichlorobenzene isomers during Gd 6-15 conducted histological evaluations o f tissues and organs from 
the dams sacrificed on Gd 22 (Black et al. 1988). The liver and possibly the thyroid appeared to be 
targets for trichlorobenzenes; however, no quantitative data were presented, so NOAELs or LOAELs 
could not be defined and the study could not be used for MRL derivation. A 14-day gavage study with
1,2,4-trichlorobenzene in rats by Carlson and Tardiff (1976) identified the liver as a target for this isomer 
based on increases in liver weight and enzyme induction, but did not provide data regarding 
histopathology o f the liver; therefore, it was considered inadequate for MRL derivation. While additional 
studies that provide adequate data for establishing dose-response relationships for acute exposure to the 
trichlorobenzenes would be valuable, particularly for liver effects, it is unlikely that acute oral exposure to 
high amounts o f trichlorobenzenes w ill occur in humans. Studies in animals are available indicating that 
trichlorobenzenes are mild to moderate skin and eye irritants (Brown et al. 1969; Dow Chemical 1956;
E.I. Dupont 1971; Jorgenson et al. 1976; Yamamoto et al. 1978). Additional acute-duration dermal 
studies do not seem necessary at this time.
Intermediate-Duration Exposure. No studies were located regarding health effects in humans 
exposed to trichlorobenzenes for intermediate duration periods by any route o f exposure. Intermediate- 
duration inhalation studies in animals are available for 1,2,4-trichlorobenzene in various animal species 
(Coate et al. 1977; Gage 1970; Kociba et al. 1981) and for 1,3,5-trichlorobenzene in rats (Sasmore et al. 
1983). The results showed that exposure to up to 100 ppm 1,2,4-trichlorobenzene for up to 26 weeks or 
130 ppm 1,3,5-trichlorobenzene for 13 weeks had no significant effect on hematological and clinical 
chemistry tests or on histological appearance o f tissues and organs. Although there is suggestive evidence 
from some studies that the liver might be a target for 1,2,4-trichlorobenzene, inadequacies in the studies 
(no quantitative data, too few animals) precluded derivation o f an intermediate-duration inhalation MRL 
for this isomer. No intermediate-duration inhalation study for 1,2,3-trichlorobenzenes was located;
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however, there is no reason to believe that the results would have been different than those obtained for
1.2.4-trichlorobenzene or 1,3,5-trichlorobenzene. It should be noted that the exposure levels used in the 
animal studies are several orders o f magnitude higher than those monitored in outdoor air in the United 
States in 2008 (EPA 2010a; see Section 6.4, Levels Monitored or Estimated in the Environment). 
Additional inhalation studies in animals do not seem necessary at this time. Wide-scope intermediate- 
duration oral studies in animals are available for 1,2,4-trichlorobenzene in rats (CMA 1989; Côté et al. 
1988) and mice (Hiles 1989) and for 1,2,3-trichlorobenzene and 1,3,5-trichlorobenzene in rats (Côté et al. 
1988). These studies identified the liver as the main target for trichlorobenzenes. Kidney effects were 
also reported in male rats, but this response was characterized by hyaline droplet accumulation and was 
unique to the male and considered not relevant for human risk assessment. The studies by CMA (1989) 
in rats and Hiles (1989) in mice provided quantitative histological data, and the former was used to derive 
an intermediate-oral MRL for 1,2,4-trichlorobenzene. The study with 1,2,3-trichlorobenzene and
1.3.5-trichlorobenzene in rats (Côté et al. 1988) reported quantitative changes in liver weight and 
histological alterations in the liver and thyroid in treated groups o f rats. However, quantitative 
histological data were not provided and, therefore, NOAELs and LOAELs for histological alterations 
could not be defined; thus, the study was considered inadequate for derivation o f intermediate-duration 
oral MRLs for 1,2,3- and 1,3,5-trichlorobenzene. Additional studies that provide quantitative histological 
data would be valuable to define better points o f departure for MRL derivation than organ weight. 
Intermediate-duration dermal studies are available for 1,2,4-trichlorobenzene (Brown et al. 1969; Powers 
et al. 1975; Rao et al. 1982). For the most part, effects were limited to the site o f application o f the 
chemical. Additional dermal studies with 1,2,4-trichlorobenzene do not seem necessary. Although no 
intermediate-dermal studies were located for 1,2,3-trichlorobenzene or 1,3,5-trichlorobenzene, it is 
unclear what key new information such studies would provide.
Chronic-Duration Exposure and Cancer. No studies were located regarding health effects in 
humans exposed chronically to trichlorobenzenes. Health evaluations o f workers exposed to 
trichlorobenzenes may have been conducted, but none were identified in the literature reviewed. No 
chronic-duration inhalation animal studies are available for trichlorobenzenes. Since chlorobenzenes 
have been detected in outdoor air from cities in the United States (EPA 2010a), the general population is 
exposed to these chemicals by inhalation. However, as mentioned above, the exposure levels monitored 
in that study were several orders o f magnitude lower than those used in intermediate-duration inhalation 
studies in animals which did not induce significant health effects. Therefore, the value o f conducting 
chronic-duration inhalation studies with exposure concentrations around environmental levels is 
questionable. There are chronic-duration oral studies with 1,2,4-trichlorobenzene in rats (Moore 1994a)
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and mice (Moore 1994b). These studies reported adverse histological effects in the liver from rats and 
mice and also renal lesions in male rats. The liver effects in rats served as basis for the derivation o f a 
chronic-duration oral MRL for 1,2,4-trichlorobenzene.
There are no studies o f cancer in humans exposed to trichlorobenzenes. Both the chronic-duration oral 
study with 1,2,4-trichlorobenzene in rats (Moore 1994a) and mice (Moore 1994b) evaluated the animals 
for tumors and reported that 1,2,4-trichlorobenzene increased the incidence o f hepatocellular carcinoma in 
both male and female mice. Additional cancer studies for this isomer do not appear necessary, but oral 
toxicity/carcinogenicity studies for 1,2,3-trichlorobenzene and 1,3,5-trichlorobenzene seem warranted 
since the general population is exposed to these isomers through the consumption o f fish and other foods 
(see Section 6.4.4, Other Environmental Media).
Genotoxicity. Trichlorobenzenes were not mutagenic in in vitro tests with prokaryotic organisms with 
or without metabolic activation (Haworth et al. 1983; Jorgenson et al. 1976; Kubo et al. 2002; Nohmi et 
al. 1985; Ono et al. 1992; Schoeny et al. 1979). It is unclear what key information additional studies 
would provide. 1,2,3-Trichlorobenzene and 1,2,4-trichlorobenzene were cytotoxic to mammalian cells in 
studies conducted in Chinese hamster V79 cells in vitro, a system that lacks metabolic activation capacity, 
indicating that the effect was due to the parent compound (Fratello et al. 1997). Other studies in vitro 
with mammalian cells also showed 1,2,4-trichlorobenzene to be cytotoxic (Garrett and Lewtas 1983; 
Shimada et al. 1983). Fratello et al. (1997) suggested that the toxicity o f these chemicals was related to 
their ability to penetrate/perturbate the cellular membranes, but further studies examining this issue would 
be valuable. Limited studies o f the genotoxicity o f trichlorobenzenes in vivo, mostly micronuclei assays, 
indicate that these compounds are clastogenic (Mohtashamipur et al. 1987; Parrini et al. 1990). Studies 
that evaluate whether metabolites o f trichlorobenzenes, such as methylsulfones, thought to be responsible 
for the induction o f drug-metabolizing enzymes and alterations in heme metabolism (Kato and Kimura 
2002; Kato et al. 1993) could provide insight into the mechanism o f action o f trichlorobenzenes.
Reproductive Toxicity. There is no information regarding reproductive effects in humans exposed to 
trichlorobenzenes. A multi-generation reproductive study in rats exposed to 1,2,4-trichlorobenzene in the 
drinking water is available (Robinson et al. 1981). In that study, 1,2,4-trichlorobenzene did not affect 
fertility. None o f the intermediate-duration oral, inhalation, or dermal studies or the chronic-duration oral 
studies conducted with trichlorobenzenes reported treatment-related histological alterations in the 
reproductive organs o f male and female animals (Black et al. 1988; CMA 1989; Coate et al. 1977; Côté et 
al. 1988; Hiles 1989; Kociba et al. 1981; Moore 1994a, 1994b; Rao et al. 1982; Sasmore et al. 1983).
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Additional studies with 1,2,4-trichlorobenzene or multi-generation studies with 1,2,3-trichlorobenzene or
1,3,5-trichlorobenzene do not seem warranted at this time.
Developmental Toxicity. No information was located regarding developmental effects in humans 
exposed to trichlorobenzenes. The three trichlorobenzene isomers have been tested for potential 
developmental toxicity in rats (Black et al. 1988; Kitchin and Ebron 1983; Robinson et al. 1981);
1.2.4-trichlorobenzene has also been tested in mice (Chernoff and Kavlock 1983; Gray and Kavlock 
1984; Gray et al. 1986). In all these studies, 1,2,4-trichlorobenzene was administered by oral gavage 
during pregnancy. Kitchin and Ebron (1983) reported retarded development o f the fetuses from rats 
dosed with 360 mg/kg/day 1,2,4-trichlorobenzene; this dose level also induced significant weight loss in 
the dams, which may have contributed to the slower fetal development. In the studies in pregnant mice 
dosed with up to 130 mg/kg/day 1,2,4-trichlorobenzene on Gd 8-12, the chemical did not affect pup’s 
viability or growth, or offspring’s locomotor activity or fertility to produce a second generation. In the 
study by Black et al. (1988) with the three trichlorobenzene isomers, the only significant effect reported 
was the presence o f microscopic alterations in the lenses o f the eye o f fetuses from rats treated with 
150 mg/kg/day; no lesions were observed in fetuses from dams dosed with 75 or 300 mg/kg/day
1.2.4-trichlorobenzene. This lesion was not observed in fetuses from dams dosed with 150, 300, or 
600 mg/kg/day 1,2,3-trichlorobenzene, but occurred in fetuses from dams administered 150, 300, or 
600 mg/kg/day 1,3,5-trichlorobenzene; however, because no quantitative data were presented, it is not 
known whether the incidences were dose-related. It seems important to try to duplicate these findings 
and/or test a different animal species, and to also perform quantitative analyses o f the results to obtain 
dose-response relationships. Since the toxicity o f trichlorobenzenes does not seem to be route-dependent, 
developmental studies by the inhalation and dermal routes do not appear necessary.
Immunotoxicity. No information was located regarding immunological effects in humans exposed to 
trichlorobenzenes. The information available from studies in animals is limited to results o f evaluations 
o f the gross and microscopic morphology o f lymphoreticular organs and tissues in some inhalation, oral, 
and dermal studies conducted with trichlorobenzenes (Black et al. 1988; CMA 1989; Coate et al. 1977; 
Côté et al. 1988; Hiles 1989; Kociba et al. 1981; Moore 1994a, 1994b; Powers et al. 1975; Rao et al.
1982; Sasmore et al. 1983). For the most part, no significant alterations have been reported. Tests for 
skin sensitization conducted with 1,2,4-trichlorobenzene or 1,3,5-trichlorobenzene in guinea pigs were 
negative (Brown et al. 1969; E.I. DuPont 1971; Jorgenson et al. 1976). No studies were located that 
examined immunocompetence in animals exposed to trichlorobenzenes. Since it is not uncommon to find 
that subtle changes in immunological parameters occur at exposure levels or doses o f chemicals lower
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than (sometimes much lower) those that produce systemic toxicity, it would be useful to conduct 
screening studies (Tier I) to assess, for example, cell-mediated and humoral-mediated immunity in 
rodents exposed to trichlorobenzenes.
Neurotoxicity. No studies were located regarding neurological effects in humans exposed to 
trichlorobenzenes. Tremors and convulsions were reported in rats and mice administered lethal doses of
1,2,4-trichlorobenzene or 1,3,5-trichlorobenzene (Brown et al. 1969; Jorgenson et al. 1976). Several 
inhalation, oral, and dermal intermediate- and chronic-duration studies in animals examined the gross and 
microscopic appearance o f the brain, spinal cord, and peripheral nerve and reported no significant 
alterations (Black et al. 1988; CMA 1989; Coate et al. 1977; Côté et al. 1988; Hiles 1989; Kociba et al. 
1981; Moore 1994a, 1994b; Rao et al. 1982; Sasmore et al. 1983). One intermediate-duration inhalation 
study in monkeys exposed to 1,2,4-trichlorobenzene conducted operant behavior tests in the animals 
throughout the exposure period and reported no exposure-related alterations (Coate et al. 1977). The data 
available suggest that the nervous system is not a sensitive target for trichlorobenzenes, but there has not 
been extensive testing o f neurological parameters in animals during prolonged exposure to 
trichlorobenzenes.
Epidemiological and Human Dosimetry Studies. No epidemiological studies were identified for 
trichlorobenzenes. It is likely that health evaluations o f workers exposed to 1,2,4-trichlorobenzene during 
the production o f this chemical have been conducted at some point, but no data were located in the 
literature available for review. Studies in animals indicate that the main target for trichlorobenzenes is the 
liver. Therefore, should a population be identified as being exposed to high levels o f trichlorobenzenes, 
liver function should be monitored with the appropriate tests.
Biomarkers of Exposure and Effect.
Exposure. A biomarker o f exposure is an exogenous substance, or its metabolite(s) or the product o f the 
interaction between a xenobiotic agent and some target molecule or cell that is measured within a 
compartment o f an organism (e.g., measurement o f the parent compound or its metabolite(s), NA adducts, 
etc.).
Body burdens o f trichlorobenzenes do not necessarily indicate that exposure to trichlorobenzenes 
occurred or is occurring because they can also be generated in the body from the metabolism o f higher 
chlorinated benzenes such as tetrachlorobenzenes, pentachlorobenzene, hexachlorobenzene, or the
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pesticide lindane. Studies o f the metabolism o f trichlorobenzenes in workers exposed solely to 
trichlorobenzenes are needed to elucidate a metabolite profile which might include a metabolite that is not 
produced following exposures to other chlorinated benzenes. This would allow the differentiation 
between exposures to trichlorobenzenes from exposures to other chlorinated benzenes.
Effect. For the purpose o f this data need, a biomarker o f effect is a measurable biochemical, 
physiological, or other alteration within an organism that, depending on the magnitude, can be recognized 
as an established or potential health impairment or disease.
There is virtually no information regarding health effects o f trichlorobenzenes in humans, so no specific 
effect o f exposure has been identified. Studies in animals have identified the liver as the main target for 
trichlorobenzenes toxicity. Even i f  this were the case in humans exposed to trichlorobenzenes, similar 
liver alterations can be produced by exposure to many other chemicals. Health evaluations of 
trichlorobenzene workers may provide useful information regarding health effects that may be specific to 
exposure to these substances.
Absorption, Distribution, Metabolism, and Excretion. There is virtually no information 
regarding toxicokinetics o f trichlorobenzenes in humans. Studies in animals have shown that 
trichlorobenzenes are readily absorbed through the gastrointestinal tract following oral exposure (Bakke 
et al. 1992; Chu et al. 1987; Tanaka et al. 1986), but no information is available regarding absorption 
through the lungs or the skin. Since trichlorobenzenes are present in outdoor air in cities in the United 
States (EPA 2010a), absorption studies in animals exposed by inhalation would provide useful 
information.
Radioactivity derived from the labeled trichlorobenzenes was found widely distributed in tissues o f rats 
and rabbits following administration o f single doses o f 14C-trichlorobenzenes (Chu et al. 1987; Parke and 
Williams 1960). Elimination half-lives o f 1,2,4-trichlorobenzene from the blood, liver, and kidneys from 
male rats given a single intraperitoneal injection o f the chemical were 5.8, 5.2, and 6.2 hours, respectively 
(Kato et al. 1993). Elimination half-lives for the other isomers are not available. While short-term 
studies showed that trichlorobenzenes did not accumulate in tissues, information from repeated-dosing 
studies is lacking. One 13-week dietary study reported that 1,3,5-trichlorobenzene accumulated at higher 
levels in fat and liver from rats than 1,2,3-trichlorobenzene or 1,2,4-trichlorobenzene; the levels in fat 
were one order o f magnitude higher than those measured in the liver (Côté et al. 1988).
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The only relevant information regarding metabolism o f trichlorobenzenes in humans is that in microsomal 
preparations from human livers, CYP2E1 was the major enzyme in the formation o f 2,3,4-trichlorophenol 
and 2,3,5-trichlorophenol, while CYP3A4 was responsible for the formation o f 2,3,6-trichlorophenol 
(Bogaards et al. 1995). The metabolism o f trichlorobenzenes in animals exposed orally and parenterally 
has been fairly well studied, but no information is available following inhalation or dermal exposure. The 
specific enzymes involved in the initial formation o f phenolic intermediates are not known, but probably 
involve cytochrome P-450 isozymes. The role o f metabolism in the toxicity o f 1,2,4-trichlorobenzene has 
been studied (Kato and Kimura 2002; Kato et al. 1993), but no information is available for the other two 
trichlorobenzene isomers. A study in which 1,2,4-trichlorobenzene was incubated in vitro with 
microsomes isolated from the liver o f male rats reported the formation o f quinone metabolites, which 
bound covalently with microsomal protein and with exogenously added DNA (Den Besten et al. 1991). 
Further studies are needed to examine whether this can also occur in vivo and to determine the role that 
these metabolites may play in the toxicity o f trichlorobenzenes.
Data are available on the elimination and excretion o f metabolites o f the three trichlorobenzene isomers 
following single or short-term oral exposure to these chemicals (Chu et al. 1987; Jondorf et al. 1955; 
Lingg et al. 1982; Parke and Williams 1960; Tanaka et al. 1986). Further information regarding route of 
excretion in relation to increasing dose levels in single dose studies and in relation to duration o f exposure 
would be useful.
Comparative Toxicokinetics. There are no data regarding toxicokinetics o f trichlorobenzenes in 
humans. Studies in animals have reported qualitative differences in metabolite production and disposition 
between species. For example, glutathione conjugation was the predominant pathway in rats, whereas 
glucuronidation was predominant in monkeys (Lingg et al. 1982). The same study also showed that rats 
excreted 1,2,4-trichlorobenzene-derived radioactivity in the urine 2-3 times faster than monkeys. 
However, since there are no toxicokinetic data in humans, the animal species that is the most appropriate 
model for humans is unknown. Analyses o f the urine o f workers exposed to trichlorobenzenes would 
provide valuable information.
Methods for Reducing Toxic Effects. No specific methods for the mitigation o f effects o f acute 
exposure to trichlorobenzenes were located other than measures to support vital functions. No 
information was located concerning mitigation o f effects o f lower-level or longer-term exposure to 
trichlorobenzenes. This, in part, may reflect the fact that no population has been identified as having been 
subjected or currently undergoing exposure to excessive amounts o f trichlorobenzenes. Therefore, it is
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difficult to design studies or methods for reducing toxic effects i f  no significant health effects have been 
reported to date.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above.
It is not known whether children are more or less susceptible to the effects o f exposure to 
trichlorobenzenes than adults because there are no studies that specifically addressed this question. There 
is no information on whether the developmental process is altered in humans exposed to trichloro- 
benzenes. For the most part, studies in rats and mice did not show trichlorobenzenes to be embryotoxic or 
teratogenic (Black et al. 1988; Chernoff and Kavlock 1983; Gray and Kavlock 1984; Gray et al. 1986; 
Kitchin and Ebron 1983). However, Black et al. (1988) reported lesions in the lenses o f the eye o f fetuses 
from rats dosed with 1,2,4-trichlorobenzene and 1,3,5-trichlorobenzene on Gd 6-15 and sacrificed on 
Gd 22. Since no quantitative data were shown, the shape o f the dose-response relationship could not be 
verified. Replication o f these results would be useful. The information available does not suggest that 
trichlorobenzenes have endocrine-disrupting ability, but this issue has not been systematically studied.
There are no data to evaluate whether pharmacokinetics o f trichlorobenzenes in children are different 
from adults. There is no information on whether trichlorobenzenes can cross the placenta, but they have 
been detected in human breast milk, so they could be transferred to newborns (Mes et al. 1993; Newsome 
et al. 1995). There are no data to permit an evaluation o f whether metabolism o f trichlorobenzenes is 
different in children than in adults.
Research into the development o f sensitive and specific biomarkers o f exposures and effects for 
trichlorobenzenes would be valuable for both adults and children. There are no data on the interactions of 
trichlorobenzenes with other chemicals in children. There are no pediatric-specific methods to reduce 
peak absorption, body burdens, or to interfere with the mechanisms o f action o f trichlorobenzenes. Based 
on the information available, it is reasonable to assume that the supportive methods recommended for 
maintaining vital functions in adults w ill also be applicable to children.
Child health data needs relating to exposure are discussed in 6.8.1, Identification o f Data Needs:
Exposures o f Children.
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4.1 CHEMICAL IDENTITY
There are three possible isomers for trichlorobenzene: 1,2,3-trichlorobenzene; 1,2,4-trichlorobenzene; 
and 1,3,5-trichlorobenzene. The chemical identity o f each isomer is shown in Table 4-1.
4.2 PHYSICAL AND CHEMICAL PROPERTIES
Trichlorobenzenes are relatively volatile, hydrophobic substances. The physical and chemical properties 
o f each isomer are shown in Table 4-2.
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4. CHEMICAL AND PHYSICAL INFORMATION
Table 4-1. Chemical Identity of Trichlorobenzenesa
Characteristic 1,2,3-Trichlorobenzene 1,2,4-Trichlorobenzene 1,3,5-Trichlorobenzene
Synonym(s) Benzene, 1,2,3-trichloro-; Benzene, 1,2,4-trichloro-; Benzene, 1,3,5-trichloro-;
vic-trichlorobenzene; unsym-Trichlorobenzene; s-Trichlorobenzene; sym-
AI3-15516 AI3-07775; 1,2,4-Tricloro- 
benceno (Spanish)
Trichlorobenzene











CAS registry 87-61-6 120-82-1 108-70-3
RTECS No data DC2100000b No data
EPA hazardous waste No data No data No data
EPA/OPP pesticide 
Code
No data No data No data
OHM/TADS No data No data No data
DOT/UN/NA/IMDG
shipping
No data No data No data
HSDB 1502 1105 132
EINECS No data 204-428-0c No data
NCI No data No data No data
aAll information from HSDB 2010, unless otherwise noted. 
bNIOSH 1994.
cEuropean Communities 2003.
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4. CHEMICAL AND PHYSICAL INFORMATION
Table 4-2. Physical and Chemical Properties of Trichlorobenzenesa
Property 1,2,3-Trichlorobenzene 1,2,4-Trichlorobenzene 1,3,5-Trichlorobenzene
Molecular weight 181.45 181.45 181.45
Physical
description
Platelets from alcohol Colorless liquid White crystals
Melting point 51.3 °C 16.92 °C 62.8 °C
Boiling point 218.5 °C 213.5 °C 208 °C
Density 1.4533 g/cm3 at 25 °C 1.459 g/cm3 at 20 °C 1.456 g/cm3 at 20 °C
Odor No data Aromatic odor No data
Solubility:
Water 18 mg/L at 25 °C 49 mg/L at 25 °C 6.01 mg/L at 25 °C
Organic
solvent(s)
Slightly soluble in ethanol; 
very soluble in ether and 
benzene. Freely soluble in 
carbon disulfide
Sparingly soluble in alcohol; 
miscible with ether, 
benzene, petroleum ether, 
carbon disulfide
Sparingly soluble in alcohol; 
freely soluble in ether, 
benzene, petroleum ether, 
carbon disulfide, glacial 
acetic acid
Partition coefficients:
Log Kow 4.05 4.02 4.19
Log Koc 3.21-3.90 3.10-4.03 2.80-3.82
Henry’s Law 
constant
1.25x10-3 atm-m3/mol 1.42x10-3 atm-m3/mol 1.89x10-3 atm-m3/mol
Vapor pressure 0.21 mm Hg at 25 “C 0.46 mm Hg at 25 °C 0.24 mm Hg at 25 °C
Autoignition
temperature
No data 571 °C No data
Flashpoint 112.7 “C 105 °C 107 °C
Flammability 
limits in air
No data Lower flammable limit:
2.5% by volume at 302 °F 
(150 °C). Upper flammable 
limit: 6.6% by volume at 




1 mg/m3=0.13 ppm 1 mg/m3=0.13 ppm 1 mg/m3=0.13 ppm
Explosive limits No data 2.5-6.6 % volume (at 
150 °C)
No data
aAll information from HSDB 2010, unless otherwise noted. 
bVerschueren 2001
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5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1 PRODUCTION
No information is available in the Toxics Release Inventory (TRI) database on facilities that manufacture 
or process 1,2,3-trichlorobenzene and 1,3,5-trichlorobenzene because this chemical is not required to be 
reported under Section 313 o f the Emergency Planning and Community Right-to-Know Act (Title III o f 
the Superfund Amendments and Reauthorization Act o f 1986) (EPA 1998c).
Table 5-1 lists the facilities in each state that manufacture or process 1,2,4-trichlorobenzene, the intended 
use, and the range o f maximum amounts o f trichlorobenzenes that are stored on site. The data listed in 
Table 5-1 are derived from the Toxics Release Inventory (TRI08 2010). These data should be used with 
caution, however, since only certain types o f facilities are required to report (EPA 2005b). Therefore, this 
is not an exhaustive list.
Chlorobenzenes are prepared industrially by reacting liquid benzene with gaseous chlorine in the presence 
o f a Lewis acid catalyst such as ferric chloride (Rossberg et al. 2006). The reaction is carried out at 
moderate temperature and atmospheric pressure. Generally, mixtures o f isomers and compounds with 
varying degrees o f chlorination are obtained, because any given chlorobenzene can react further until 
hexachlorobenzene is ultimately produced. 1,2,3-Trichlorobenzene and 1,2,4-trichlorobenzene are 
formed in minor quantities in the production o f monochlorobenzene and dichlorobenzene; however, 
trichlorobenzenes become the primary product i f  the chlorine input is increased to about 3 moles of 
chlorine per mole o f benzene (Rossberg et al. 2006). 1,2,4-Trichlorobenzene can be obtained more 
directly via chlorination o f 1,4-dichlorobenzene.
An additional method employed to produce 1,2,4- and 1,2,3-trichlorobenzene is based on the dehydro- 
halogenation o f 1,2,3,4,5,6-hexachlorocyclohexane. By reacting hexachlorocyclohexane with aqueous 
alkali or alkaline earth solutions, ammonia, or other catalysts in the temperature range o f 90-250 °C, 
trichlorobenzene is produced. The yield is generally high, ranging between 80 and 99%, with the mixture 
consisting o f 70-85% 1,2,4-trichlorobenzene and 13-30% 1,2,3-trichlorobenzene (Rossberg et al. 2006).
1,3,5-Trichlorobenzene is usually only produced in minor quantities during the chlorination o f liquid 
benzene; however, it can be produced by Sandmeyer reaction on 3,5-dichloroaniline or by reacting
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Table 5-1. Facilities that Produce, Process, or Use 1,2,4-Trichlorobenzene
Minimum Maximum
Number of amount on site amount on site
Statea facilities in poundsb in poundsb Activities and usesc
AL 10 0 999,999 0 2, 3, 4, 0, 6, 7, 0, 0, 10, 11, 12, 0, 0
AR 4 100 99,999 0, 0, 0, 0, 0, 0, 7, 0, 0, 0, 0, 12, 0, 0
AZ 3 1,000 9,999 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 11, 12, 0, 0
CA 13 100 999,999 0, 0, 0, 4, 0, 0, 7, 8, 9, 10, 11, 12, 0, 0
CT 1 1,000 9,999 1, 0, 3, 0, 0, 0, 7, 0, 0, 0, 11, 0, 0, 0
DE 5 1,000,000 49,999,999 1, 2, 3, 4, 0, 0, 7, 0, 0, 0, 0, 0, 0, 0
FL 4 1,000 99,999 0, 0, 0, 0, 0, 0, 0, 0, 0, 10, 11, 12, 0, 0
GA 10 0 99,999 0, 0, 0, 0, 0, 6, 7, 0, 0, 10, 11, 0, 0, 0
IL 5 1,000 99,999 1, 0, 0, 0, 5, 0, 0, 0, 0, 10, 0, 12, 0, 0
IN 7 100 999,999 0, 2, 3, 0, 0, 0, 7, 0, 9, 0, 11, 12, 0, 0
KS 5 0 499,999,999 0, 0, 0, 0, 0, 0, 0, 0, 9, 0, 0, 12, 0, 0
KY 9 1,000 999,999 1, 0, 3, 0, 5, 6, 0, 0, 9, 10, 0, 12, 0, 0
LA 8 0 999,999 1, 0, 0, 0, 5, 6, 0, 0, 0, 0, 0, 12, 0, 0
MI 4 0 99,999 0, 0, 0, 0, 0, 0, 0, 8, 0, 10, 0, 12, 0, 0
MO 3 0 99,999 0, 0, 0, 0, 0, 0, 0, 0, 9, 0, 0, 12, 0, 0
MS 3 0 999,999 1, 0, 0, 0, 5, 0, 0, 0, 0, 0, 0, 12, 0, 0
NC 25 100 999,999 1, 2, 3, 4, 0, 6, 7, 8, 0, 10, 11, 12, 0, 0
NE 3 1,000 999,999 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 12, 0, 0
NJ 5 1,000 99,999 0, 0, 0, 0, 0, 0, 7, 0, 9, 0, 11, 12, 0, 0
NY 3 1,000 99,999 0, 0, 0, 0, 0, 0, 0, 0, 9, 10, 0, 12, 13, 0
OH 13 0 49,999,999 0, 0, 0, 0, 0, 0, 7, 8, 9, 10, 11, 12, 0, 0
OK 5 100 9,999,999 1, 0, 0, 0, 0, 0, 0, 0, 0, 10, 0, 12, 13, 0
OR 1 100,000 999,999 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 12, 0, 0
PA 14 0 9,999,999 1, 2, 3, 0, 5, 0, 7, 0, 9, 10, 0, 12, 13, 0
PR 2 1,000 9,999 0, 0, 0, 0, 0, 0, 7, 0, 0, 10, 0, 0, 0, 0
RI 3 1,000 99,999 0, 2, 0, 0, 0, 0, 0, 0, 9, 10, 0, 12, 13, 0
SC 11 1,000 99,999 0, 2, 3, 0, 0, 6, 7, 8, 9, 10, 0, 12, 0, 0
SD 1 10,000 99,999 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 12, 0, 0
TN 2 10,000 999,999 0, 0, 0, 0, 0, 0, 0, 0, 0, 10, 0, 12, 0, 0
TX 21 0 49,999,999 1, 2, 3, 0, 5, 6, 7, 0, 9, 10, 11, 12, 0, 0
UT 3 100 99,999 0, 0, 0, 0, 0, 0, 7, 8, 0, 0, 11, 12, 0, 0
VA 6 0 99,999 0, 0, 0, 0, 0, 0, 0, 0, 0, 10, 11, 12, 0, 0
WA 3 1,000 999,999 0, 0, 0, 0, 0, 0, 7, 0, 0, 0, 0, 12, 0, 0
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Table 5-1. Facilities that Produce, Process, or Use 1,2,4-Trichlorobenzene
Minimum Maximum
Number of amount on site amount on site
State3 facilities in poundsb in poundsb Activities and usesc
WI 1 1,000 9,999 0, 0, 0, 0, 0, 0, 0, 0, 0, 10, 0, 0, 0, 0
WV 3 10,000 9,999,999 1, 0, 0, 4, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0
Post office state abbreviations used 
















Source: TRI08 2010 (Data are from 2008)
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benzene-1,3,5-trisulfonic acid derivatives with phosgene (Rossberg et al. 2006). It can also be produced 
by diazotization o f 2,4,6-trichloroaniline, followed by treatment with a reducing agent such as 
hypophosphorous acid (O’Neil et al. 2006).
The EPA Inventory Update Reporting rule requires chemical companies to submit data for compounds 
manufactured or imported in quantities o f >25,000 pounds at a single site during a calendar year. For 
fiscal year 2005, three companies (Ashland Incorporated, BASF Corporation, and PPG Industries, Inc.) 
reported either manufacturing or importing quantities o f 1,2,4-trichlorobenzene in quantities of 
>25,000 pounds (EPA 2010b, 2010f). Two o f these corporations (Ashland Incorporated and BASF 
Corporation) also imported 1,2,3-trichlorobenzene. No data were located for 1,3,5-trichlorobenzene.
5.2 IMPORT/EXPORT
Non-confidential data obtained from the EPA Inventory Update Reporting rule indicated that 
<500,000 pounds o f 1,2,3-trichlorobenzene were imported into the United States in 2005 and 1- 
<10 million pounds o f 1,2,4-trichlorobenzene were imported in 2005 (EPA 2010b, 2010f). No export 
volumes were located.
5.3 USE
Trichlorobenzenes have primarily been used as solvents and chemical intermediates. In the past, mixed 
isomers o f trichlorobenzene had been used for termite control in soil; however, there are currently no 
registered uses o f trichlorobenzenes as a pesticide (HSDB 2010). 1,2,4-Trichlorobenzene is currently 
used in solvents in chemical reactions and to dissolve special materials such as oils, waxes, resins, 
greases, and rubber (Rossberg et al. 2006). It is used as a dye carrier and in the production o f dyes 
(Rossberg et al. 2006). Other uses are associated with textile auxiliaries and as a dielectric liquid (a 
substance that conducts little or no electricity). 1,2,4-Trichlorobenzene is also one o f the most important 
solvents used for extracting fullerenes from soot (Beer et al. 1997). 1,2,3-Trichlorobenzene is used as an 
intermediate for the manufacture o f pesticides (through the production o f 2,3,4-trichloronitrobenzene), 
and as an intermediate in several fine chemical products and particularly herbicides, pigments, and dyes 
(Euro Chlor 2002). There is some use o f 1,3,5-trichlorobenzene but only as a chemical intermediate and 
in low quantities (Euro Chlor 2002). In Europe, 1,2,4-trichlorobenzene, has also been used in anti­
corrosives paint or rust removing agents and as an additive in polish and maintenance products; however, 
most o f these uses have been discontinued (European Communities 2003). Other former uses of 
trichlorobenzene include use o f the substance in degreasing agents, septic tanks and drain cleaners, wood
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preservatives, and abrasive formulations (European Communities 2003). Approximately 7,000 metric 




The preferred method o f disposal o f trichlorobenzene is incineration, preferably after mixing with another 
combustible fuel (HSDB 2010). Care must be exercised to assure complete combustion to prevent the 
formation o f phosgene. An alkali scrubber is necessary to remove the halo acids produced. Powdered 
activated carbon treatment (PACT) is used with the activated sludge for waste water treatment of 
trichlorobenzene (HSDB 2010). Primary treatment consists o f neutralization with lime and settling 
followed by combined powdered activated carbon-activated sludge for secondary/tertiary treatment. 
Primary sludge consisting o f metal salts and unreacted lime is dewatered before disposal in a lined 
landfill. Powdered activated carbon and return powdered activated carbon treatment sludge are added to 
the primary effluent as it is fed to aeration tanks. Treated effluent is discharged after first passing through 
a settling lagoon. Consistency and efficiency o f removal varies greatly with reported ranges from 44% 
for 1,2-dichlorobenzene to 99% for a number o f volatile organic compounds. For 1,2,4-trichlorobenzene, 
66% was removed.
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6.1 OVERVIEW
1.2.3-Trichlorobenzene, 1,2,4-trichlorobenzene, and 1,3,5-trichlorobenzene have been identified in 31, 
187, and 4 o f the 1,699 hazardous waste sites that have been proposed for inclusion on the EPA National 
Priorities List (NPL) (HazDat 2007). However, the number o f sites evaluated for trichlorobenzenes is not 
known. The frequency o f these sites can be seen in Figures 6-1, 6-2, and 6-3.
Trichlorobenzenes can be released to the environment from their production and use as solvents, dye 
carriers and chemical intermediates (Rossberg et al. 2006). They are also formed unintentionally during 
the combustion o f organic materials when chlorine is present and from the degradation o f higher 
chlorinated benzenes, such as tetrachlorobenzene, pentachlorobenzene, and hexachlorobenzene, or the 
degradation o f the pesticide, lindane (y-hexachlorocyclohexane). Since trichlorobenzenes are minor 
impurities in mono- and dichlorobenzene; their production and use may also result in the release of 
trichlorobenzenes to the environment. A t one time, mixed isomers o f trichlorobenzene were used for the 
control o f termites around the foundations o f buildings, which also led to their direct release into the 
environment. Trichlorobenzenes are volatile substances; consequently, they partition to the atmosphere 
and are frequently detected in ambient air samples. In addition to being detected in air, trichlorobenzenes 
have been identified in water, soil, sediment, plants, fish, animals, and food samples. It is often difficult 
to determine whether levels monitored in environmental samples arise from the direct release o f 
trichlorobenzenes or their unintentional formation from other processes.
1.2.4-Trichlorobenzene is one o f 188 chemicals that is designated as a hazardous air pollutant (HAP) 
under the Clean A ir Act. Monitoring data from 2008 indicate that average atmospheric levels in the 
United States are typically <1 ppbv; however, maximum levels >3 ppbv have been observed (EPA 
2010a). In the atmosphere, trichlorobenzenes exist primarily in the vapor phase. Vapor-phase 
trichlorobenzenes are removed from air by reacting with photochemically produced hydroxyl radicals.
The half-life for this reaction is approximately 16-38 days, suggesting that they are susceptible to long- 
range atmospheric transport.
Trichlorobenzenes volatilize from water surfaces; however, they also tend to adsorb to suspended solids 
in the water column and partition to sediment, which attenuates the rate at which volatilization occurs.
The rate o f hydrolysis and biodegradation is generally considered slow under environmental conditions.
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Figure 6-1. Frequency of NPL Sites with 1,2,3-Trichlorobenzene Contamination
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Figure 6-2. Frequency of NPL Sites with 1,2,4-Trichlorobenzene Contamination
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Figure 6-3. Frequency of NPL Sites with 1,3,5-Trichlorobenzene Contamination
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These substances have the potential to bioconcentrate in fish and other aquatic species. Trichloro- 
benzenes have been detected in surface water, groundwater, and drinking water sources near hazardous 
waste sites or industrialized areas that produce chlorinated substances. Levels are typically in the parts 
per trillion (ng/L) range in surface water and drinking water, but vary based on location and emission 
sources. Trichlorobenzenes have low mobility in soil and typically do not leach into groundwater unless 
there is a large spill to a soil surface. 1,2,3-Trichlorobenzene and 1,2,4-trichlorobenzene were not 
detected in an analyses o f groundwater samples collected at about 2,400 domestic wells and about 
1,100 public wells in a monitoring program conducted by the United States Geological Survey (USGS) to 
assess groundwater quality in major aquifers in the United States (USGS 2006). However,
1,2,4-trichlorobenzene was detected in groundwater in the ppm range at superfund sites where chlorinated 
substances were used and disposed o f (Carmichael et al. 1999; EPA 1976).
Volatilization is expected to be an important environmental fate process for trichlorobenzenes released to 
soil; however, adsorption may reduce the rate at which trichlorobenzenes evaporate from soil surfaces. 
Trichlorobenzenes biodegrade slowly in soils under aerobic conditions, but undergo reductive 
dechlorination under methanogenic conditions, yielding lower chlorinated species (monochlorobenzene 
and dichlorobenzenes).
Exposure o f the general population to trichlorobenzenes is possible through inhalation o f ambient air and 
ingestion o f contaminated food and water. The average daily intake (AVDI) o f 1,2,4-trichlorobenzene 
was estimated to range from 3.34x10-5 to 0.0715 mg/kg/day, with ingestion o f root crops, fish, and 
drinking water identified as the primary exposure routes (European Communities 2003). Occupational 
exposure to trichlorobenzenes is possible through inhalation and dermal contact at workplaces where 
these substances are manufactured and used.
6.2 RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of 
facilities are required to report (EPA 2005b). This is not an exhaustive list. Manufacturing and 
processing facilities are required to report information to the TRI only i f  they employ 10 or more full-time 
employees; i f  their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20-39, 4911 (limited to facilities that combust coal and/or oil for the 
purpose o f generating electricity for distribution in commerce), 4931 (limited to facilities that combust 
coal and/or oil for the purpose o f generating electricity for distribution in commerce), 4939 (limited to
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facilities that combust coal and/or oil for the purpose o f generating electricity for distribution in 
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities 
primarily engaged in solvents recovery services on a contract or fee basis); and i f  their facility produces, 
imports, or processes >25,000 pounds o f any TRI chemical or otherwise uses >10,000 pounds o f a TRI 
chemical in a calendar year (EPA 2005b).
6.2.1 Air
Estimated releases o f 30,373 pounds (~13.8 metric tons) o f 1,2,4-trichlorobenzene to the atmosphere from 
17 domestic manufacturing and processing facilities in 2008, accounted for about 83% o f the estimated 
total environmental releases from facilities required to report to the TRI (TRI08 2010). These releases are 
summarized in Table 6-1. There is no information on releases o f 1,2,3-trichlorobenzene and
1,3,5-trichlorobenzene to the atmosphere from manufacturing and processing facilities because these 
releases are not required to be reported (EPA 1998c).
Section 112 o f the Clean A ir Act (CAA) lists 1,2,4-trichlorobenzene as one o f 188 hazardous air 
pollutants (HAPs) known to cause or suspected o f causing cancer or other serious human health effects or 
ecosystem damage (EPA 2000b). EPA's National Emission Inventory (NEI) database contains detailed 
information about sources that emit criteria air pollutants and their precursors, and HAPs for the 
50 United States, Washington DC, Puerto Rico, and the U.S. Virgin Islands (prior to 1999, criteria 
pollutant emission estimates were maintained in the National Emission Trends [NET] database and HAP 
emission estimates were maintained in the National Toxics Inventory [NTI] database). The NEI database 
derives emission data from several sources including state and local environmental agencies, the TRI 
database, computer models for on-road and off-road emissions, and databases related to EPA's Maximum 
Achievable Control Technology (MACT) programs to reduce emissions o f hazardous air pollutants.
Table 6-2 provides emissions data for 1,2,4-trichlorobenzene obtained from the NEI in 2005. The total 
emissions o f 1,2,4-trichlorobenzene in 2005 are significantly lower than total emissions from previous 
years. According to the National-Scale A ir Toxic Assessment that used data from the NEI, total 
emissions o f 1,2,4-trichlorobenzene were approximately 264 tons in 2002. Using composite data from 
the NTI database from 1990 to 1993, it was estimated that the annual emissions o f 1,2,4-trichlorobenzene 
in the United States was nearly 6,000 tons per year during that time frame (EPA 2000b).
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Table 6-1. Releases to the Environment from Facilities that Produce, Process, or
Use 1,2,4-Trichlorobenzenea
Statec RFd
Reported amounts released in pounds per yearb
Aire Waterf UIg Landh Otheri On-site*
Total release
Off-sitek On- and off-site
AL 2 150 0 0 0 0 150 0 150
FL 1 21,503 0 0 0 0 21,503 0 21,503
GA 1 0 0 0 0 0 0 0 0
KY 1 0 0 0 0 0 0 0 0
LA 2 1 0 0 20 0 1 20 21
OH 2 6,573 0 0 46 39 6,573 85 6,658
PA 3 37 0 0 30 0 37 30 67
TN 1 0 0 0 0 0 0 0 0
TX 3 363 0 6,200 1 0 6,563 1 6,564
WV 1 1,747 0 0 0 0 1,747 0 1,747
Total 17 30,373 0 6,200 97 39 36,573 136 36,709
aThe TRI data should be used with caution since only certain types of facilities are required to report. This is not an
exhaustive list. Data are rounded to nearest whole number.
bData in TRI are maximum amounts released by each facility.
cPost office state abbreviations are used.
dNumber of reporting facilities.
eThe sum of fugitive and point source releases are included in releases to air by a given facility.
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal
and metal compounds).
gClass I wells, Class II-V wells, and underground injection.
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 
impoundments, other land disposal, other landfills.
Storage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for 
disposal, unknown
jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
kTotal amount of chemical transferred off-site, including to POTWs.
RF = reporting facilities; UI = underground injection
Source: TRI08 2010 (Data are from 2008)
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Table 6-2. Emissions of 1,2,4-Trichlorobenzene in 2005
Emission category Type of source Annual emissions (tons)
Fuel combustion, commercial/institutional Point 0.00
Surface coating, industrial Point 3.61
Industrial process, pulp and paper Point 161.96
Graphic arts Nonpoint 0.06
Industrial process, storage and transfer Nonpoint 6.33
Industrial process, storage and transfer Point 0.22
Industrial process, cement manufacturing Point 0.00
Industrial process, not elsewhere classified Nonpoint 0.11
Solvent, not elsewhere classified Point 0.32
Industrial process, chemical manufacturing Point 17.94
Waste disposal, open burning Nonpoint 0.88
Fuel comb, electric utility Point 0.57
Waste disposal Point 2.87
Waste disposal Nonpoint 4.87
Industrial process, petroleum refineries Point 0.00
Bulk gasoline terminals Point 0.00
Industrial process, chemical manufacturing Nonpoint 0.05
Industrial process, not elsewhere classified Point 19.71
Industrial process, oil and gas production Point 0.00
Industrial process-metals Point 0.00
Graphic arts Point 0.02
Fuel comb-industrial boilers, internal combustion engine Point 1.28
Total 220.79
Source: EPA 2010c
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Trichlorobenzenes are also indirectly released to air from combustion processes, such as those that might 
occur at hazardous waste incinerators. The European Union Risk Assessment for 1,2,4-Trichlorobenzene 
(European Communities 2003) summarized several combustion experiments, which resulted in the 
formation o f trichlorobenzenes. Plastic waste, including polyethylene and polyvinyl chloride (PVC), was 
burned in a laboratory scale rotary kiln simulator. Combustion at temperatures exceeding 1,066 °C and 
excess air resulted in the formation o f dichlorobenzenes, trichlorobenzenes, pentachlorobenzene, and 
hexachlorobenzene when polyethylene and PVC were burned together. No chlorinated aromatics were 
formed, when polyethylene was burned alone. No higher chlorinated (>2) benzenes were formed, when 
PVC was burned alone (European Communities 2003).
1.2.4-Trichlorobenzene was detected in air samples at nine current or former NPL hazardous waste sites 
where it was detected in some environmental media (HazDat 2007). The other two isomers,
1.2.3-trichlorobenzene and 1,3,5-trichlorobenzene, were not detected in air samples at any o f the current 
or former NPL hazardous waste sites.
6.2.2 Water
There were no estimated releases o f 1,2,4-trichlorobenzene to surface water from facilities required to 
report to the TRI (TRI08 2010). There is no information on releases o f 1,2,3-trichlorobenzene and
1.3.5-trichlorobenzene to the water from manufacturing and processing facilities because these releases 
are not required to be reported (EPA 1998c).
1.2.3-Trichlorobenzene, 1,2,4-trichlorobenzene, and 1,3,5-trichlorobenzene were detected in waste water 
effluents from treatment plants located along the Niagara River and Grand River in Western, New York at 
mean concentrations o f 2, 11, and 0.3 ng/L, respectively (Oliver and Nicol 1982). 1,2,4-Trichlorobenzene 
was detected in the industrial effluents o f 10 out o f 114 industrial sites monitored in the Rhone-Alpes 
region in France in 1993 (European Communities 2003). Measured levels in these effluents ranged from
9 ^g/L (paint manufacturing plant) to 6,150 ^g/L (textile dying facility).
1.2.3-Trichlorobenzene, 1,2,4-trichlorobenzene, and 1,3,5-trichlorobenzene were detected in groundwater 
samples at 20, 114, and 2 current or former NPL hazardous waste sites, respectively, where they were 
detected in some environmental media (HazDat 2007). 1,2,4-Trichlorobenzene was detected in surface 
water samples at 18 NPL hazardous waste sites where it was detected in some environmental media
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(HazDat 2007). The other two isomers, 1,2,3-trichlorobenzene and 1,3,5-trichlorobenzene, were not 
detected in surface water samples at any o f the NPL hazardous waste sites.
6.2.3 Soil
Estimated releases o f 97 pounds o f 1,2,4-trichlorobenzene to soils from 17 domestic manufacturing and 
processing facilities in 2008, accounted for <1% o f the estimated total environmental releases from 
facilities required to report to the TRI (TRI08 2010). An additional 6,200 pounds (~2.8 metric tons), 
constituting about 17% o f the total environmental emissions, were released via underground injection 
(TRI08 2010). These releases are summarized in Table 6-1. There is no information on releases of
1.2.3-trichlorobenzene and 1,3,5-trichlorobenzene to the soil from manufacturing and processing facilities 
because these releases are not required to be reported (EPA 1998c).
The reductive dechlorination o f highly chlorinated benzenes, such as tetrachlorobenzene, pentachloro- 
benzene, and hexachlorobenzene, results in the formation o f trichlorobenzenes in soils and sediment. In 
addition, the degradation of the pesticide, lindane, has also been demonstrated to result in the formation of
1.2.4-trichlorobenzene (Bharati et al. 1998; Nagpal and Paknikar 2006). Hexachlorobenzene was 
dechlorinated to tri- and dichlorobenzenes in anaerobic sewage sludge within a three-week incubation 
period (Fathepure et al. 1988). Greater than 90% o f the added hexachlorobenzene was recovered as
1.3.5-trichlorobenzene, and there was no evidence for further dechlorination o f 1,3,5-trichlorobenzene 
The former use o f trichlorobenzenes as a soil treatment to control termite damage around the foundation 
o f buildings also released these compounds directly to the environment; however, the quantitative amount 
released from this former use is unknown.
1,2,3-Trichlorobenzene, 1,2,4-trichlorobenzene and 1,3,5-trichlorobenzene were detected in soil samples 
at 17, 125, and 1 current or former NPL hazardous waste sites, respectively where they were detected in 
some environmental media (HazDat 2007). 1,2,3-Trichlorobenzene was detected in sediment samples at 
1 NPL site and 1,2,4-trichlorobenzene was detected in sediment samples at 34 NPL sites.
1.3.5-Trichlorobenzene was not detected in sediment samples at any o f the current or former NPL 
hazardous waste sites.
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6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning
A ll three isomers o f trichlorobenzene possess vapor pressures and Henry’s Law constants (see Table 4-2) 
that suggest a tendency for these compounds to partition into the atmosphere where they w ill exist 
predominantly in the vapor phase. In the atmosphere, trichlorobenzenes have fairly long half-lives and 
therefore, may be subject to long-range atmospheric transport.
Trichlorobenzenes are expected to possess low mobility in soil given their soil adsorption coefficients.
The soil adsorption coefficient (Koc) measured in the upper horizon (0-28 cm depth) o f a sandy forest soil 
obtained from North Carolina (91% sand, 8.4% silt, 0.6% clay) was 2,850 (Njoroge et al. 1998). The Koc 
value o f 1,2,3-trichlorobenzene, 1,2,4-trichlorobenzene, and 1,3,5-trichlorobenzene have been also 
reported as 1,622 (log Koc 3.21), 10,715 (log Koc 4.03), and 4,898 (log Koc 3.69), respectively (Beck et al. 
1995).
Laboratory and field studies demonstrated that volatilization is an important environmental fate process 
for trichlorobenzenes released to surface water (Wakeham et al. 1983a, 1983b). Volatilization half-lives 
ranged from approximately 11 days (summer-time conditions) to 22 days (spring-time conditions) for
1,2,4-trichlorobenzene in mesocosm experiments used to simulate ecosystem conditions o f Narragansett 
Bay, Rhode Island (Wakeham et al. 1983a). Trichlorobenzenes are hydrophobic substances that are 
expected to adsorb to suspended solids and sediment in natural waters. Using water and sediment from 
the Niagara River, the sediment-water adsorption coefficient o f 1,2,4-trichlorobenzene was measured to 
range from 63,096 to 199,526 (log Koc 4.8-5.3) (Oliver 1987). Other studies have also indicated that 
trichlorobenzenes adsorb strongly to sediment in the water column. Jonker and Smedes (2000) measured 
the log Koc values o f 1,2,3-trichlorobenzene, 1,2,4-trichlorobenzene, and 1,3,5-trichlorobenzene as 5.79, 
6.12, and 5.96, respectively, using water and sediment (0-30 cm depth) from Lake Ketelmeer, the 
Netherlands. The log Koc values were reported as 5.56 (1,2,3-trichlorobenzene), 5.50 (1,2,4-trichloro­
benzene), and 5.36 (1,3,5-trichlorobenzene) using sediment from a deeper (40-120 cm) layer. The rate of 
adsorption to sediment as well as the extent to which adsorption takes place within the water column may 
attenuate the rate o f volatilization o f trichlorobenzenes under environmental conditions.
Trichlorobenzenes have been shown to bioconcentrate in fish. The measured bioconcentration factors 
(BCF) o f 1,2,3-trichlorobenzene, 1,2,4-trichlorobenzene, and 1,3,5-trichlorobenzene measured at different 
concentrations in carp over a 6-week incubation period are provided in Table 6-3 (NITE 2002). The
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Table 6-3. Measured Bioconcentration Factors (BCF) of Trichlorobenzenes in
Carp




350-980 (concentration 100 pg/L); 130-1,200 (concentration 10 pg/L) 
420-1,140 (concentration 100 pg/L); 120-1,320 (concentration 10 pg/L) 
620-1,620 (concentration 100 pg/L); 150-1,700 (concentration 10 pg/L)
Source: NITE 2002
***DRAFT FOR PUBLIC COMMENT***
TRICHLOROBENZENES 171
mean BCF values o f 1,2,4-trichlorobenzene measured in rainbow trout maintained in a flow-through 
aquarium at initial concentrations o f 3.2 and 52 ng/L, were 1,300 and 3,200, respectively, over an 
exposure period exceeding 100 days (Oliver and Niim i 1983). The mean BCF values o f 1,3,5-trichloro- 
benzene using initial concentrations o f 2.3 and 45 ng/L were measured as 1,800 and 4,100, respectively 
(Oliver and Niim i 1983). American flagfish (Jordanellafloridae) exposed to 3.8 ^g/L (3,800 ng/L) of
1,2,4-trichlorobenzene for 28 days followed by a depuration period o f 5-7 days, had a whole-body BCF 
of 2,026 and the metabolic half-life was estimated to be 1.21 days (European Communities 2003). Spot 
fish (Leiostomus xanthurus) were placed in aquariums containing 10 ^g/L (10,000 ng/L) 1,2,4-trichloro­
benzene and fed either shrimp exposed to 1,2,4-trichlorobenzene or non contaminated shrimp over a 
28-day exposure period (Heitmuller and Clark 1989). Uptake was determined to occur primarily through 
the gills rather than accumulation from food. BCF values o f 69-135 measured for these fish suggest only 
modest bioconcentration o f 1,2,4-trichlorobenzene and the rapid rate o f depuration (half-life o f 0.2 days) 
appeared to be responsible for the lack o f accumulation in these fish.
A field study measured the bioaccumulation factor (BAF) o f 1,2,3-trichlorobenzene and 1,2,4-trichloro­
benzene in four aquatic species (mummichog, blue crabs, gulf menhaden and Atlantic croaker) living in 
an effluent/cooling water canal receiving discharge from a chemical manufacturing plant in the Bayou 
d’Inde, Louisiana (Burkhard et al. 1997). The lipid-normalized log BAFs for the three species o f fish 
ranged from approximately 4.64 to 4.80 for 1,2,3-trichlorobenzene and 4.68 to 4.86 for 1,2,4-trichloro­
benzene (Burkhard et al. 1997). The log BAF for blue crabs were 4.63 and 4.62 for 1,2,3-trichloro­
benzene and 1,2,4-trichlorobenzene, respectively. These values were found to be consistent with 
measurements made for trichlorobenzenes in Atlantic croaker, spotted sea trout, blue crabs, and blue 
catfish obtained from another sampling location o f in the Bayou d’Inde (Pereira et al. 1988).
In general, whole-body BCF and BAF values that are >5,000 suggest a high potential for a chemical 
substance to bioaccumulate under typical environmental conditions, while values <1,000 suggest a much 
lower potential. Given the range o f BCF and BAF values for the trichlorobenzenes, the weight of 
evidence suggests that these substances may bioconcentrate and bioaccumulate to some extent in the 
environment, but do not possess the same high degree o f bioaccumulation potential as higher chlorinated 
substances such as hexachlorobenzene.
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6.3.2 Transformation and Degradation
6.3.2.1 Air
Trichlorobenzenes released to the atmosphere w ill degrade by reacting with photochemically generated 
hydroxyl radicals. Degradation by reaction with other common atmospheric oxidants such as nitrate 
radicals or ozone, and degradation by direct sunlight photolysis are not expected to be important 
environmental fate pathways. Second-order hydroxyl radical rate constants were estimated using a 
quantitative structure estimation method (Meylan and Howard 1993). Using these estimated rate 
constants and assuming a 12-hour hydroxyl radical concentration o f 1.5x106 hydroxyl radicals per cubic 
cm o f air, estimated half-lives for 1,2,3-trichlorobenzene, 1,2,4-trichlorobenzene, and 1,3,5-trichloro- 
benzene are 38, 38, and 16 days, respectively.
6.3.2.2 Water
Trichlorobenzenes are expected to biodegrade slowly in water. The rate o f aerobic biodegradation of 
chlorinated aromatic substances decreases as the degree o f chlorination on the benzene ring increases. 
Standardized screening methods used to characterize the capability o f rapid mineralization o f a substance 
have determined that trichlorobenzenes and higher chlorinated benzenes are not readily biodegradable 
under aerobic conditions. A mixture o f trichlorobenzene isomers present at 100 mg/L achieved 0% o f its 
theoretical biochemical oxygen demand (BOD) using an activated sludge inoculum at 30 mg/L and the 
modified M ITI test (OECD 301C) over a 28-day incubation period (NITE 2002).
The degradation pattern o f 1,2,3-trichlorobenzene and 1,2,4-trichlorobenzene was studied using 
methanogenic water-sediment slurries obtained from nine eutrophic ponds and slow moving streams 
(Peijnenburg et al. 1992). The degradation pattern was bi-phasic in each water-sediment slurry with an 
initial half-life range o f 62-212 days for 1,2,4-trichlorobenzene and 63-323 days for 1,2,3-trichloro­
benzene after a characteristic lag period o f approximately 4-8 weeks.
1,2,3-, 1,2,4-, and 1,3,5-Trichlorobenzene were shown to undergo photoreductive dechlorination in water 
with the presence o f a photosensitizing agent, suggesting that photolysis in sunlit surface waters 
containing natural photosensitizers may be an important environmental fate process (Choudhry et al. 
1986). Hydrolysis is not expected to be an important environmental fate process for the trichlorobenzene 
isomers. The hydrolysis half-life o f 1,2,4-trichlorobenzene at pH 7 and 25 °C was reported as 3.4 years 
(USGS 1998).
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6.3.2.3 Sediment and Soil
Degradation o f highly chlorinated benzenes is generally slow under aerobic conditions but occurs under 
methanogenic conditions by reductive dechlorination, yielding lower chlorinated benzenes.
1.2.4-Trichlorobenzene was completely degraded within 4 days using a methanogenic microbial culture 
isolated from sediment obtained from polluted regions o f the Rhine River, Lake Ketelmeer, and an 
anaerobic waste water treatment plant located in the Netherlands (Middeldorp et al. 1997). 1,4-Dichloro- 
benzene and monochlorobenzene were observed as the main biodegradation byproducts. The degradation 
o f trichlorobenzenes was studied using sediment obtained from the Rhine River and a municipal water 
treatment facility in the Netherlands (Bosma et al. 1996). 1,2,4-Trichlorobenzene was partially degraded 
under aerobic conditions, but only after a long lag time. 1,3,5-Trichlorobenzene and 1,2,3-trichloro- 
benzene were not degraded under aerobic conditions. Under methanogenic conditions, degradation to 
mono- and dichlorobenzenes were observed for all three isomers after a 2-month lag period. A ll three 
isomers o f trichlorobenzene were biodegraded by an acclimated anaerobic sediment slurry using sediment 
and water from the Tsurumi River, Japan (Masunaga et al. 1996). The first-order biodegradation rate 
constants for 1,2,3-, 1,2,4-, and 1,3,5-trichlorobenzene were 0.0299/days, 0.017/days, and 0.0198/days, 
respectively; corresponding to half-lives were about 23 days (1,2,3-trichlorobenzene), 41 days 
(1,2,4-trichlorobenzene), and 35 days (1,3,5-trichlorobenzene).
The biodegradation rate o f 1,2,3-trichlorobenzene and 1,2,4-trichlorobenzene were studied in a Nixon 
sandy loam under aerobic conditions (Marinucci and Bartha 1979). It was determined that the 
trichlorobenzenes became increasingly toxic to soil microorganisms at concentrations exceeding 50 ^g/g 
soil and that mineralization proceeded at very slow rates (approximately 0.35 nanomoles/day/20 g soil for
1,2,3-trichlorobenzene and 1.0 nanomoles per day per 20 grams o f soil for 1,2,4-trichlorobenzene). 
Primary degradation products o f 1,2,3-trichlorobenzene were identified as 3,4,5-trichlorophenol and
2.4- and 2,6-dichlorophenol. The primary degradation products of 1,2,4-trichlorobenzene were 2,4-, 2,5-, 
and 3,4-dichlorophenol. 1,2,4-Trichlorobenzene was not significantly biodegraded in soil slurries using a 
silty loam soil containing 8% organic matter or a loamy sand soil containing 2.6% organic matter over the 
course o f a 30-day incubation period (Brunsbach and Reineke 1994). Trichlorobenzene isomers were 
extensively degraded under aerobic conditions by enriched microbial cultures that were isolated from 
contaminated soil samples obtained from a location heavily polluted with electrical transformer fluids 
(Adebusoye et al. 2007). Both 1,2,3- and 1,3,5-trichlorobenzene were degraded 91% over the course o f a 
202-hour incubation period using two strains o f bacteria isolated from the contaminated soil.
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6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation o f the potential for human exposure to trichlorobenzenes depends in part on the 
reliability o f supporting analytical data from environmental samples and biological specimens. 
Concentrations o f trichlorobenzenes in unpolluted atmospheres and in pristine surface waters are often so 
low as to be near the limits o f current analytical methods. In reviewing data on trichlorobenzenes levels 
monitored or estimated in the environment, it should also be noted that the amount o f chemical identified 
analytically is not necessarily equivalent to the amount that is bioavailable. The analytical methods 
available for monitoring trichlorobenzenes in a variety o f environmental media are detailed in Chapter 7 
(Analytical Methods).
6.4.1 Air
The A ir Quality System (AQS) database is EPA's repository o f criteria air pollutant and hazardous air 
pollutants monitoring data. Detailed air monitoring data for 1,2,4-trichlorobenzene in various cities in the 
United States for 2008 are shown in Table 6-4. Data for other years are available as zipped Microsoft 
Access database files that may be accessed directly from the EPA website. In general, the average 
concentration o f 1,2,4-trichlorobenzene in outdoor air is <1 ppbv for the majority o f the U.S. locations 
sampled. Maximum concentrations >3 ppbv were identified at three U.S. cities (Davie, Florida; 
Hollywood, Florida; Tulsa, Oklahoma). The mean and median daily concentrations o f 1,2,4-trichloro­
benzene in outdoor air samples in the United States had previously been reported as 0.172 and 
0.100 ppbv, respectively (Shah and Singh 1988). Grosjean (1991) reported a maximum concentration of
1.2.4-trichlorobenzene o f 0.34 ppbv in measurements o f air quality o f cities in California. Indoor air 
concentrations o f 1,2,3-, 1,2,4-, and 1,3,5-trichlorobenzene were reported as <1 ^g/m3 (<0.13 ppbv) at 
unspecified locations (Brown et al. 1994). Unspecified isomers o f trichlorobenzene were reportedly 
identified in indoor air at two buildings in the United States at a mean concentration o f 0.065 ppbv (Otson 
and Fellin 1992). In a survey o f 300 Dutch homes, 1,2,3-, 1,2,4-, and 1,3,5-trichlorobenzene were 
measured in indoor air at maximum levels o f 28, 33, and 5 ^g/m3 (3.6, 4.3, and 0.65 ppbv), respectively 
(Otson and Fellin 1992).
6.4.2 Water
1.2.4-Trichlorobenzene was detected at mean concentrations o f 0.6 and 0.2 ng/L in Lake Ontario and 
Lake Huron, respectively, in surface water samples collected between April and November o f 1980
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Table 6-4. 1,2,4-Trichlorobenzene Air Levels at Monitoring Stations Throughout





23 0.09 Phoenix Arizona
39 0.103 Phoenix Arizona
4e 0.09 Grand Junction Colorado
1 e 0.12 Washington District of Columbia
32 1.232 Davie Florida
11 0.09 Davie Florida
1 e 1.125 Pompano Beach Florida
25 1.294 Hollywood Florida
23 0.817 Not specified Florida
12 0.09 Not specified Florida
42 0.205 Tampa Florida
45 0.206 Plant City Florida
19 0.497 Tallahassee Florida
38 0.22 Winter Park Florida
4e 0.203 Saint Petersburg Florida
45 0.213 Pinellas Park Florida
14 0 .0 e Milledgeville Georgia
11 0.07 Macon Georgia
13 0 .0 e Savannah Georgia
14 0 .0 e Douglas Georgia
14 0 .0 e Not specified Georgia
29 0 .0 e Decatur Georgia
14 0 .0 e Decatur Georgia
15 0 .0 e Rome Georgia
15 0 .0 e Not specified Georgia
15 0 .0 e Not specified Georgia
10 0 .0 e Brunswick Georgia
19 0 .0 e Gainesville Georgia
12 0 .0 e Warner Robins Georgia
13 0 .0 e Valdosta Georgia
13 0 .0 e Columbus Georgia
15 0 .0 e Not specified Georgia
12 0 .0 e Augusta Georgia
5 0.45 Not specified Idaho
7 0.45 Boise City (corporate name for) Idaho
e 0.45 Nampa Idaho
5 0.45 Not specified Idaho
42 0.092 Schiller Park Illinois
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the United States in 2008a
Number of Mean concentration
observations (ppbv) City State
49 0.09 Northbrook Illinois
5 0.09 Northbrook Illinois
4 0.05 Clarksville Indiana
51 0.05 Gary Indiana
13 0.05 East Chicago Indiana
14 0.05 Whiting Indiana
16 0.05 Hammond Indiana
15 0.05 Indianapolis (remainder) Indiana
16 0.05 Indianapolis Indiana
15 0.05 Indianapolis (remainder) Indiana
16 0.05 Ogden Dunes (Wickliffe) Indiana
14 0.05 Lafayette Indiana
14 0.05 Evansville Indiana
25 0.38 Cedar Rapids Iowa
17 0.329 Des Moines Iowa
25 0.4 Davenport Iowa
28 0.12 Essex Maryland
30 0.12 Beltsville Maryland
30 0.12 Baltimore Maryland
31 0.12 Baltimore Maryland
30 0.506 Sault Ste. Marie Michigan
5 0.09 Dearborn Michigan
44 0.01 Rosemount Minnesota
45 0.01 Inver Grove Heights Minnesota
48 0.01 Rosemount Minnesota
48 0.01 Rosemount Minnesota
50 0.01 Apple Valley Minnesota
46 0.01 Richfield Minnesota
49 0.01 Minneapolis Minnesota
46 0.01 Minneapolis Minnesota
46 0.01 Minneapolis Minnesota
50 0.01 Minneapolis Minnesota
46 0.01 Minneapolis Minnesota
45 0.01 St. Louis Park Minnesota
49 0.01 St. Paul Minnesota
31 0.01 St. Paul Minnesota
41 0.01 Duluth Minnesota
46 0.01 St. Paul Park Minnesota
29 0.01 St. Paul Park Minnesota
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the United States in 2008a
Number of Mean concentration
observations (ppbv) City State
47 0.01 Newport Minnesota
29 0.01 Bayport Minnesota
50 0.01 Bayport Minnesota
10 0.09 Gulfport Mississippi
12 0.09 Tupelo Mississippi
4e 0.09 St. Louis Missouri
34 0.09 Camden New Jersey
43 0.09 North Brunswick Township New Jersey
44 0.09 Chester New Jersey
41 0.09 Elizabeth New Jersey
45 0.05 New York New York
4e 0.11 New York New York
41 0.08 Lackawanna New York
39 0.05 Tonawanda New York
43 0.05 Tonawanda New York
37 0.05 Tonawanda New York
4e 0.05 Tonawanda New York
28 0.05 Tonawanda New York
29 0.05 Not specified New York
40 0.05 Not specified New York
45 0.1 New York New York
45 0 .0 e Rochester New York
31 0.07 New York New York
39 0.07 Niagara Falls New York
42 0 .1 e New York New York
30 0 .0 e Troy New York
39 0.09 Troy New York
39 0 .0 e Troy New York
44 0.12 New York New York
44 0.08 New York New York
24 0.32 Asheville North Carolina
2 e 0.3 Not specified North Carolina
12 0.37 Charlotte North Carolina
2 e 0.33 Candor North Carolina
24 0.39 Not specified North Carolina
24 0.3e Not specified North Carolina
22 0.33 Raleigh North Carolina
16 0.47 Middletown Ohio
15 0.38 Cleveland Ohio
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Number of Mean concentration
observations (ppbv) City State
14 0.39 Cleveland Ohio
15 0.38 Cleveland Ohio
13 0.39 Cleveland Ohio
22 0.44 Columbus Ohio
23 0.46 Steubenville Ohio
22 0.46 Marietta Ohio
14 0.09 Not specified Oklahoma
41 0.09 Tulsa Oklahoma
5 0.09 Tulsa Oklahoma
43 0.167 Tulsa Oklahoma
4 0.09 Tulsa Oklahoma
44 0.093 Tulsa Oklahoma
e 0.09 Tulsa Oklahoma
30 0 .0 e Not specified Pennsylvania
24 0 .0 e Not specified Pennsylvania
18 0 .0 e Not specified Pennsylvania
18 0 .0 e Chester Pennsylvania
17 0 .0 e Marcus Hook Pennsylvania
22 0 .0 e Erie Pennsylvania
31 0.12 Lancaster Pennsylvania
2 e 0 .0 e Lancaster Pennsylvania
2 e 0 .0 e West Norriton Pennsylvania
32 0 .0 e Collegeville Pennsylvania
29 0.07 Philadelphia Pennsylvania
30 0.09 Philadelphia Pennsylvania
30 0.1 Philadelphia Pennsylvania
28 0.07 Philadelphia Pennsylvania
30 0.05 Philadelphia Pennsylvania
17 0 .0 e Not specified Pennsylvania
31 0.05 Not specified South Carolina
31 0.05 Not specified South Carolina
45 0.09 Not specified South Dakota
4e 0.09 Sioux Falls South Dakota
45 0.09 Loudon Tennessee
4 0.09 Loudon Tennessee
45 0.09 Loudon Tennessee
5 0.09 Loudon Tennessee
17 0.09 Memphis Tennessee
47 0.09 Bountiful Utah
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34 0.214 Underhill (town of) Vermont
18 0.214 Burlington Vermont
18 0.214 Burlington Vermont
18 0.214 Rutland Vermont
18 0.214 Brattleboro (town of) Vermont
15 0.12 Franconia Virginia
16 0.12 Not specified Virginia
16 0.12 Virginia Beach Virginia
4e 0.09 Seattle Washington
4 0.09 Seattle Washington
Source: EPA 2010a
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(Oliver and Nicol 1982). 1,2,3-Trichlorobenzene and 1,3,5-trichlorobenzene were also detected in Lake 
Ontario at mean concentrations o f 0.1 ng/L; however, neither isomer was detected in surface water 
obtained from Lake Huron. A ll three isomers o f trichlorobenzene were detected in certain locations of 
the Niagara River. 1,2,3-Trichlorobenzene was identified in three o f four sampling locations at 
concentrations ranging from 2 to 38 ng/L; 1,2,4-trichlorobenzene was identified at four out o f four 
sampling locations at levels ranging from 0.1 to 107 ng/L; and 1,3,5-trichlorobenzene was detected in 
three out o f four sampling locations at levels ranging from 1 to 8 ng/L (Oliver and Nicol 1982).
1.2.3-Trichlorobenzene and 1,2,4-trichlorobenzene were detected at concentrations o f 12 and 40 ng/L, 
respectively, in surface water obtained from the Bayou d’Inde, Louisiana near an industrial plant that 
produced trichloroethylene and perchloroethylene (Pereira et al. 1988). In surface water obtained from 
the Niagara River at Niagara on the Lake, 1,2,3-, 1,2,4-, and 1,3,5-trichlorobenzene were detected at 
levels o f 1.8, 6.4, and 0.7 ng/L, respectively (Fox et al. 1983). During the same sampling period,
1.2.4-trichlorobenzene was detected in Fort Erie water samples at a concentration o f 0.1 ng/L. Neither
1.2.3- nor 1,3,5-trichlorobenzene were detected at this location.
Both 1,2,3- and 1,2,4-trichlorobenzene were monitored for, but not detected in, aquifer samples in a 
comprehensive survey conducted by the USGS o f volatile organic compounds in private and public 
groundwater wells used for drinking water (USGS 2006). Neither isomer was detected in samples 
obtained from nearly 2,000 public and private wells across the United States. However, 1,2,3-trichloro- 
benzene was detected in 2 o f 19 groundwater wells two years after a polychlorinated biphenyls/ 
trichlorobenzene spill o f transformer fluid near Kingston, Tennessee at concentrations o f 0.18 and 
0.097 mg/L (EPA 1976). 1,2,4-Trichlorobenzene was detected at levels ranging from 4.43 to 5.02 mg/L 
in groundwater at the Ciba-Geigy Toms River, New Jersey Superfund site, a location that manufactured 
dyes, pigments, resins, and epoxy additives from 1952 to 1990 (Carmichael et al. 1999).
1.2.3- and 1,2,4-Trichlorobenzene were detected at mean concentrations o f 0.1 and 2 ng/L from municipal 
drinking water samples obtained from three cities in the Lake Ontario region (Oliver and Nicol 1982). 
Samples were obtained prior to and immediately after chlorine treatment, and no increase in the levels of 
trichlorobenzene and other chlorobenzenes were observed following chlorination. 1,3,5-Trichloro- 
benzene was monitored for, but not detected in drinking water at these locations. 1,2,3-Trichlorobenzene 
was detected at a level o f approximately 100 ng/L in chlorinated drinking water samples from 2 out of
10 Canadian water treatment plants (Otson et al. 1986).
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6.4.3 Sediment and Soil
Chlorobenzenes, including trichlorobenzenes are widespread in Western, New York, particularly in the 
Niagara Falls region. 1,2,3-Trichlorobenzene was detected in soil samples at mean concentrations of 
0.19, 0.54, 0.42, 0.17, and 0.16 ng/g at five locations in Erie County, New York, including the Love 
Canal area (Ding et al. 1992). 1,2,4-Trichlorobenzene was detected at mean concentrations o f 0.96, 2.53, 
1.80, 1.00, and 0.48 ng/g in soils at the same five locations. 1,2,4-Trichlorobenzene levels in soil samples 
in the Toms River Superfund site in New Jersey ranged from below detection limits to 440 ng/g 
(Carmichael et al. 1999).
Trichlorobenzenes were detected in surficial sediment samples obtained from four o f the Great Lakes 
during sampling conducted between April and November o f 1980 (Oliver and Nicol 1982). The results 
are summarized in Table 6-5. The substantial concentrations o f trichlorobenzenes (and other chlorinated 
substances) observed in the sediment samples obtained from Lake Ontario in comparison to the levels in 
the other lakes were attributed to the large amount o f waste disposal sites and chemical manufacturing 
plants along the Niagara River leading into Lake Ontario. Suspended solids obtained from the Niagara 
River contained 1,2,3-, 1,2,4-, and 1,3,5-trichlorobenzene at levels o f 5.4-38, 33-210, and 1.5-23 ng/g, 
respectively (Fox et al. 1983). 1,2,3-, 1,2,4-, and 1,3,5-Trichlorobenzene were detected at concentrations 
o f 9.6, 306.0, and 83.0 ^g/kg (ng/g), respectively, in bottom sediment obtained from the Bayou d’Inde, 
Louisiana near an industrial plant that produced trichloroethylene and perchloroethylene (Pereira et al. 
1988).
1,2,4-Trichlorobenzene was detected in stream bed sediment samples obtained at 1 out o f 517 sites in
20 major river basins in the continental United States sampled from August 1992 to September 1995 
(Lopes and Furlong 2001). The maximum concentration was reported as 68 ^g/kg (ng/g).
6.4.4 Other Environmental Media
Trichlorobenzenes have been detected in a variety o f environmental media including plants, fish, animals, 
and foods. 1,2,4-Trichlorobenzene was identified, not quantified, in various plant material grown in an 
Illinois coal refuse reclamation site (Webber et al. 1994) and was also present in plants at an average 
concentration o f 0.002 mg/kg in localities contaminated by agrochemical and communal waste 
(Veningerova et al. 1997).
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Table 6-5. The Range and Mean Concentration of Trichlorobenzene Isomers in 
Sediment Samples Obtained From the Great Lakes
Lake Superior Lake Heron Lake Erie Lake Ontario
Isomer (ng/g) (ng/g) (ng/g) (ng/g)
1,2,3-Trichlorobenzene ND-1.0 (range); 0.1-1 (range); 0.1-1 (range); 1-16 (range);
0.2 (mean) 0.3 (mean) 0.4 (mean) 7 (mean)
1,2,4-Trichlorobenzene 0.1-4 (range); 1-26 (range); 1-9 (range); 20-220 (range);
1 (mean) 6 (mean) 3 (mean) 94 (mean)
1,3,5-Trichlorobenzene ND-0.4; ND-4 (range); 0.1-5 (range); 7-250 (range);
0.2 (mean) 0.7 (mean) 1 (mean) 60 (mean)
ND = Not detected
Source: Oliver and Nicol 1982
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Catfish obtained from the Bayou d’Inde, Louisiana near an industrial plant that produced 
trichloroethylene and perchloroethylene had levels o f 1,3,5-trichlorobenzene, 1,2,4-trichlorobenzene, and
1,2,3-trichlorobenzene o f 480, 3,900, and 770 ng/g, respectively (Pereira et al. 1988). The levels 
decreased to 250 ng/g (1,3,5-trichlorobenzene), 1,900 ng/g (1,2,4-trichlorobenzene), and 370 ng/g 
(1,2,3-trichlorobenzene) in catfish obtained 1 mile downstream from the plant. Atlantic croakers, blue 
crabs, and spotted sea trout obtained 1 mile downstream from the plant had levels o f 1,3,5-trichloro­
benzene, 1,2,4-trichlorobenzene, and 1,2,3-trichlorobenzene o f 50-420, 140-3,200, and 20-710 ng/g, 
respectively (Pereira et al. 1988). 1,2,3-Trichlorobenzene, 1,2,4-trichlorobenzene, and 1,3,5-trichloro- 
benzene were detected in trout from Lake Superior, Lake Huron, Lake Erie, Lake Ontario, and the 
Niagara River (Oliver and Nicol 1982). Levels o f 1,2,3-trichlorobenzene ranged from 0.1 to 1 ng/g, 
levels o f 1,2,4-trichlorobenzene ranged from 0.5 to 5 ng/g, and levels o f 1,3,5-trichlorobenzene ranged 
from 0.1 to 4 ng/g. In each case, the highest levels were obtained from trout in Lake Ontario or the 
Niagara River. 1,3,5-Trichlorobenzene and 1,2,4-trichlorobenzene were also detected in trout caught near 
the Niagara River mouth in Lake Ontario at levels o f 1.0 and 3.7 ng/g, respectively (Fox et al. 1983).
Hoekstra et al. (2003) measured the levels o f persistent chlorinated substances in muscle and liver tissue 
o f Arctic foxes obtained from Holman, Canada, Arviat, Canada, and Barrow, Alaska. Total 
chlorobenzene levels (1,2-dichlorobenzene, 1,4-dichlorobenzene, 1,2,3-trichlorobenzene, 1,2,4-trichloro­
benzene, 1,3,5-trichlorobenzene, pentachlorobenzene, and hexachlorobenzene) ranged from 4.4 to
17.6 ng/g in muscle tissue and 4.2 to 12 ng/g in liver tissue.
Trichlorobenzene isomers were detected in nine different vegetables collected from supermarkets in Great 
Britain (Wang and Jones 1994). The results o f this study are summarized in Table 6-6. Peattie et al. 
(1984) identified isomers o f trichlorobenzene in seed oils produced from corn, soybean, rape, sunflower, 
peanut, sesame, walnut, hazelnut, and poppy. 1,2,3-, 1,2,4-, and 1,3,5-Trichlorobenzene were detected in 
various foods purchased at grocery stores in Ontario, Canada (Davies 1988). Leafy vegetables, fruits, 
milk, and eggs/meat contained trichlorobenzene levels o f 0.11-0.40, 0.12-0.14, 0.14-1.2, and 0.70­
0.74 ^g/kg, respectively. These results suggest that ingestion o f some foods may be a significant source 
o f trichlorobenzene exposure to the general population.
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
The general population is exposed to trichlorobenzene from inhalation o f ambient air and ingestion of 
food and drinking water (see Sections 6.4.1-6.4.4 for background environmental levels). In a European
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Table 6-6. Trichlorobenzene Concentrations in Whole Vegetables
1,2,3-Trichlorobenzene 1,2,4-Trichlorobenzene 1,3,5-Trichlorobenzene 
Vegetable (^g/kg) (^g/kg) (^g/kg)
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Carrots ND ND ND
Potato 0.0484 0.0038 0.010
Cabbage ND 0 .0 0 e8 0.0225
Cauliflower ND 0.0309 ND
Lettuce ND 0.0027 0.0030
Onion 0.0490 ND 0.03e3
Beans ND ND ND
Peas ND 0.0342 0.117
Tomatoes 0.0440 ND ND
ND = not detected
Source: Wang and Jones 1994
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Union Risk Assessment Report, four different exposure scenarios were developed to estimate the average 
daily intake o f 1,2,4-trichlorobenzene. The total daily intake was 0.0715 mg/kg/day for the exposure 
scenario, which yielded the highest estimated total daily intake for humans (European Communities 
2003). The estimates suggest that the most important human intake routes are ingestion o f root crops, 
fish, and drinking water. Davies (1988) used the concentration o f trichlorobenzene residues in food items 
purchased in Ontario, Canada and estimated an annual dietary intake o f approximately 147 ^g/year 
(0.402 ^g/day) for all three combined isomers. MacLeod and Mackay (1999) estimated the daily intake 
o f 1,2,4-trichlorobenzene for residents in Southern Ontario, Canada as 0.3 ^g/day, with the greatest 
contribution arising from inhalation o f ambient air (75.4% o f the total exposure) followed by ingestion of 
meat (14.3%), milk (6.4%), and eggs (2.5%).
Trichlorobenzenes have been detected in human body burden studies. In autopsies o f Canadian citizens,
1,2,3- and 1,3,5-trichlorobenzene were detected in biopsy fatty tissue at median levels o f 1.9 and 1.1 ng/g, 
respectively, and at maximum levels o f 9.1 and 3.7 ng/g, respectively (Mes 1992). Levels were below the 
detection limits in blood samples. 1,2,4-Trichlorobenzene was detected in human follicular fluid at a 
mean concentration o f 214 pg/mL for patients undergoing in vitro fertilization in Canada (Y ounglai et al. 
2002). 1,2,4-Trichlorobenzene was detected in follicular fluid in over 50% of the patients tested. It was 
also identified, but not quantified in human female serum obtained at the time o f oocyte retrieval for in 
vitro fertilization (Younglai et al. 2002).
Occupational exposure to trichlorobenzenes arises from inhalation and dermal contact with these 
compounds at workplaces where they are produced and used. According to the National Occupational 
Exposure Study (NOES) conducted by NIOSH from 1981 to 1983, an estimated 691 workers (all 
employed in the textile m ill trade) were potentially exposed to 1,2,3-trichlorobenzene in the workplace 
(NIOSH 1990a, 1990b). In addition, 4,033 workers, including 1,463 female employees, were potentially 
exposed to 1,2,4-trichlorobenzene (NIOSH 1990a, 1990b). The NOES database does not contain 
information on the frequency, concentration, or duration o f occupational exposure to any o f the chemicals 
listed. The survey provides only estimates o f the numbers o f workers for whom potential exposure in the 
workplace is an issue. Data from the EPA Inventory Update Reporting database indicate that 
>1,000 workers can be reasonably expected to have some form o f exposure to 1,2,4-trichlorobenzene and 
between 100 and 999 workers are expected to be exposed to 1,2,3-trichlorobenzene in the United States 
(EPA 2010b, 2010f). However, this database does not indicate the level o f exposure or the primary 
exposure route for these workers. Levels o f 1,2,3-trichlorobenzene and 1,2,4-trichlorobenzene in the 
breathing zone at different locations o f a chemical warehouse located in Michigan ranged from 0.03 to
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0.06 ppmv and 0.57 to 1.4 ppmv, respectively (Dow Chemical 1981). The highest levels were observed 
in locations where trichlorobenzenes and trichloroethane were being packaged into drums. The NIOSH 
ceiling lim it (concentration not to be exceeded at any time during the work day) is 5 ppmv (37 mg/m3) for
1.2.4-trichlorobenzene (NIOSH 2005).
6.6 EXPOSURES OF CHILDREN
This section focuses on exposures from conception to maturity at 18 years in humans. Differences from 
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults. A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram o f body weight, and have a 
larger skin surface in proportion to their body volume. A child’s diet often differs from that o f adults.
The developing human’s source o f nutrition changes with age: from placental nourishment to breast milk 
or formula to the diet o f older children who eat more o f certain types o f foods than adults. A child’s 
behavior and lifestyle also influence exposure. Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors. Children 
also are closer to the ground, and they do not use the judgment o f adults to avoid hazards (NRC 1993).
Children are exposed to trichlorobenzenes by the same means that adults are: inhalation o f ambient air, 
and ingestion o f contaminated food and drinking water. Trichlorobenzenes have also been identified in 
breast milk; therefore, infants may also be potentially exposed through breast feeding. The mean, 
median, and maximum concentrations o f 1,2,3-trichlorobenzene from 412 breast milk samples obtained 
from different provinces in Canada in 1986 were 0.98, 0.49, and 18.33 ng/g, respectively, for whole milk 
samples and 38.7, 15.3, and 466.3 ng/g, respectively, in milk fat (Mes et al. 1993). Only maximum levels 
o f 1,2,4-trichlorobenzene and 1,3,5-trichlorobenzene were reported. The maximum levels of
1.2.4-trichlorobenzene in whole milk and milk fat were 17.40 and 4490.9 ng/g, respectively. The 
maximum levels o f 1,3,5-trichlorobenzene in whole milk and milk fat were 5.18 and 128.2 ng/g, 
respectively. The mean concentrations o f 1,2,3-, 1,2,4-, and 1,3,5-trichlorobenzene in whole milk 
obtained from 497 breast milk samples in Canada collected in 1992 were reported as 0.07, 0.11, and 
0.04 ng/g, respectively (Newsome et al. 1995). The mean concentrations in milk fat were 2.79 ng/g for
1,2,3-trichlorobenzene, 3.81 ng/g for 1,2,4-trichlorobenzene, and 1.40 ng/g for 1,3,5-trichlorobenzene.
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No studies were located that expressed the level o f trichlorobenzenes or its metabolites in amniotic fluid, 
meconium, cord blood, or neonatal blood. Children are unlikely to be exposed to trichlorobenzenes from 
their parents clothing or playing on the ground (soil, carpeting, etc.) due to the volatility o f these 
substances.
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES
High levels o f trichlorobenzenes have been identified in soil and water samples in heavily industrialized 
areas or at superfund sites. Populations residing near these locations may be exposed to higher levels of 
trichlorobenzenes than the general population. In addition, certain food items have been shown to contain 
high levels o f trichlorobenzenes, in particular fish and root crops. Individuals who consume large 
amounts o f these products may have higher exposures to trichlorobenzenes as compared to the general 
population.
6.8 ADEQUACY OF THE DATABASE
Section 104(i)(5) o f CERCLA, as amended, directs the Administrator o f ATSDR (in consultation with the 
Administrator o f EPA and agencies and programs o f the Public Health Service) to assess whether 
adequate information on the health effects o f trichlorobenzenes is available. Where adequate information 
is not available, ATSDR, in conjunction with NTP, is required to assure the initiation o f a program of 
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) o f trichlorobenzenes.
The following categories o f possible data needs have been identified by a joint team o f scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that i f  met would 
reduce the uncertainties o f human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs w ill be 
evaluated and prioritized, and a substance-specific research agenda w ill be proposed.
6.8.1 Identification of Data Needs
Physical and Chemical Properties. The physical and chemical properties necessary for 
characterizing the environmental fate o f all three isomers o f trichlorobenzene have been measured or can 
be adequately estimated. No data needs have been identified.
6. POTENTIAL FOR HUMAN EXPOSURE
***DRAFT FOR PUBLIC COMMENT***
TRICHLOROBENZENES 188
Production, Import/Export, Use, Release, and Disposal. According to the Emergency 
Planning and Community Right-to-Know Act o f 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA. The TRI, which contains this 
information for 2008, became available in February o f 2010. This database is updated yearly and should 
provide a list o f industrial production facilities and emissions.
Data are available through the U.S. EPA Inventory Update Reporting system regarding the levels of 
trichlorobenzenes that are either manufactured or imported in quantities o f >25,000 pounds at a single site 
during a calendar year. Data are available for 1,2,4-trichlorobenzene and 1,2,3-trichlorobenzene. No data 
are available for 1,3,5-trichlorobenzene. Trichlorobenzenes appear to have no significant uses in 
household products in which the general population may be exposed, but have been identified in food. 
Sufficient use and disposal data exists for the trichlorobenzenes (HSDB 2010; Rossberg et al. 2006); 
however, a data need exists to determine the quantity of trichlorobenzenes that may have been exported.
A data need also exists to estimate the amount o f trichlorobenzenes released to the environment from both 
direct emissions and indirect releases via the degradation o f higher chlorinated benzenes and lindane.
Environmental Fate. Trichlorobenzenes are volatile substances that tend to partition to air and 
sediment when released to the environment and are generally slow to degrade in the environment 
(European Communities 2003; Peijnenburg et al. 1992;USGS 1998). Sufficient data exists to characterize 
the transport and environmental fate o f trichlorobenzenes and consequently no data needs are identified.
Bioavailability from Environmental Media. Studies characterizing the ADME (Absorption, 
Distribution, Metabolism, and Elimination) o f 1,2,3-, 1,2,4-, and 1,3,5-trichlorobenzene following oral 
exposure in humans are not available. In addition no ADME, data are available for inhalation and dermal 
exposure in humans and animals. A data need to determine the bioavailability o f trichlorobenzenes from 
environmental media exists.
Food Chain Bioaccumulation. Trichlorobenzenes have the potential to bioconcentrate and 
bioaccumulate in the environment and have been quantified in fish (Burkhard et al. 1997; Pereira et al. 
1988), animals (Hoekstra et al. 2003) and food crops (Wang and Jones 1994). No data needs are 
identified.
Exposure Levels in Environmental Media. Monitoring data are available for trichlorobenzenes in 
air (EPA 2010a; Grosjean 1991; Shah and Singh 1988), water (Carmichael et al. 1999; Fox et al. 1983;
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Oliver and Nicol 1982; Pereira et al. 1988), soil and sediment (Carmichael et al. 1999; Fox et al. 1983; 
Pereira et al. 1988), plants (Veningerova et al. 1997; Webber et al. 1994) and food (Davies 1988; Wang 
and Jones 1994). Human intakes have been estimated from environmental media (European 
Communities 2003; MacLeod and Mackay 1999). Reliable monitoring data for the levels of 
trichlorobenzenes in contaminated media at hazardous waste sites are needed so that the information 
obtained on levels o f trichlorobenzenes in the environment can be used in combination with the known 
body burden o f trichlorobenzenes to assess the potential risk o f adverse health effects in populations 
living in the vicinity o f hazardous waste sites.
Exposure Levels in Humans. Limited studies have shown that trichlorobenzenes have been 
detected in human blood (Mes 1992), adipose tissue (Mes 1992), follicular fluid (Y ounglai et al. 2002), 
and breast milk (Mes et al. 1993) in Canada. Additional studies on exposure levels to the U.S. population 
are needed.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. Children are exposed to trichlorobenzenes by the same routes that affect 
adults. Trichlorobenzenes have been detected in breast milk samples collected from Canadian females 
(Mes et al. 1993; Newsome et al. 1995). A data need exists to determine current trichlorobenzene 
residues and their sources in breast milk o f members o f the U.S. general population and whether children 
differ in weight-adjusted intakes o f trichlorobenzenes as compared to adult populations.
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification o f Data 
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for trichlorobenzene were located. This substance is 
not currently one o f the compounds for which a sub-registry has been established in the National 
Exposure Registry. The substance w ill be considered in the future when chemical selection is made for 
sub-registries to be established. The information that is amassed in the National Exposure Registry 
facilitates the epidemiological research needed to assess adverse health outcomes that may be related to 
exposure to this substance.
Few populations are expected to have high exposures to trichlorobenzenes. Persons residing near 
hazardous waste sites where chlorinated substances are disposed o f may be subject to higher levels of
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trichlorobenzene than the general population. In addition, certain food items have been shown to contain 
high levels o f trichlorobenzenes, in particular fish and root crops. Individuals who consume large 
amounts o f these products may have higher exposures to trichlorobenzenes as compared to the general 
population.
6.8.2 Ongoing Studies
The Federal Research in Progress (FEDRIP 2010) database provides additional information obtainable 
from a few ongoing studies that may fill in some o f the data needs identified in Section 6.8.1.
Researchers at Rutgers University are studying the adsorption/desorption kinetics o f 1,3,5-trichloro- 
benzene in 11 different solid materials including a peat, a topsoil, a sediment, three humic acids extracted 
from the peat, the topsoil, and the sediment, a coal sample, a black carbon material, a silica gel, kaolinite, 
and bentonite.
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The purpose o f this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring trichlorobenzenes, their metabolites, and other biomarkers o f exposure and 
effect to trichlorobenzenes. The intent is not to provide an exhaustive list o f analytical methods. Rather, 
the intention is to identify well-established methods that are used as the standard methods o f analysis. 
Many o f the analytical methods used for environmental samples are the methods approved by federal 
agencies and organizations such as EPA and the National Institute for Occupational Safety and Health 
(NIOSH). Other methods presented in this chapter are those that are approved by groups such as the 
Association o f Official Analytical Chemists (AOAC) and the American Public Health Association 
(APHA). Additionally, analytical methods are included that modify previously used methods to obtain 
lower detection limits and/or to improve accuracy and precision.
7.1 BIOLOGICAL MATERIALS
Trichlorobenzenes are typically analyzed for in blood, adipose tissue, and breath samples using gas 
chromatographic (GC) analysis. Detection limits are typically in the ng/g range. Representative methods 
are summarized in Table 7-1. For analytes such as trichlorobenzenes, electron capture detection (ECD) is 
often employed since it is highly sensitive to halogenated compounds and is less costly than mass 
spectrometer (MS) detection systems. However, the specific identification o f a compound is determined 
only by its retention time, which can be subject to shifts or to interference from other non-targeted 
compounds. GC using a quadrupole mass spectrometer operating in either the select ion monitoring 
(SIM) mode or the SCAN mode allows for positive identification o f the compound.
Blood or tissue samples are typically prepared by homogenizing and extracting the sample using a solvent 
such as benzene or acetone, followed by centrifugation and filtration (Mes 1992). In order to eliminate 
potential interferences from the sample matrix, cleanup and fractionation o f the filtrate is accomplished 
with a Florisil® column using hexane as the eluting solvent prior to introduction to the GC. Average 
recoveries o f the trichlorobenzenes from fortified adipose tissue or blood have been reported to exceed 
75% (Bristol et al. 1982; Mes 1992). Alternatively, a purge-and-trap method can be employed in which 
blood samples are warmed while passing an inert gas over the heated samples (Pellizari et al. 1985a). 
Trichlorobenzene vapors are trapped onto an adsorbent polymeric resin (Tenax®) and released by thermal 
desorption, followed by analysis with GC/MS or GC/ECD.
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detection limit recovery Reference
Blood Blood samples were 
homogenized with 









Blood Trichlorobenzenes are 
volatilized from blood by 
warming the sample and 
collecting in Tenax 
cartridges
GC/MS 3 ng/L 80 Pellizzari et al. 
1985a
Blood Samples of whole blood 
were extracted with 
hexane, centrifuged, and 








Bristol et al. 1982
Adipose
tissue
Blood samples were 
homogenized with 
benzene, centrifuged, and 








Breath Collection on Tenax 
tubes, dried using calcium 
sulfate and desorb to GC 
inlet
GC/MS No data No data Pellizzari et al. 
1985b
ECD = electron capture detector; GC = gas chromatography; MS = mass spectrometry; TCB = trichlorobenzene
***DRAFT FOR PUBLIC COMMENT***
TRICHLOROBENZENES 193
Trichlorobenzenes can be analyzed in human breath by collecting exhaled air samples onto a Tenax® GC 
cartridge, followed by drying with calcium sulfate and thermal desorption to a GC/MS (Pellizari et al. 
1985b). Detection limits and recoveries for trichlorobenzene were not reported; however, the detection 
lim it and quantification lim it for m-dichlorobenzene was 0.27 and 1.37 ^g/m3, respectively, suggesting 
that similar limits w ill be observed for trichlorobenzenes (Pellizari et al. 1985b).
7.2 ENVIRONMENTAL SAMPLES
Methods are available for determining the level o f trichlorobenzenes in a variety o f environmental 
matrices. A summary o f representative methods is shown in Table 7-2. Validated methods, approved by 
EPA and NIOSH, are available for air, water, soil, and sediment. GC using ECD or GC/MS is the most 
widely used analytical technique for identifying and quantifying trichlorobenzenes in environmental 
matrices.
NIOSH Method 5517 summarizes a method to analyze ambient air for the presence o f trichlorobenzenes. 
A ir samples are collected by a sampling pump at a flow rate between 0.01 and 0.2 L/minute for a total 
sample size o f 3-12 L, and adsorption occurs onto a charcoal tube or Tenax® GC cartridge.
Identification and quantification is accomplished using GC/ECD following ultrasonic desorption from the 
charcoal or Tenax® cartridge (NIOSH 1994). EPA Method TO-14 is similar to the previously described 
NIOSH method; however, collection o f ambient air samples is performed using specially prepared 
passivated stainless steel canisters rather than adsorbant tubes. The collection o f ambient air samples in 
these canisters provides a number o f advantages as compared to the adsorbant tubes including:
(1) convenient integration o f ambient samples over a specific time period (e.g., 24 hours); (2) remote 
sampling and central analysis; (3) ease o f storing and shipping samples; (4) unattended sample collection;
(5) analysis o f samples from multiple sites with one analytical system; (6) collection o f sufficient sample 
volume to allow assessment o f measurement precision and/or analysis o f samples by several analytical 
systems; and (7) storage stability for many volatile organic compounds (VOCs) over periods o f up to 
30 days (EPA 1999). Detection limits for trichlorobenzenes in ambient air are typically in the low ppbv 
range.
Trichlorobenzenes in water, soil, and sediment are typically analyzed by GC/MS or GC/ECD after 
extraction from the environmental matrix. EPA Method 8260B is used to quantitatively analyze a variety 
o f VOCs, including trichlorobenzenes, with GC/MS. Analysis can be performed on contaminated 
groundwater and surface water, aqueous sludges, caustic liquors, acid liquors, waste solvents, oily wastes,
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detection limit recovery Reference
Air Collection at flow rate of GC/ECD 
0.01 and 0.2 L/minute 
onto sorbent tubes and 
desorb with hexane
0.002 mg/m3 No data NIOSH 1994 
(NIOSH 
method 5517)
Air Collection in passivated GC/ECD or 
stainless steel canisters GC/MS














Water and waste Continuous liquid-liquid GC/ECD 
samples extraction or separatory 








No data EPA 1994 
(Method 8121)
Groundwater Continuous liquid-liquid GC/MS 
extraction or separatory 
funnel extraction using 
methylene chloride





Soxhlet Extraction using GC/ECD 
methylene
chloride/acetone (1:1) 
as the extraction solvent 












Closed-system purge- GC/MS 
and-trap process
0.44 .̂g/kg 11.4-75.4 EPA 1996b
(Method
8260B)
Sediment Soxhlet Extraction using GC/MS 
dichloromethane.
Cleanup with GPC
50 |ag/kg No data Lopes and 
Furlong 2001
Fruit and Homogenize in a GC/ECD 0.007- 76.5-125 Wang and
vegetables blender followed by 








aValue is dependent upon the GC column used and isomer measured.
ECD = electron capture detector; GC = gas chromatography; GPC = gel permeation chromatography; MS = mass 
spectrometry; TCB = trichlorobenzene
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mousses, tars, fibrous wastes, polymeric emulsions, filter cakes, spent carbons, spent catalysts, soils, and 
sediments (EPA 1996b). Purge-and-trap methods such as EPA Method 5035 are usually employed in 
conjunction with Method 8260B for sample preparation. Detection limits in water and waste samples are 
generally <1 ppb for trichlorobenzenes; however, the actual value depends upon the specific isomer and 
GC column used for the analysis. Detection limits in soil and sediment are also <1 ppb. Wang and Jones 
(1994) described an analytical method using GC/ECD to analyze levels o f trichlorobenzenes in fruits and 
vegetables. Soxhlet extraction using a hexane/acetone (2:1) solvent mixture followed by cleanup using a 
Florisil® column was used for the sample preparation. Recoveries in fortified samples exceeded 75% for 
each isomer, and detection limits in the sub-ppb range were reported.
7.3 ADEQUACY OF THE DATABASE
Section 104(i)(5) o f CERCLA, as amended, directs the Administrator o f ATSDR (in consultation with the 
Administrator o f EPA and agencies and programs o f the Public Health Service) to assess whether 
adequate information on the health effects o f trichlorobenzenes is available. Where adequate information 
is not available, ATSDR, in conjunction with NTP, is required to assure the initiation o f a program of 
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) o f trichlorobenzenes.
The following categories o f possible data needs have been identified by a joint team o f scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that i f  met would 
reduce the uncertainties o f human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs w ill be 
evaluated and prioritized, and a substance-specific research agenda w ill be proposed.
7.3.1 Identification of Data Needs
Methods for Determining Biomarkers of Exposure and Effect.
Exposure. There are no unique biomarkers o f exposure for trichlorobenzenes other than the parent 
compound. Methods are available that can detect trichlorobenzenes in blood (Bristol et al. 1982; Mes 
1992; Pellizzari et al. 1985a), adipose tissue (Mes 1992), and exhaled breath (Pellizzari et al. 1985b). No 
data needs are identified. Trichlorobenzenes detected in humans may arise from direct exposure to the 
parent compound, but may also arise from the metabolism o f other chlorinated compounds such as 
tetrachlorobenzenes, pentachlorobenzene, or hexachlorobenzene.
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Effect. There are no unique biomarkers o f effect for trichlorobenzenes.
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Trichlorobenzene levels in air, water, and food are o f most concern for human health. Methods 
are available to determine levels o f trichlorobenzene in air (EPA 1999; NIOSH 1994), water (EPA 
1996b), soil (EPA 1996b), sediment (EPA 1996b), and foods (Wang and Jones 1994). These methods are 
sensitive enough to detect trichlorobenzene levels in environmental matrices that may be a concern to 
human health. No data needs are identified.
7.3.2 Ongoing Studies
The Environmental Health Laboratory Sciences Division o f the National Center for Environmental 
Health, Centers for Disease Control and Prevention, is developing methods for the analysis of 
trichlorobenzenes and other volatile organic compounds in blood. These methods use purge and trap 
methodology, high-resolution gas chromatography, and magnetic sector mass spectrometry, which give 
detection limits in the low parts per trillion (ppt) range.
No ongoing studies pertaining to analytical methods for trichlorobenzenes were identified in a search of 
the Federal Research in Progress database (FEDRIP 2010).
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8. REGULATIONS, ADVISORIES, AND GUIDELINES
MRLs are substance specific estimates, which are intended to serve as screening levels, are used by 
ATSDR health assessors and other responders to identify contaminants and potential health effects that 
may be o f concern at hazardous waste sites.
The international and national regulations, advisories, and guidelines regarding trichlorobenzenes in air, 
water, and other media are summarized in Table 8-1.
ATSDR has derived an intermediate-duration oral MRL o f 0.1 mg/kg/day for 1,2,4-trichlorobenzene 
based on an increased incidence o f centrilobular hepatocyte hypertrophy in male rats administered
1.2.4-trichlorobenzene in the diet for 13 weeks (CMA 1989). The MRL was derived using BMD 
modeling o f incidence data for hepatocyte hypertrophy in male rats. The predicted dose associated with a 
10% extra risk (BMDJ0) for hepatocyte hypertrophy was 33.09 mg/kg/day; the lower 95% confidence 
lim it on this dose (BMDLJ0) was 14.35 mg/kg/day. An uncertainty factor o f 100 was used (10 for animal 
to human extrapolation and 10 for human variability).
ATSDR has derived a chronic-duration oral MRL o f 0.1 mg/kg/day for 1,2,4-trichlorobenzene based on 
an increased incidence o f hepatocellular hypertrophy in male rats administered 1,2,4-trichlorobenzene in 
the diet for 104 weeks (Moore 1994a). The MRL was derived using BMD modeling o f incidence data for 
hepatocellular hypertrophy in male rats. The predicted dose associated with a 10% extra risk (BMD10) for 
hepatocellular hypertrophy was 23.25 mg/kg/day; the lower 95% confidence lim it on this dose (BMDL10) 
was 13.33 mg/kg/day. An uncertainty factor o f 100 was used (10 for animal to human extrapolation and 
10 for human variability).
EPA (IRIS 2010) has established an oral reference dose (RfD) for 1,2,4-trichlorobenzene of
0.01 mg/kg/day based on a NOAEL o f 14.8 mg/kg/day for increased adrenal weights in rats exposed to
1.2.4-trichlorobenzene in drinking water (Robinson et al. 1981). The uncertainty factor used in this 
assessment was 1,000 (10 for extrapolation from laboratory studies, 10 for the protection o f sensitive 
human subpopulations, and 10 to account for a lack of chronic studies). EPA’s assessment was 
conducted in 1991.
EPA has not derived an inhalation reference concentration (RfC) for trichlorobenzenes.
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Extremely hazardous substances No 
and its threshold planning quantity
TSCA chemical lists and reporting No
periods









RCRA waste minimization PBT priority Yes 
chemical list (1,2,4-trichlorobenzene)
Standards of performance for 
equipment leaks of VOC in the 
synthetic organic chemicals 
manufacturing industry
Trichlorobenzenes Yes
Organic hazardous air pollutant
1,2,4-Trichlorobenzene Yes
EPA 2009h 
40 CFR 355, 
Appendix A
EPA 2009b 




e3 FR e0332 
EPA 2009f 
40 CFR e0 
Subpart VV
EPA 2009k 
40 CFR e3, Table 2 
to Subpart F
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Table 8-1. Regulations and Guidelines Applicable to Trichlorobenzenes
Agency Description Information Reference
NATIONAL (cont.)
NTP Carcinogenicity classification No NTP 2005
aGuideline value not established because total trichlorobenzenes occur in drinking water at concentrations below 
those at which toxic effects may occur, and health-based value would exceed lowest reported odor threshold (WHO 
2006).
bCeiling: the concentration should not be exceeded during any part of the working exposure.
cTrichlorobenzenes are included on the list of 371 priority chemicals that are acutely toxic and represent the selection
of chemicals for AEGL development by the NAC/AEGL committee during the next several years.
dGroup III pesticides pose minimal risk of adverse acute effects even at relatively high doses.
eTEEL-0 is the threshold concentration below which most people will experience no adverse health effects.
fPAC-1 is the airborne concentration (expressed as ppm or mg/m3) of a substance above which it is predicted that the
general population, including susceptible individuals, could experience discomfort, irritation, or certain asymptomatic,
nonsensory effects. However, these effects are not disabling and are transient and reversible upon cessation of
exposure.
gPAC-2 is the airborne concentration (expressed as ppm or mg/m3) of a substance above which it is predicted that 
the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting, 
adverse health effects or an impaired ability to escape.
hPAC-3 is the airborne concentration (expressed as ppm or mg/m3) of a substance above which it is predicted that 
the general population, including susceptible individuals, could experience life-threatening health effects or death.
11.2.4-Trichlorobenzene was originally recommended to the MTL by the TSCA Interagency Testing Committee in 
1990 and was removed in 1994 because the TSCA Section 4 Final Rule-Making testing program was completed.
1.2.4-T richlorobenzene was again recommended to the MTL in 1995 by the Organization for Economic Cooperation 
and Development (OECD) and by the U.S. EPA Office of A ir and Radiation (OAR). The OECD chemical testing 
program is currently underway by a voluntary testing agreement and the testing needs include SIDS screening data 
for health effects, environmental effects, and environmental fate and exposure. The OAR chemical testing action 
development is currently underway and the testing needs for health effects include acute toxicity, neurotoxicity, 
developmental toxicity and immunotoxicity.
jD: not classifiable as to human carcinogenicity based on a dermal exposure study in mice that was found 
inadequate for drawing conclusions as to carcinogenicity in humans.
kDesignated CERCLA hazardous substance pursuant to Section 311(b)(2) of the Clean Water Act and Section 112 of 
the Clean Air Act.
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;
AIHA = American Industrial Hygiene Association; CERCLA = Comprehensive Environmental Response, 
Compensation, and Liability Act; CFR = Code of Federal Regulations; DOE = Department of Energy;
DWEL = drinking water equivalent level; EAFUS = Everything Added to Food in the United States;
EPA = Environmental Protection Agency; ERPG = emergency response planning guidelines; FDA = Food and Drug 
Administration; IARC = International Agency for Research on Cancer; IRIS = Integrated Risk Information System; 
MCL = maximum contaminant level; MCLG = maximum contaminant level goal; MTL = Master Testing List;
NAC = National Advisory Committee; NIOSH = National Institute for Occupational Safety and Health; NTP = National 
Toxicology Program; OSHA = Occupational Safety and Health Administration; PAC = protective action criteria;
PBT = persistent, bioaccumulative, and toxic; PEL = permissible exposure limit; RCRA = Resource Conservation and 
Recovery Act; REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference 
dose; SIDS = Screening Information Data Sets; STEL = short-term expsoure limit; TEEL = temporary emergency 
exposure limits; TLV = threshold limit values; TSCA = Toxic Substances Control Act; TWA = time-weighted average; 
USC = United States Code; VOC = volatile organic compound; VTA = Voluntary Testing Agreement; WHO = World 
Health Organization
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EPA has designated 1,2,4-trichlorobenzene as a hazardous air pollutant (HAP) under the Clean A ir Act 
(CAA) (EPA 2006b). 1,2,4-Trichlorobenzene is on the list o f chemicals appearing in “Toxic Chemicals 
Subject to Section 313 o f the Emergency Planning and Community Right-to-Know Act o f 1986" and has 
been assigned a reportable quantity (RQ) lim it o f 100 pounds (EPA 2009g). The RQ represents the 
amount o f a designated hazardous substance which, when released to the environment, must be reported 
to the appropriate authority.
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10. GLOSSARY
Absorption—The taking up o f liquids by solids, or o f gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration o f 14 days or less, as specified in the 
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer o f molecules (as o f gases, solutes, or liquids) to the 
surfaces o f solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio o f the amount o f a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration o f the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount o f a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount o f chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms o f chemical sorbed per gram o f soil or 
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence lim it on the dose that produces a 
specified magnitude o f changes in a specified adverse response. For example, a BMDJ0 would be the 
dose at the 95% lower confidence lim it on a 10% response, and the benchmark response (BMR) would be 
10%. The BMD is determined by modeling the dose response curve in the region o f the dose response 
relationship where biologically observable data are feasible.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient o f the concentration o f a chemical in aquatic organisms 
at a specific time or during a discrete time period o f exposure divided by the concentration in the 
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers o f exposure, markers o f effect, and markers o f susceptibility.
Cancer Effect Level (CEL)—The lowest dose o f chemical in a study, or group o f studies, that produces 
significant increases in the incidence o f cancer (or tumors) between the exposed population and its 
appropriate control.
Carcinogen—A chemical capable o f inducing cancer.
Case-Control Study—A type o f epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety o f potential causative agents (such as toxic 
chemicals). In a case-controlled study, a group o f people with a specified and well-defined outcome is 
identified and compared to a similar group o f people without outcome.
Case Report—Describes a single individual with a particular disease or exposure. These may suggest 
some potential topics for scientific research, but are not actual research studies.
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Case Series—Describes the experience o f a small number o f individuals with the same disease or 
exposure. These may suggest potential topics for scientific research, but are not actual research studies.
Ceiling Value—A concentration o f a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles.
Cohort Study—A type o f epidemiological study o f a specific group or groups o f people who have had a 
common insult (e.g., exposure to an agent suspected o f causing disease or a common disease) and are 
followed forward from exposure to outcome. At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type o f epidemiological study o f a group or groups o f people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs— Substance-specific informational needs that i f  met would reduce the uncertainties o f human 
health assessment.
Developmental Toxicity—The occurrence o f adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time o f sexual maturation. Adverse developmental effects may be detected at any point 
in the life span o f the organism.
Dose-Response Relationship—The quantitative relationship between the amount o f exposure to a 
toxicant and the incidence o f the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result o f prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage o f development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero 
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate o f acceptable drinking water 
levels for a chemical substance based on health effects information. A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation o f factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.
Genotoxicity—A specific adverse effect on the genome o f living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because o f specific 
alteration o f the molecular structure o f the genome.
Half-life—A measure o f rate for the time required to eliminate one half o f a quantity o f a chemical from 
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration o f a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects.
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Immunologic Toxicity—The occurrence o f adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals.
Immunological Effects—Functional changes in the immune response.
Incidence—The ratio o f individuals in a population who develop a specified condition to the total 
number o f individuals in that population who could have developed that condition in a specified time 
period.
Intermediate Exposure—Exposure to a chemical for a duration o f 15-364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration^ )  (LClo )—The lowest concentration o f a chemical in air that has been reported 
to have caused death in humans or animals.
Lethal Concentration^ )  (LC50)—A calculated concentration o f a chemical in air to which exposure for 
a specific length o f time is expected to cause death in 50% o f a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose o f a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose o f a chemical that has been calculated to cause death in 50% o f a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period o f time within which a specific concentration o f a chemical 
is expected to cause death in 50% o f a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level o f chemical in a study, 
or group o f studies, that produces statistically or biologically significant increases in frequency or severity 
o f adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function.
Minimal Risk Level (MRL)—An estimate o f daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk o f adverse noncancer health effects over a specified route and 
duration o f exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation o f a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1.
Morbidity— State o f being diseased; morbidity rate is the incidence or prevalence o f disease in a specific 
population.
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Mortality—Death; mortality rate is a measure o f the number o f deaths in a population during a specified 
interval o f time.
Mutagen—A substance that causes mutations. A mutation is a change in the DNA sequence o f a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination o f the organs and tissues o f a dead body to determine the cause of 
death or pathological conditions.
Neurotoxicity—The occurrence o f adverse effects on the nervous system following exposure to a 
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose o f a chemical at which there were no 
statistically or biologically significant increases in frequency or severity o f adverse effects seen between 
the exposed population and its appropriate control. Effects may be produced at this dose, but they are not 
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio o f the concentrations o f a chemical 
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means o f measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate o f relative risk (risk as a ratio o f the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk o f disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift o f a 40-hour workweek.
Pesticide—General classification o f chemicals specifically developed and produced for use in the control 
o f agricultural and public health pests.
Pharmacokinetics—The dynamic behavior o f a material in the body, used to predict the fate 
(disposition) o f an exogenous substance in an organism. Utilizing computational techniques, it provides 
the means o f studying the absorption, distribution, metabolism, and excretion o f chemicals by the body.
Pharmacokinetic Model—A set o f equations that can be used to describe the time course o f a parent 
chemical or metabolite in an animal system. There are two types o f pharmacokinetic models: data-based 
and physiologically-based. A data-based model divides the animal system into a series o f compartments, 
which, in general, do not represent real, identifiable anatomic regions o f the body, whereas the 
physiologically-based model compartments represent real anatomic regions o f the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type o f physiologically based dose- 
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance o f physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance.
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Physiologically Based Pharmacokinetic (PBPK) Model—Comprised o f a series o f compartments 
representing organs or tissue groups with realistic weights and blood flows. These models require a 
variety o f physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities. The models also utilize biochemical 
information, such as air/blood partition coefficients, and metabolic parameters. PBPK models are also 
called biologically based tissue dosimetry models.
Prevalence—The number o f cases o f a disease or condition in a population at one point in time.
Prospective Study—A type o f cohort study in which the pertinent observations are made on events 
occurring after the start o f the study. A group is followed over time.
qi *—The upper-bound estimate o f the low-dose slope o f the dose-response curve as determined by the 
multistage procedure. The q1* can be used to calculate an estimate o f carcinogenic potency, the 
incremental excess cancer risk per unit o f exposure (usually ^g/L for water, mg/kg/day for food, and 
^g/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) o f a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk o f deleterious noncancer health effects during a lifetime. 
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units o f mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order o f magnitude) o f the 
daily exposure o f the human population to a potential hazard that is likely to be without risk o f deleterious 
effects during a lifetime. The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application o f uncertainty factors that reflect 
various types o f data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment o f the entire database on the chemical. The RfDs are not applicable to 
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity o f a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 o f the Clean Water Act. Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence o f adverse effects on the reproductive system that may result 
from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related 
endocrine system. The manifestation o f such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system.
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Retrospective Study—A type o f cohort study based on a group o f persons known to have been exposed 
at some time in the past. Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors o f the cohort.
Risk—The possibility or chance that some adverse effect w ill result from a given exposure to a chemical.
Risk Factor—An aspect o f personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence o f disease or other health-related 
event or condition.
Risk Ratio—The ratio o f the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk o f disease in the exposed 
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference o f Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Lim it Value-Time Weighted Average (TLV-TWA) may 
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio o f the observed number o f deaths and the expected 
number o f deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range o f adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime o f exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development o f an organism.
Threshold Limit Value (TLV)—An American Conference o f Governmental Industrial Hygienists 
(ACGIH) concentration o f a substance to which most workers can be exposed without adverse effect.
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Lim it 
(STEL), or as a ceiling lim it (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek.
Toxic Dose(50) (TD50)—A calculated dose o f a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% o f a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination o f toxic compounds in the living organism.
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Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data. UFs are intended to 
account for (1) the variation in sensitivity among the members o f the human population, (2) the 
uncertainty in extrapolating animal data to the case o f human, (3) the uncertainty in extrapolating from 
data obtained in a study that is o f less than lifetime exposure, and (4) the uncertainty in using lowest- 
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; i f  complete certainty in data exists, a value o f 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system.
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APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99­
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order o f priority, a list o f hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list o f hazardous substances; and assure the initiation 
o f a research program to f ill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation o f available toxicological 
information and epidemiologic evaluations o f a hazardous substance. During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) o f effect or the most sensitive health effect(s) for a specific duration for a 
given route o f exposure. An MRL is an estimate o f the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk o f adverse noncancer health effects over a specified duration 
o f exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be o f 
concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or 
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects. MRLs are derived for acute (1-14 days), intermediate (15-364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes o f exposure. Currently, 
MRLs for the dermal route o f exposure are not derived because ATSDR has not yet identified a method 
suitable for this route o f exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be o f relevance to humans. Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level 
above the MRL does not mean that adverse health effects w ill occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that
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are not expected to cause adverse health effects. Most MRLs contain a degree o f uncertainty because o f 
the lack o f precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects o f hazardous substances. ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle o f prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking. In the absence o f evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects o f hazardous substance than animals and that certain persons 
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the 
Division o f Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL 
Workgroup reviews, with participation from other federal agencies and comments from the public. They 
are subject to change as new information becomes available concomitant with updating the toxicological 
profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels.
For additional information regarding MRLs, please contact the Division o f Toxicology and 
Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, 
Mailstop F-62, Atlanta, Georgia 30333.
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Final Pre-Public Comment 
[ ] Inhalation [X] Oral 
[ ] Acute [X] Intermediate [ ] Chronic
21 
Rat
Minimal Risk Level: 0.1 [x] mg/kg/day [ ] ppm
Reference: CMA. 1989. A three month dietary range-finding study o f 1,2,4-trichlorobenzene in rats 
final report with letter dated 2/2/89 from Chemical Manufacturers Association. Chemical Manufacturers 
Association. Submitted to the U.S. Environmental Protection Agency under TSCA Section 4. EPA 
Document No. 40-98201006. OTS0523023.
Experimental design: Groups o f Fisher-344 rats (10/sex/group) were fed a diet containing 0, 200, 600, or 
1,800 ppm 1,2,4-trichlorobenzene for 14 weeks; this diet provided doses o f 0, 14.6, 45.6, or 
133.7 mg/kg/day for males and 0, 17, 52.5, or 150.6 mg/kg/day for females. These doses were calculated 
by dividing the sum o f the weekly doses provided by the investigators by 14 weeks. End points 
monitored included clinical signs (daily), physical examination (weekly), ophthalmology (initiation and 
termination), body weight and food consumption (weekly), hematology and clinical chemistry 
(termination), gross necropsy (all rats at termination), selected organ weights, and histopathology o f all 
major organs and tissues o f the control and high-dose group and liver and kidney o f the low- and mid­
dose groups.
Effect noted in study and corresponding doses: Treatment with 1,2,4-trichlorobenzene did not affect 
survival rate. Clinical signs were limited to chromodacryorrhea and lacrimation, which occurred more 
frequently in treated groups, but without dose-response. The test for ocular abnormalities did not reveal 
compound-related effects. Administration o f 1,2,4-trichlorobenzene did not significantly affect body 
weight or weight gain. Food consumption was significantly higher in the mid- and high-dose groups than 
in controls. Hematological alterations consisted o f decreased mean erythrocyte count (5%), hemoglobin 
(7%), and hematocrit (5%) in males dosed with 133.7 mg/kg/day and decreased hemoglobin (4%) and 
hematocrit (4%) in females dosed with 150.6 mg/kg/day. These changes are within the normal range and 
are not considered biologically significant. Platelets were significantly increased (16%) in males dosed 
with 133.7 mg/kg/day; the toxicological significance o f this finding is unclear. Significant clinical 
chemistry changes included elevated BUN in high-dose males (12%) and females (20%), elevated total 
protein, albumin, and calcium in high-dose males, and lower serum AST activity in males dosed with
45.6 mg/kg/day (22%) and 133.7 mg/kg/day (28%). The elevated BUN was consistent with microscopic 
alterations in kidneys from male rats. The clinical significance o f the alterations in protein and calcium 
were unclear and the lower transaminase activity was not considered o f biological significance.
Significant changes in organ weight included dose-related increases in absolute and relative liver weight 
in all male groups and in mid- and high-dose females, and increased absolute and relative kidneys weight 
and absolute testes weight in males dosed with 133.7 mg/kg/day. No compound-related gross lesions 
were observed. Histopathological alterations were limited to the kidneys and liver. Kidney lesions were 
evident in males dosed with 45.6 and 133.7 mg/kg/day and consisted o f dilated tubules, granular casts, 
hyaline droplets, interstitial nephritis, and papillary mineral deposition. In the liver, centrilobular 
hepatocyte hypertrophy occurred in males dosed with 45.6 and 133.7 mg/kg/day (0/10, 0/10, 5/10, and 
10/10) and in females dosed with 150.6 mg/kg/day (0/10, 0/10, 0/10, and 10/10). Hepatocyte hypertrophy
***DRAFT FOR PUBLIC COMMENT***
TRICHLOROBENZENES A-4
was the probable cause o f the increases in liver weight. Liver changes were more prominent in males 
than in females.
Data for renal effects in male rats were not considered for MRL derivation due to the strong possibility 
that this may be a unique response o f the male rat and not relevant for quantitative risk assessment (EPA 
1991). Specific indications that this may be the case include the increased incidences o f hyaline droplets, 
granular casts, and tubule dilation, and the fact that none o f these lesions occurred in female rats. In 
addition, since there is not enough evidence to dissociate the interstitial nephritis from the male-specific 
nephropathy, interstitial nephritis was also not considered for modeling. In support o f this position is the 
fact that interstitial nephritis did not occur in female rats.
Dose and end point used for MRL derivation: BMDLJ0 o f 14.35 mg/kg/day for centrilobular hepatocyte 
hypertrophy in male rats.
[ ] NOAEL [ ] LOAEL [ X ] BMDL10
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X] 10 for extrapolation from animals to humans
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Yes, done by the 
investigators.
I f  an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL: The liver was also a 
target in an additional 3-month study in rats and in a 13-week study in mice. The study in Sprague- 
Dawley rats evaluated hematology, clinical chemistry and histopathology o f the major organ and tissues, 
and reported histological alterations in the liver, kidneys, and thyroid in the various dose groups (doses 
ranged from 0.07 to 82 mg/kg/day in males and from 0.11 to 101 mg/kg/day in females) (Côté et al.
1988). However, the investigators provided only a qualitative description o f the results regarding 
histopathology. In that study, high-dose males showed increases o f 13 and 20% in absolute and relative 
liver weight, respectively, and o f 31 and 36% in absolute and relative kidneys weight, respectively. 
Hematology and clinical chemistry tests were unremarkable. In the 13-week study in mice, groups of 
B6C3Fi mice (10/sex/group) were administered a diet that provided doses o f 0, 67, 850, or 
1,222 mg/kg/day to males and 0, 86, 1,183, or 1,345 mg/kg/day to females (Hiles 1989). End points 
monitored included clinical signs twice daily and body weight and food consumption weekly.
Hematology and clinical chemistry tests were conducted at initiation and during week 14. At termination, 
gross necropsy was conducted, selected organs were weighed, and selected tissues were examined 
microscopically. The lungs, liver, and kidneys from all groups were examined; other organs from only 
the control and high-dose group were examined. Final body weight was significantly reduced in high­
dose males (9%) and females (8.3%). Cumulative body weight gain was significantly reduced in low- 
dose males (27%), high-dose males (40%) and high-dose females (33%); these changes were associated 
with significant reductions in food consumption throughout the study. Ophthalmologic examinations 
were conducted at initiation and termination. Significant, treatment-related alterations occurred only in 
the liver from males dosed with >850 mg/kg/day and females dosed with >1,183 mg/kg/day; the
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respective NOAELs were 67 and 86 mg/kg/day. The lesions consisted o f hepatocellular cytomegaly with 
karyomegaly and hepatocellular atrophy and degeneration. The incidences in males and females were 
0/10, 0/10, 10/10, and 10/10 and 0/9, 0/10, 10/10, and 9/9, respectively (one control female and one high­
dose female were accidentally killed during the study).
Agency Contacts (Chemical Managers): Obaid Faroon, D.V.M., Ph.D.
BENCHMARK MODELING OF HEPATOCELLULAR HYPERTROPHY IN MALE RATS
Models in the EPA Benchmark Software (BMDS version 2.1) were fit to the incidence data for 
centrilobular hepatocyte hypertrophy in male rats from the CMA (1989) study. Only incidences in males 
were modeled (0/10, 0/10, 5/10, 10/10); incidences in females (0/10, 0/10, 0/10, 10/10) were judged not 
amenable for benchmark analysis. A BMR o f 10% was selected in the absence o f data that would support 
a lower BMR. In accordance with EPA (2000a) guidance, BMDs and BMDLs associated with an extra 
risk o f 10% are calculated for all models. Adequate model fit is judged by three criteria: goodness-of-fit 
(p>0.1), visual inspection o f the dose-response curve, and scaled residual at the data point (except the 
control) closest to the predefined benchmark response (BMR). Among all o f the models providing 
adequate fit to the data, the BMDL from the model with the lowest AIC is chosen. The Gamma model 
was selected for MRL derivation (Table A-1).
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APPENDIX A
Table A-1. Model Predictions for the Incidence of Centrilobular Hepatocyte
Hypertrophy in Male Rats Exposed to 1,2,4-Trichlorobenzene
Model






Gammab,c 1.00 15.86 33.09 14.35
Logistic 1.00 17.86 41.94 18.95
Log-Logisticd 1.00 17.86 40.29 16.74
Log-Probitd 1.00 17.86 35.74 16.04
Multistage (1-degree)e 0.26 23.05 6.43 4.04
Multistage (2-degree) 0.85 17.29 18.59 8.90
Multistage (3-degree) 0.97 16.31 24.71 10.07
Probit 1.00 17.86 38.66 17.28
Weibullb 1.00 17.86 37.74 13.40
Quantal-Linear 0.26 23.05 6.43 4.04
aValues <0.10 fail to meet conventional goodness-of-fit criteria. 
bPower restricted to >1.
cBest-fitting model. Among models with adequate fit, the model with the lowest AIC was selected (Gamma). 
dSlope restricted to >1. 
eBetas restricted to >0.
AIC = Akaike's Information Criterion; BMD = maximum likelihood estimate of the dose associated with the selected 
benchmark response; BMDL = 95% lower confidence limit on the BMD
Source: CMA 1989
The dose-response curve is shown in Figure A -1.











Figure A-1. Fit of Gamma Model to Data on 1,2,4-Trichlorobenzene, Incidence of 
Centrilobular Hepatocyte Hypertrophy in Male Rats
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Minimal Risk Level: 0.1 [x] mg/kg/day [ ] ppm
Reference: Moore MR. 1994a. Final report (6 copies), 104-week dietary carcinogenicity study with
1,2,4-trichlorobenzene in rats, with cover letter dated 6/15/94. Chemical Manufacturers Association. 
Submitted to the U.S. Environmental Protection Agency under TSCA Section 4. EPA Document No. 
OPPTS-44612. 0TS0558832.
Experimental design: Groups o f Fisher-344 rats (50/sex/group) were fed a diet containing 0, 100, 350, or 
1,200 ppm 1,2,4-trichlorobenzene for 104 weeks. The diet provided doses o f 0, 5.6, 19.4, or 
66.5 mg/kg/day 1,2,4-trichlorobenzene to males and 0, 6.9, 23.5, or 81.4 mg/kg/day 1,2,4-trichloro­
benzene to females. Parameters evaluated included mortality (twice daily), clinical signs, body weight 
and food consumption (weekly for 16 weeks and every 4 weeks thereafter), hematology (week 52 and 
78 for cellular morphology and leukocyte differential, from control and high-dose groups), organ weight 
(at termination, brain, brainstem, liver, kidneys, testes and epididymis), and gross necropsy and 
histological examination o f all major organs and tissues at termination.
Effect noted in study and corresponding doses: Treatment with 1,2,4-trichlorobenzene resulted in a 
significant reduction in survival rate in males dosed with 66.5 mg/kg/day. Survival rate in the control,
5.6, 19.4, and 66.5 mg/kg/day males at week 104 were 84, 80, 84, and 60% respectively. There were no 
distinct or pronounced compound-related differences in clinical signs between treated and control groups. 
Differences in body weight between treated and control rats were <10% throughout the study. Food 
consumption was decreased 4-7% in treated groups relative to controls during the study. The only 
statistically significant hematology findings were a decrease in basophiles at week 52 and monocytes at 
week 105 in males dosed with 66.5 mg/kg/day, which the investigators considered minor. No evidence of 
leukemia was noted. Gross necropsy at termination showed increased incidence o f liver and kidney 
abnormalities in males dosed with 19.4 and 66.5 mg/kg/day and a slight increase in incidence o f uterine 
masses in treated females relative to controls; these changes were not discussed any further. Significant 
changes in organ weight were limited to an increase in absolute and relative liver weight in both male and 
female rats receiving the highest doses o f 1,2,4-trichlorobenzene and a decrease in absolute and relative 
testes weight in males dosed with 5.6 and 19.4 mg/kg/day. Treatment-related histological alterations 
were restricted to the liver o f males and females and to the kidneys o f males and consisted o f the 
following: hepatocellular hypertrophy (which probably caused the increase in liver weight), focal cystic 
degeneration, diffuse fatty change, transitional renal cell hyperplasia, and increased severity o f chronic rat 
nephropathy in males. Incidences o f liver lesions are presented in Table A-2 (note that a smaller number 
o f animals from the low-dose groups were examined for histopathology).
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Dose (mg/kg/day) 0 5.6 19.4 66.5
Hepatocellular hypertrophy 2/50(4%) 1/26(3.8%) 5/50(10%) 30/50(60%)
Focal cystic degeneration 9/50(18%) 3/26(11.5%) 4/50(8%) 19/50(38%)
Diffuse fatty change 5/50(10%) 3/26(11.5%) 5/50(10%) 14/50(28%)
Females
Dose (mg/kg/day) 0 6.9 23.5 81.4
Hepatocellular hypertrophy 6/50(12%) 5/25(20%) 5/50(10%) 37/50(74%)
Diffuse fatty change 15/50(30%) 6/25(24%) 21/50(42%) 30/50(60%)
Source: Moore 1994a
The incidences o f transitional cell hyperplasia in the kidneys o f male rats were as follows: 0/50, 0/19, 
2/50, and 34/50 in males dosed with 0, 5.6, 19.4, and 66.5 mg/kg/day 1,2,4-trichlorobenzene, 
respectively. Since there is strong evidence from the 14-week study (CMA 1989) suggesting that the 
renal lesions in male rats may represent a male-specific response not relevant for MRL derivation, and 
that the renal cell hyperplasia reported in the 104-week study is a typical response seen in the male rat 
nephropathy, renal cell hyperplasia was not considered as a potential end point for MRL derivation.
Table A-2 shows that: (1) diffuse fatty change was significantly increased in males and females only at 
the highest dose; (2) focal cystic degeneration occurred at lower incidence in the low- and mid-dose males 
compared to controls, and was significantly increased only at the highest dose; (3) hepatocellular 
hypertrophy in female rats occurred at increased frequency only at the highest dose; and (4) only 
hepatocellular hypertrophy in male rats exhibited dose-response characteristics. Based on these facts, 
only the hepatocellular hypertrophy in male rats was considered for MRL derivation.
Dose and end point used for MRL derivation: BMDLJ0 o f 13.33 mg/kg/day for hepatocellular 
hypertrophy in male rats.
[ ] NOAEL [ ] LOAEL [ X ] BMDL10
Uncertainty Factors used in MRL derivation:
[ ] 10 for use o f a LOAEL
[X] 10 for extrapolation from animals to humans
[X] 10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Yes, done by the 
investigators.
I f  an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not 
applicable.
Was a conversion used from intermittent to continuous exposure? Not applicable.
Other additional studies or pertinent information that lend support to this MRL: Treatment o f B6C3Fj 
mice with 1,2,4-trichlorobenzene in the diet for 104 weeks produced hepatocellular carcinoma (Moore
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1994b). Two intermediate-duration studies in rats and one in mice also suggested that the liver is a target 
for 1,2,4-trichlorobenzene (CMA 1989; Côté et al. 1988; Hiles 1989).
Agency Contacts (Chemical Managers): Obaid Faroon, D.V.M., Ph.D.
APPENDIX A
B ENCH M ARK M O D E LIN G  OF HEPATO CELLULAR HYPERTRO PHY IN  M A LE RATS
Models in the EPA Benchmark Software (BMDS version 2.1) were fit to the data set for hepatocellular 
hypertrophy in the liver o f male rats. A BMR of 10% was selected in the absence o f data that would 
support a lower BMR. In accordance with EPA (2000a) guidance, BMDs and BMDLs associated with an 
extra risk o f 10% are calculated for all models. Adequate model fit is judged by three criteria: goodness- 
o f-fit (p>0.1), visual inspection o f the dose-response curve, and scaled residual at the data point (except 
the control) closest to the predefined BMR. Among all o f the models providing adequate fit to the data, 
the BMDL from the model with the lowest AIC is chosen. Details o f the modeling are presented below in 
Table A-3 and Figure A-2.









Gammab 0.92 131.09 23.40 13.76
Logistic 0.95 129.18 25.44 20.54
Log-Logisticc 0.91 131.10 23.34 14.03
Log-Probitc 0.96 131.08 22.72 14.39
Multistage (1-degree)d 0.06 135.48 10.13 7.62
Multistage (2-degree)d,e 0.98 129.12 23.25 13.33
Multistage (3-degree)d 0.87 131.11 23.94 13.02
Probit 0.92 129.24 22.92 18.65
Weibullb 0.88 131.11 23.95 13.62
Quantal-Linear 0.06 135.48 10.13 7.62
aValues <0.10 fail to meet conventional goodness-of-fit criteria. 
bPower restricted to >1. 
cSlope restricted to >1. 
dBetas restricted to >0.
eBest-fitting model. Among models with adequate fit, the model with the lowest AIC was selected (Multistage 
2-degree model).
AIC = Akaike's Information Criterion; BMD = maximum likelihood estimate of the dose/concentration associated with 
the selected benchmark response; BMDL = 95% lower confidence limit on the BMD
Source: Moore 1994a
In accordance with the selection criteria mentioned above, the Multistage (2-degree) model was selected 
for MRL derivation. The dose-response curve is shown in Figure A-2.










Figure A-2. Fit of Multistage (2-degree) Model to Data on 1,2,4-Trichlorobenzene, 
Incidence of Hepatocellular Hypertrophy in Male Rats
APPENDIX A
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Source: Moore 1994a
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This chapter o f the profile is a health effects summary written in non-technical language. Its intended 
audience is the general public, especially people living in the vicinity o f a hazardous waste site or 
chemical release. I f  the Public Health Statement were removed from the rest o f the document, it would 
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics o f concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that 
w ill direct the reader to chapters in the profile that w ill provide more information on the given topic.
Chapter 2 
Relevance to Public Health
This chapter provides a health effects summary based on evaluations o f existing toxicologic, 
epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight- 
of-evidence discussions for human health end points by addressing the following questions:
1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be o f concern to humans?
3. What exposure conditions are likely to be o f concern to humans, especially around hazardous 
waste sites?
The chapter covers end points in the same order that they appear within the Discussion o f Health Effects 
by Route o f Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human 
data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). 
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.
The carcinogenic potential o f the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer 
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points ( if 
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation o f the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes o f entry at each duration o f exposure (acute, intermediate, and chronic). These MRLs are not
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meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.
MRLs should help physicians and public health officials determine the safety o f a community living near 
a chemical emission, given the concentration o f a contaminant in air or the estimated daily dose in water. 
MRLs are based largely on toxicological studies in animals and on reports o f human occupational 
exposure.
MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance. Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology. MRLs are derived using a 
modified version o f the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration. ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects. I f  this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) o f 10 must be employed. Additional uncertainty factors o f 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans). In 
deriving an MRL, these individual uncertainty factors are multiplied together. The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 




Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk o f 1 in 
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review o f the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in 
conjunction with the text. A ll entries in these tables and figures represent studies that provide reliable, 
quantitative estimates o f NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures. Representative 
examples o f LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column o f the legends 
correspond to the numbers in the example table and figure.
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See Sample LSE Table 3-1 (page B-6)
(1) Route o f  Exposure. One o f  the first considerations when reviewing the toxicity o f  a substance 
using these tables and figures should be the relevant and appropriate route o f  exposure. Typically 
when sufficient data exist, three LSE tables and two LSE figures are presented in the document. 
The three LSE tables present data on the three principal routes o f  exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes. N ot all substances will have data on each 
route o f  exposure and will not, therefore, have all five o f  the tables and figures.
(2) Exposure Period. Three exposure periods— acute (less than 15 days), intermediate (15­
364 days), and chronic (365 days or more)— are presented within each relevant route o f  exposure. 
In this example, an inhalation study o f  intermediate exposure duration is reported. For quick 
reference to health effects occurring from a known length o f  exposure, locate the applicable 
exposure period within the LSE table and figure.
(3) Health Effect. The major categories o f  health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. 
Systemic effects are further defined in the "System" column o f  the LSE table (see key number 
18).
(4) Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure. In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1).
(5) Species. The test species, whether animal or human, are identified in this column. Chapter 2, 
"Relevance to Public Health," covers the relevance o f  animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. 
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL.
(6) Exposure Frequency/Duration. The duration o f  the study and the weekly and daily exposure 
regimens are provided in this column. This permits comparison o f  NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to “Chemical x ” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review o f  the dosing regimen, 
refer to the appropriate sections o f  the text or the original reference paper (i.e., Nitschke et al. 
1981).
(7) System . This column further defines the systemic effects. These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems. In the example o f  key number 18, one systemic effect (respiratory) was 
investigated.
(8) NO A EL. A  NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied. Key number 18 reports a NOAEL o f  3 ppm for the respiratory system,
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which was used to derive an intermediate exposure, inhalation MRL o f  0.005 ppm (see 
footnote "b").
(9) LOAEL. A  LOAEL is the lowest dose used in the study that caused a harmful health effect.
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help 
readers identify the levels o f  exposure at which adverse health effects first appear and the 
gradation o f  effects with increasing dose. A  brief description o f  the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL o f  10 ppm. MRLs are not derived from
Serious LOAELs.
(10) Reference. The complete reference citation is given in Chapter 9 o f  the profile.
(11) CEL. A  CEL is the lowest exposure level associated with the onset o f  carcinogenesis in
experimental or epidemiologic studies. CELs are always considered serious effects. The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases.
(12) Footnotes. Explanations o f  abbreviations or reference notes for data in the LSE tables are found 
in the footnotes. Footnote "b" indicates that the NOAEL o f  3 ppm in key number 18 was used to 
derive an MRL o f  0.005 ppm.
LEGEND  
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13) Exposure Period. The same exposure periods appear as in the LSE table. In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated.
(14) Health Effect. These are the categories o f  health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15) Levels o f  Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log 
scale "y" axis. Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16) NO A EL. In this example, the open circle designated 18r identifies a NOAEL critical end point in
the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 
corresponds to the entry in the LSE table. The dashed descending arrow indicates the 
extrapolation from the exposure level o f  3 ppm (see entry 18 in the table) to the MRL o f
0.005 ppm (see footnote "b" in the LSE table).
(17) CEL. Key number 38m is one o f  three studies for which CELs were derived. The diamond
symbol refers to a CEL for the test species-mouse. The number 38 corresponds to the entry in the
LSE table.
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(18) Estimated Upper-Bound Human Cancer Risk L evels. This is the range associated with the upper- 
bound for lifetime cancer risk o f  1 in 10,000 to 1 in 10,000,000. These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates o f  the slope o f  the 
cancer dose response curve at low  dose levels (qi*).
(19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.
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Nitschke et al. 1981
(CEL, multiple 
organs)
(CEL, lung tumors, 
nasal tumors)
(CEL, lung tumors, 
hemangiosarcomas)
Wong et al. 1982
NTP 1982
NTP 1982
12 ^  a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).
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APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference o f  Governmental Industrial Hygienists
ACOEM American College o f  Occupational and Environmental Medicine
ADI acceptable daily intake
ADM E absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office o f  Safety and Health
ALT alanine aminotransferase
AML acute m yeloid leukemia
AOAC Association o f  Official Analytical Chemists
AOEC Association o f  Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BM D/C benchmark dose or benchmark concentration
BM Dx dose that produces a X% change in response rate o f  an adverse effect
BM DLX 95% lower confidence limit on the BM DX
BM DS Benchmark D ose Software
BM R benchmark response
BSC Board o f  Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer A ssessm ent Group o f  the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code o f  Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic m yeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department o f  Health, Education, and Welfare
DHHS Department o f  Health and Human Services
DNA deoxyribonucleic acid
DOD Department o f  Defense
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DOE Department o f Energy
DOL Department o f Labor
DOT Department o f Transportation
DOT/UN/ Department o f Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code 
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram 
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization o f the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization




Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% k ill
LCLo lethal concentration, low
LD50 lethal dose, 50% k ill




LSE Levels o f Significant Exposure
LT50 lethal time, 50% k ill
m meter
MA trans, trans--muconic acid
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MAL maximum allowable level
mCi millicurie
MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor




mmHg millimeters o f  mercury
mmol millimole
mppcf millions o f  particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQ S National Ambient Air Quality Standard
N AS National Academy o f  Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
N D not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute o f  Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System




NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
N R not reported
NRC National Research Council
NS not specified
NSPS N ew  Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office o f  Drinking Water, EPA
OERR Office o f  Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data Sys
OPP Office o f  Pesticide Programs, EPA
OPPT Office o f  Pollution Prevention and Toxics, EPA
OPPTS Office o f  Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
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OSW Office o f  Solid W aste, EPA
OTS Office o f  Toxic Substances
OW Office o f  Water
OWRS Office o f  Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell





RTECS Registry o f  Toxic Effects o f  Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory




USD A United States Department o f  Agriculture
USGS United States G eological Survey
VOC volatile organic compound
W BC white blood cell
WHO World Health Organization




> greater than or equal to
= equal to
< less than








qi* cancer slope factor
- negative
+ positive
(+) weakly positive result
(-) weakly negative result
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absorbed d ose................................................................................................................................................... 114, 122, 133
adipose tissu e ....................................................................................................................... 116, 133, 189, 191, 192, 195
adrenal gland......................................................................................................................................  19, 48, 103, 116, 200
adrenals..................................................................................................................................................... 15, 18, 87, 93, 116
adsorption.................................................................................................................................................. 163, 169, 190, 193
aerobic..............................................................................................................................................................9, 163, 172, 173
alanine aminotransferase (see A L T )................................................................................................................................. 85
ALT (see alanine aminotransferase)................................................................................................................................. 85
ambient a ir ...........................................................................................................  10, 115, 159, 163, 183, 185, 186, 193
anaerobic..................................................................................................................................................................... 168, 173
anem ia................................................................................................................................................................................. 10, 32
aspartate aminotransferase (see A S T ).............................................................................................................................. 20




biodegradation..................................................................................................................................................  159, 172, 173
biomarker........................................................................................................... 132, 133, 144, 145, 147, 191, 195, 196
blood cell count.......................................................................................................................................................................46
body weight effects............................................................................................................................................. 49, 88, 105
breast m ilk................................................................................................................................... 5, 117, 132, 147, 186, 189
cancer............................................................................................................................................ 4, 13, 106, 131, 142, 164
carcinogenic.......................................................................................................................................................................13, 31
carcinogenicity.................................................................................................................... 4, 13, 94, 107, 136, 142, 202
carcinoma..............................................................................................................................................  13, 24, 94, 107, 142
cardiovascular effects............................................................................................................................................33, 82, 100
cholinesterase...................................................................................................................................................................... 134
chromosomal aberrations.................................................................................................................................................112
death.................................................................................................................................. 31, 32, 51, 52, 94, 100, 106, 202
deoxyribonucleic acid (see D N A )........................................................................................................................107, 110
dermal effects.......................................................................................................................................................... 48, 88, 103
developmental e ffe c ts ................................................................................................................ 51, 92, 93, 106, 143, 147
D N A (see deoxyribonucleic acid)........................................................................  107, 109, 110, 121, 128, 133, 146
elimination rate...................................................................................................................................................................114
endocrine.......................................................................................................................................................48, 88, 129, 147
endocrine e ffec ts .................................................................................................................................................... 48, 87, 103
erythema...................................................................................................................................................................... 103, 104
estrogenic..............................................................................................................................................................................130
fetal t issu e .................................................................................................................................................................................92
fetus........................................................................................................................................................................................ 130
gastrointestinal e f fe c ts ......................................................................................................................................... 46, 82, 100
general population..................................................  3, 10, 115, 132, 141, 142, 163, 183, 187, 188, 189, 190, 202
genotoxic.......................................................................................................................................................................... 31, 107
genotoxicity.......................................................................................................................................................107, 112, 142
groundwater.....................................................................................................................................2, 9, 163, 167, 180, 193
half-life.............................................................................................................................................. 2, 9, 132, 159, 171, 172
hematological e ffec ts ............................................................................................................................................46, 83, 100
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hepatic e ffec ts .......................................................................................................................................................46, 84, 103
hydrolysis...................................................................................................................................................................... 159, 172
hydroxyl radical................................................................................................................................................... 9, 159, 172
im m unological.............................................................................................................................................. 31, 49, 90, 143
immunological effects..................................................................................................................................................49, 143
Kow.............................................................................................................................................................................................151
LD50...................................................................................................................................................................51, 52, 94, 133
leukem ia............................................................................................................................................................................. 22, 84
lymphoreticular............................................................................................................................................. 49, 50, 90, 143
metabolic e ffec ts .....................................................................................................................................................49, 89, 90
m icronuclei...................................................................................................................................................................112, 142
m ilk ..........................................................................................................................  3, 5, 10, 92, 134, 183, 185, 186, 189




neurological effects....................................................................................................................................50, 90, 106, 144
ocular effects......................................................................................................................................................... 48, 88, 105
pharmacodynamic.................................................................................................................................................................124
pharmacokinetic.................................................................................................................. 124, 125, 126, 130, 132, 147
photolysis................................................................................................................................................................................ 172
placenta....................................................................................................................................................................................147
porphyria......................................................................................................................................  10, 11, 86, 127, 128, 135
rate constant..................................................................................................................................................................172, 173
renal effects.....................................................................................................................................................21, 47, 86, 103
reproductive effects.............................................................................................................................50, 51, 91, 106, 142
respiratory effects.................................................................................................................................................33, 52, 100
retention.........................................................................................................................................................................115, 191
systemic effects.................................................................................................................................... 32, 33, 52, 100, 133
T 3 .................................................................................................................................................................................................34
thyroid................................................................................................ 12, 16, 19, 27, 28, 29, 48, 87, 88, 103, 140, 141
toxicokinetic.............................................................................................................................................. 31, 113, 145, 146
trem ors....................................................................................................................................................................................... 52
tum ors.................................................................................................................................................................  106, 136, 142
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